(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 10 November 2005 (10.11.2005)

PCT

(10) International Publication Number $WO\ 2005/105136\ A1$

(51) International Patent Classification⁷: 9/00, 9/127, 9/51, A61P 35/00

A61K 38/21,

(21) International Application Number:

PCT/US2005/014626

(22) International Filing Date: 27 April 2005 (27.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/565,756 27 April 2004 (27.04.2004) US

(71) Applicant (for all designated States except US): UNIVER-SITY OF SOUTH FLORIDA [US/US]; 4202 East Fowler Avenue, FAO 126, Tampa, FL 33620-7900 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MOHAPATRA, Shyam, S. [US/US]; 18510 Country Crest Place, Tampa, FL 33647 (US).

(74) Agents: LADWIG, Glenn, P. et al.; Saliwanchik, Lloyd & Saliwanchik, P.O. Box 142950, Gainesville, FL 32614-2950 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NANOGENE THERAPY FOR CELL PROLIFERATION DISORDERS

(57) Abstract: The present invention concerns particles comprising a chitin component, such as chitosan or a derivative thereof, associated with a polynucleotide encoding an interferon (IFN) molecule, 2-5' oligoadenylate synthetase (2-5 AS), or a combination thereof. Preferably, the chitin component comprises chitosan or a derivative thereof. The particles of the invention are useful for delivery and expression of the interferon-encoding and/or 2-5 AS-encoding polynucleotide within a host *in vitro* or *in vivo*. The invention further concerns pharmaceutical compositions comprising particles of the invention and a pharmaceutically acceptable carrier, and a method for producing particles of the present invention. The present invention further pertains to a method of inducing apoptosis in a cancer cell, such as a lung cancer cell, by contacting a target cancer cell *in vitro* or *in vivo* with an effective amount of particles of the invention. In one embodiment, a therapeutically effective amount of particles are administered to target cancer cells within a patient *in vivo*, for treatment of cancer, such as lung cancer. The particles and therapeutic methods of the invention provide anti-metastatic and anti-cancer therapeutics for cancer patients, particularly lung cancer patients.





1

DESCRIPTION

NANOGENE THERAPY FOR CELL PROLIFERATION DISORDERS

5

10

15

CROSS-REFERENCE TO RELATED APPLICATION

This application claims benefit of U.S. Provisional Application Serial No. 60/565,756, filed April 27, 2004, which is hereby incorporated by reference herein in its entirety, including any figures, tables, nucleic acid sequences, amino acid sequences, and drawings.

FIELD OF THE INVENTION

This invention pertains to particles including a chitin component, a polynucleotide encoding an interferon molecule, such as IFN-gamma (IFN- γ), or an interferon-inducible molecule such as 2'-5' oligoadenylate synthetase (2-5 AS) or interferon regulatory factor (IRF-1), or a combination of any of the foregoing, and the use of such particles for treatment of cell proliferation disorders, such as lung cancer.

BACKGROUND OF THE INVENTION

20

25

30

Lung cancer is one of the leading causes of death worldwide. Despite progress made in our understanding of the multiple risk factors associated with the development of lung cancer, and progress in developing novel approaches, this disease remains difficult to treat effectively. Lung cancer patients often present with locally advanced or disseminated disease. Their long-term survival is poor and such aggressive cancers are difficult to treat because of drug-induced toxicity. Non-viral plasmid DNA (pDNA)-mediated gene therapy, one of several new therapeutic approaches for lung cancer, provides a better alternative that is both safe and effective. Unlike viral vectors, which can induce an immune response with associated immunogenicity and systemic toxicity, a pDNA strategy combined with a chitosan-based nanoparticle (CBN) carrier system provides a unique approach to delivering genes by the mucosal route with limited toxicity and increased transgene expression, especially in target organs such as the lung (disclosed

2

in Mohapatra et al., international publication WO 03/028759 A1 and Mohapatra et al., U.S. patent publication 2003-0068333-A1, which are each incorporated herein by reference in their entirety).

5

10

15

20

25

30

Lung tumor development and metastasis are complex processes that include transformation, proliferation, resistance to apoptosis, neovascularization, and metastatic spread (Antoniou, K.M. et al. Chest, 2003, 123:209-216). A number of gene products have been identified that play critical roles in these processes. Inhibition of metastasis is one of the most important therapeutic strategies in the treatment of lung cancer, since approximately 70% of lung cancer patients die from the metastatic disease even after a complete resection of primary tumor. Metastasis involves the disruption of extracellular matrix (ECM) adhesion, ECM degradation, cell cycle disregulation, and escape from apoptosis. Thus, protection from metastasis would have to block one or more of these processes.

A complex array of endocrine activities controls cell proliferation and death in the respiratory, gastrointestinal and urinary mucosa, which are major sites of tumor development. Interferons (IFNs) have received wide attention for their anti-cancer effects and are currently used for many cancers. The major oncologic indications of IFNs include melanoma, renal cell carcinoma, AIDS-related carposi sarcoma, follicular lymphoma, hairy cell leukemia and chronic myelogenous leukemia (Antoniou, K.M. *et al. Chest*, 2003, 123:209-216). Exogenous recombinant IFNs have a shorter half-life *in vivo*, and systemic administration at moderate to high doses may cause substantial adverse effects (Gutterman, J.U. *PNAS*, 1994, 91:1198-1205; Antoniou, K.M. *et al. Chest*, 2003, 123:209-216).

To overcome the limitations inherent with therapy using cytokines *per se* (cytokine proteins or polypeptides), several investigators have used transient gene expression therapy involving these genes. Separately, IFN-γ and IL-12 have each proven effective both as prophylactics and adjuncts in therapy against diverse human diseases (Mohapatra, S.S. *Science*, 1995, 269(5230):1499; Murray, H.W. *Intensive Care Med*, 1996, 22(Suppl 4):S456-S461). Oromucosal IFN therapy was found to be effective for antiviral and antitumoral activity (Okubo, T. *et al. J Immunol*, 1999, 162:4013-4017). However, mucosal administration of IFN-γ pDNA has not been studied.

The last decade has seen tremendous progress in gene expression technology. Several investigators have utilized a replication-deficient episomal adenovirus as a vehicle for transient gene expression. Adenoviral vectors are very efficient at transducing target cells *in vitro* and *in vivo* and permit transgene expression in a dose-dependent manner (Behera, A.K. *et al. Hum Gene Ther.*, 2002, 13:1697-1709), but they do produce acute inflammation and an immune response to viral vector encoded antigens, which remain the major stumbling blocks to the application of adenovirus-mediated IFN-γ gene transfer for treating human diseases. Previous studies have demonstrated that the mucosal administration of pIFN-γ significantly decreased airway inflammation and airway hyper-responsiveness in a mouse model of grass allergic asthma. Adenoviral-mediated IFN-γ gene transfer effectively reversed established asthma in a BALB/c mouse model (Behera, A.K. *et al. Hum Gene Ther.*, 2002, 13:1697-1709).

It has recently been shown that intranasally delivered pDNA encoding interferon gamma (IFN-γ) can be used as an antiviral treatment against respiratory syncytial virus infection (Mohapatra *et al.*, U.S. Patent No. 6,489,306). Further, IFN-γ is known to induce interferon response factor (IRF-1) and 2'5' oligoadenylate synthetase (2-5 OAS), which also have antiviral properties (Behera, A.K. *et al.*, *JBC*, 2002, 277(28):25601-25608; Mohapatra *et al.*, U.S. patent publication 2004-0009152-A1; Mohapatra *et al.*, international publication WO 03/092618 A2; which are each incorporated herein by reference in their entirety). Also, an IFN-γ producing plasmid encapsulated in a chitin-based nanoparticle, which has been referred to as "CIN", has been shown to possess anti-inflammatory and apoptosis-inducing properties and to attenuate lung inflammation and airway hypereactivity (Kumar *et al. Genet Vacc Ther*, 2003, 1(1):3; Mohapatra, international publication WO 2004/074314 A2; which are each incorporated herein by reference in their entirety).

The present inventors reasoned that intranasally administered nanoparticles capable of *de novo* production of the IFN-γ may provide a novel means of prophylaxis and/or treatment for cancer, such as metastatic lung cancer. Research in the laboratory has identified the pIFN-γ as a potential lung cancer treatment based on its ability to induce significant apoptosis in cultured lung cancer cell lines. Also, CBN complexed p-DNA encoding pIFN-γ was found to completely abrogate the development of lung tumors in a nude mouse model of metastatic lung cancer.

4

Non-viral mediated gene expression using plasmid DNAs (pDNAs) has a number of advantages, including ease of preparation and use, stability, and room temperature storage (Hellerman, G.R. and Mohapatra, S.S. Gen Vacc & Ther, 2003, 1:1). They do not replicate in mammalian cells and do not integrate into host genomes, yet they can persist in host cells and express the cloned gene for a period of weeks to months. One problem associated with the pDNA approach is inefficient gene transfer in vivo, especially in slow and non-dividing cells such as epithelial cells (Mohapatra, S.S. Pediatr. Infect. Dis. J., 2003, 22(2 Suppl):S100-S103). CBNs protect pDNA from nuclease degradation and facilitate its entry into target cells. CBNs are prepared from chitosan, a biocompatible cationic polysaccharide from chitin extracted from crustacean shells, and have shown excellent potential for gene (Mao, H-Q. et al. J. Controlled Release, 2001, 70(3):399-421, which is incorporated herein by reference in its entirety) and controlled drug delivery. Chitosan is non-toxic, resistant to biodegradation, non-hemolytic, stimulates the immune system, is an anticoagulant, and has wound-healing and antimicrobial properties. Chitosan also increases transcellular and paracellular transport across the mucosal epithelium, thereby facilitating mucosal gene delivery. Another advantage of the use of CBNs for gene transport is their ability to target specific cells. Reduction of nonspecific interactions by shielding of net positive surface charges also improves targeting of CBNs.

5

10

15

20

25

30

BRIEF SUMMARY OF THE INVENTION

In one aspect, the present invention concerns particles comprising a chitin component, which is associated with a polynucleotide encoding an interferon (IFN) or an IFN-inducible protein, such as 2'-5' oligoadenylate synthatase (2-5 AS) or interferon regulatory factor (IRF-1). Preferably, the chitin component comprises chitosan or a derivative thereof. Optionally, the particles of the invention further comprise a lipid component and are referred to herein interchangeably as "chliposomes", "chlipids", "chitosan-lipid nanoparticles" or "CLNs". The particles of the invention are useful for delivery and expression of the interferon-encoding and/or IFN-inducible molecule-encoding polynucleotide within a host *in vitro* or *in vivo*. The invention further concerns a method for producing particles of the present invention.

In some embodiments, the particles of the invention comprise a polynucleotide encoding an interferon selected from the group consisting of alpha-interferon, beta-

5

interferon, gamma-interferon, omega-interferon, and lambda-interferon. In some embodiments, the particles of the invention comprise a polynucleotide encoding 2-5 AS or at least one catalytically active fragment thereof selected from the group consisting of the p40, p69, and p100 subunit. Such 2-5 AS subunits may be one or more splice variants, such as the 42kDa, 46kDa, 69kDa, and/or 71kDa variant. In some embodiments, the particles of the invention comprise a polynucleotide encoding IRF-1, or a biologically active fragment or homolog thereof.

5

10

15

20

25

30

In another aspect, the present invention concerns a pharmaceutical composition comprising particles comprising a chitin component and a polynucleotide encoding an interferon (IFN) molecule, an IFN-inducible molecule, or a combination thereof; and a pharmaceutically acceptable carrier. Optionally, the particles of the invention further comprise a lipid component. In one embodiment, the pharmaceutical composition is formulated for delivery through a mucosal route, such as the lungs.

In another aspect, the present invention concerns a method of treating a cell proliferation disorder by administering a therapeutically effective amount of particles to a patient in need thereof. Accordingly, a method of reducing cellular growth by administering a therapeutically effective amount of particles of the invention is contemplated, in order to reduce (partially or completely inhibit, prevent, or slow) uncontrolled cell growth. In one embodiment, an effective amount of particles are administered to a patient for treatment of cancer, such as lung cancer.

In another aspect, the present invention concerns a method of inducing apoptosis in a cancer cell, such as a lung cancer cell, by contacting a target cancer cell *in vitro* or *in vivo* with an effective amount of particles of the invention. In one embodiment, a therapeutically effective amount of particles are administered to target cancer cells within a patient *in vivo*, for treatment of cancer, such as lung cancer.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

6

Figure 1 shows an analysis of apoptosis using fluorescence microscopy in cells transfected with pIFN-γ. The micrographs show that IFN-gamma treatment of HEp-2 cells induces apoptosis.

Figure 2 shows an immunoblot demonstrating the detection of p27kip expression and PARP cleavage in IFN-gamma treated HEp-2 cells with or without RSV infection.

5

10

15

20

25

30

Figure 3 shows immunocytochemistry following pIFN-gamma treatment. BALB/c nude mice were injected with A549 cells (5 x 10⁶ cells/mouse) intravenously (i.v.) and one group treated with pIFN-gamma and another group with pVAX as control.

Figures 4A-4D show derivation and characterization of NG-042 nanoparticles. Figure 4A shows synthesis and characterization of nanochitosan particles produced by proprietary method. The products were separated by capillary gel electrophoresis. The plot shows the separation of 4 low molecular weight components. The nanogene particles were then subject to analysis of size and zeta potential using a NiComp381 Zetasizer. Results are shown in Figure 4B. The intensity weight distribution of NG042 particles showing their size of 155 nm, zeta potential=20.42. Atomic Force Microscopic analysis of Nanogene-042 particles showing oligomeric structure complexed with DNA (red arrows; upper line) is shown in Figure 4C. Figure 4D shows that lyophilzed and resuspended NG042 particles retain functionality at ambient temperatures of 23° to 55° C. Nanogene complexes of pGL3 (firefly luciferase, Promega) was lyophilized, reconstituted with water and treated for 24 hours at RT (23° C), 42° C, 55° C and -20° C. A549 cells were plated and transfected with the above complexes. Uptake and expression of DNA was allowed to occur for 24 hours. Luciferase activity was determined by using Promega's Dual Assay kit. Readings were normalized to relative luminiscence units (RLU) per mg protein.

Figures 5A-5C show characterization of NG044 particles. Figure 5A shows that expression of nanoparticle-encapsulated EGFP gene continues *in vivo* until day 10. NG044 particles were complexed with DNA (5:1) encoding green fluorescent protein and administered intranasally to groups of mice (n=3). Mice were sacrificed on the indicated days and broncho-alveolar lavage cells were examined by fluorescent microscopy. Figure 5B demonstrations the thermogelling property of NG044. NG044 forms a gel upon reacting with 2-glycerol phosphate, while NG042, another depolymerized chitosan, does not. To test the controlled release of gene expression, NG044 hydrogel was prepared

7

using pEGFP plasmid DNA and PVP/glutaraldehyde for gel formation. The hydrogel was freeze-dried and the powder was resuspended in water (NG044 hydrogel) and given intranasally to groups of mice (n=4). Another group received NG044 with pEGFP without gelling (Control). Gene expression in the mouse lung was measured by EGFP expression in BAL cells 10 and 20 days after administration. Results are shown in Figure 5C. The results at day 10 were similar (not shown) for control and hydrogel, whereas after 20 days mice given hydrogel continued EGFP show expression and no expression was detected in control mice.

5

10

15

20

25

30

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO: 1 is a nucleotide coding sequence (CDS) for the human 40kDa splice variant of the 40/46kDa subunit ("p40 subunit") of 2'-5' oligoadenylate synthetase (National Center for Biotechnology Information (NCBI) Accession Number NM 016816).

SEQ ID NO: 2 is an amino acid sequence of the human 40kDa splice variant of the 40/46kDa subunit ("p40 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number NM 016816).

SEQ ID NO: 3 is a nucleotide coding sequence (CDS) for the human 46kDA splice variant of the 40/46kDa subunit ("p40 subunit") of 2'-5' oligoadenylate synthetase (National Center for Biotechnology Information (NCBI) Accession Number NM 016816).

- **SEQ ID NO: 4** is an amino acid sequence of the human 46kDA splice variant of the 40/46kDa subunit ("p40 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number NM_016816).
- SEQ ID NO: 5 is a nucleotide coding sequence (CDS) for the human 69 kDA splice variant of the 69/71kDa subunit ("p69 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number NM_002535).
- **SEQ ID NO:** 6 is an amino acid sequence of the human 69 kDa splice variant of the 69/71kDa subunit ("p69 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number NM_002535).

5

20

25

- **SEQ ID NO:** 7 is a nucleotide coding sequence (CDS) for the human 71 kDA splice variant of the 69/71kDa subunit ("p69 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number NM_002535).
- **SEQ ID NO: 8** is an amino acid sequence of the human 71kDa splice variant of the 69/71kDa subunit ("p69 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number NM 002535).
- **SEQ ID NO: 9** is a nucleotide coding sequence (CDS) for the human 100kDa subunit ("p100 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number AF063613).
- SEQ ID NO: 10 is an amino acid sequence of the human 100kDa subunit ("p100 subunit") of 2'-5' oligoadenylate synthetase (NCBI Accession Number AF063613).
 - **SEQ ID NO: 11** is a nucleotide coding sequence (CDS) for the mouse homolog of the 2'-5' oligoadenylate synthetase 40kDa splice variant (p40 subunit) (NCBI Accession Number M33863).
- SEQ ID NO: 12 is the amino acid sequence for the mouse homolog of the 2'-5' oligoadenylate synthetase 40kDa splice variant (p40 subunit) (NCBI Accession Number M33863).
 - **SEQ ID NO: 13** is the human 2'-5' oligoadenylate synthetase 40/46kDa (p40 subunit) gene (NCBI Accession Number NM 016816).
 - SEQ ID NO: 14 is the human 2'-5' oligoadenylate synthetase 69/71kDa (p69 subunit) gene (NCBI Accession Number NM_002535).
 - **SEQ ID NO: 15** is the human 2'-5' oligoadenylate synthetase 100kDa (p100 subunit) gene (NCBI Accession Number AF063613).
 - SEQ ID NO: 16 is the mouse homolog of the 2'-5' oligoadenylate synthetase 40kDa (p40 subunit) gene (NCBI Accession Number M33863).
 - **SEQ ID NO: 17** is the nucleotide coding sequence (CDS) for human IFN-γ (NCBI Accession No: NM_000639.
 - **SEQ ID NO: 18** is the amino acid sequence for human IFN- γ (NCBI Accession No: NM 000639.
- SEQ ID NO:19 is the nucleotide coding sequence (CDS) for human interferonbeta (NCBI Accession No.: M25460).

- **SEQ ID NO:20** is the nucleotide coding sequence (CDS) for human interferonbeta-1 (NCBI Accession No.: M28622).
- **SEQ ID NO:21** is the nucleotide coding sequence (CDS) for a human interferon (NCBI Accession No.: L25664).
- SEQ ID NO:22 is the nucleotide coding sequence (CDS) for human interferonalpha (NCBI Accession No.: M54886 and M38682).

5

15

25

30

- **SEQ ID NO:23** is the nucleotide coding sequence (CDS) for human interferonalpha-J1 (NCBI Accession No.: M34913).
- **SEQ ID NO:24** is the nucleotide coding sequence (CDS) for human interferonomega-1 (NCBI Accession No.: X58822).
 - SEQ ID NO:25 is the nucleotide coding sequence (CDS) for human interleukin 28A (interferon, lambda 2; IL-28A) (NCBI Accession No.: NM_172138).
 - SEQ ID NO:26 is the nucleotide coding sequence (CDS) for human interleukin 28B (interferon lambda 3; IL-28B) (NCBI Accession No.: AY336714).
 - SEQ ID NO:27 is the nucleotide coding sequence (CDS) for human interleukin 28C (interferon lambda 4; IL-28C) (NCBI Accession No.: AY336717).
 - SEQ ID NO:28 is the nucleotide coding sequence (CDS) for human interleukin 29 (interferon lambda 1; IL-29) (NCBI Accession No.: NM_172140).
- SEQ ID NO:29 is the nucleotide coding sequence (CDS) for a human interferonlike peptide (NCBI Accession No.: EE00870).
 - **SEQ ID NO:30** is the nucleotide coding sequence (CDS) for a human interferonlike peptide (NCBI Accession No.: EE00871).
 - **SEQ ID NO:31** is the nucleotide coding sequence (CDS) for a human interferonregulatory factor 1 (IRF-1) (NCBI Accession No.: 002198).

DETAILED DESCRIPTION OF THE INVENTION

The present invention concerns particles comprising a chitin component, such as chitosan or a derivative thereof, associated with a polynucleotide encoding an interferon (IFN) molecule or an IFN-inducible molecule, or a combination thereof. Preferably, the particles further comprise a control sequence operably-linked to the polynucleotide, which is capable of causing expression of the polynucleotide within a host *in vitro* or *in vivo*.

10

In certain embodiments, the interferon molecule encoded by the polynucleotide is Type I or Type II interferon, including those commonly designated as alpha-interferon, beta-interferon, gamma-interferon, and omega-interferon (also designated α -interferon, β -interferon, γ -interferon, and ω -interferon), and combinations thereof, including the consensus sequence for alpha-interferon. In some embodiments, the alpha-interferon is alpha₁ or alpha₂-interferon. In some embodiments, the interferon is interferon α -2b. Other interferons include interferon α -2 β , a fusion interferon α -/2 α -1, interferon α -2e, human α 1 or α 2 interferon.

5

10

15

20

25

30

In some embodiments, the interferon is a hybrid interferon. The construction of hybrid polynucleotides encoding combinations of different interferon subtypes (such as α and ϵ ; α and β , and α and β) is disclosed in U.S. Patent Nos. 4,414,150; 4,456,748; and 4,678,751, each of which are incorporated herein by reference in their entirety. U.S. Patent Nos. 4,695,623; 4,897,471; and 5,831,062, which are incorporated herein by reference in their entirety, disclose novel human leukocyte interferon polypeptides having amino acid sequences that include common or predominant amino acids found at each position among naturally-occurring alpha interferon subtype polypeptides and are referred to as consensus human leukocyte interferon. In one embodiment of the invention, the hybrid interferon is interferon α 2 α 1.

In one embodiment, the interferon is an interferon-α. Recombinant interferon alphas, for instance, have been cloned and expressed in *E. coli* by several groups (*e.g.*, Weissmann *et al.*, *Science*, 1980, 209:1343-1349; Sreuli *et al.*, *Science*, 1980, 209:1343-1347; Goeddel *et al.*, *Nature*, 1981, 290:20-26; Henco *et al.*, *J. Mol. Biol.*, 1985, 185:227-260, each of which are incorporated herein by reference in their entirety). In some embodiments, the interferon is a human interferon alpha. In some embodiments, the interferon alpha is interferon alpha 2a or 2b.

The term "interferon" as used herein is intended to include all classes and subclasses of interferon, and deletion, insertion, or substitution variants, as well as "interferon-like" molecules such as interleukin 15 (IL-15), interleukin 28A (interferon lambda2; IL-28A), interleukin 28B (IL-28B), interleukin 28C (IL-28C), interleukin 29 (interferon lambda1; IL-29), and synthetic interferon-like peptides (e.g., NCBI accession nos. E00871 and E00870). In one embodiment, the interferon-encoding polynucleotide, or its polypeptide product, is the interferon-alpha-encoding polynucleotide or its

11

polypeptide product. In some embodiments, the interferon-encoding polynucleotide of the particle, or its polypeptide, is the human nucleotide or amino acid sequence. The human interferon alphas, for example, are a family of proteins including at least 24 subspecies (Zoon, K. C., *Interferon*, 1987, 9:1, Gresser, I., ed., Academic Press, NY). The interferon alphas were originally described as agents capable of inducing an antiviral state in cells but are now known as pleiotropic lymphokines affecting many functions of the immune system (Openakker *et al.*, *Experimentia*, 1989, 45:513). In some embodiments, the interferon alpha is interferon alpha 2a or 2b (see, for example, WO 91/18927, which is incorporated by reference herein in its entirety), although any interferon alpha may be used. Nucleotide sequences encoding the exemplified interferons interferon-gamma; interferon-beta; interferon-beta-1; interferon; interferon-alpha; interferon-alpha-J1; interferon omega-1; interleukin 28A; interleukin 28B; interleukin 28C, interleukin 29; and interferon-like peptides are listed as SEQ ID NOs: 17 and 19-30. Particles of the invention may contain one or more of these polynucleotides or degenerate sequences encoding the same polypeptides, for example

5

10

15

20

25

30

The interferon-encoding polynucleotide may encode gamma-interferon (IFN-γ), among others. IFN-y is a 14-18 kDalton 143 amino acid glycosylated protein that is a potent multifunctional cytokine. As used herein, "interferon-gamma", "IFN-gamma", "interferon-y", and "IFN-y refer to IFN-y protein, biologically active fragments of IFN-y, and biologically active homologs of "interferon-gamma" and "IFN-γ", such as mammalian homologs. These terms include IFN-γ-like molecules. An "IFN-γ-like molecule" refers to polypeptides exhibiting IFN-γ-like activity when the polynucleotide encoding the polypeptide is expressed, as can be determined in vitro or in vivo. For purposes of the subject invention, IFN-γ-like activity refers to those polypeptides having one or more of the functions of the native IFN-y cytokine disclosed herein (such as induction of apoptosis). Fragments and homologs of IFN-y retaining one or more of the functions of the native IFN-y cytokine, such as those disclosed herein, is included within the meaning of the term "IFN-y". In addition, the term includes a nucleotide sequence which through the degeneracy of the genetic code encodes a similar peptide gene product as IFN-y and has the IFN-y activity described herein. For example, a homolog of "interferon-gamma" and "IFN-y" includes a nucleotide sequence which contains a "silent" codon substitution (e.g., substitution of one codon encoding an amino acid for

12

another codon encoding the same amino acid) or an amino acid sequence which contains a "silent" amino acid substitution (e.g., substitution of one acidic amino acid for another acidic amino acid).

An exemplified nucleotide sequence encodes human IFN-γ (Accession No: 5 NM 000639, NCBI database, which is hereby incorporated by reference in its entirety):

1 tgaagatcag ctattagaag agaaagatca gttaagtcct ttggacctga tcagcttgat 61 acaagaacta ctgatttcaa cttctttggc ttaattctct cggaaacgat gaaatataca 121 agttatatet tggettttea getetgeate gttttgggtt etettggetg ttaetgeeag 10 181 gacccatatg taaaagaagc agaaaacctt aagaaatatt ttaatgcagg tcattcagat 241 gtagcggata atggaactct tttcttaggc attttgaaga attggaaaga ggagagtgac 301 agaaaaataa tgcagagcca aattgtctcc ttttacttca aactttttaa aaactttaaa 361 gatgaccaga gcatccaaaa gagtgtggag accatcaagg aagacatgaa tgtcaagttt 421 ttcaatagca acaaaaagaa acgagatgac ttcgaaaagc tgactaatta ttcggtaact 15 481 gaettgaatg tecaaegeaa ageaataeat gaacteatee aagtgatgge tgaaetgteg 541 ccagcagcta aaacagggaa gcgaaaaagg agtcagatgc tgtttcaagg tcgaagagca 601 teccagtaat ggttgteetg eetgeaatat ttgaatttta aatetaaate tatttattaa 661 tatttaacat tatttatatg gggaatatat ttttagactc atcaatcaaa taagtattta 721 taatagcaac ttttgtgtaa tgaaaatgaa tatctattaa tatatgtatt atttataatt 20 781 cctatatect gtgactgtct cacttaatec tttgttttct gactaattag gcaaggetat 841 gtgattacaa ggetttatet eaggggeeaa etaggeagee aacetaagea agateeeatg 901 ggttgtgtgt ttatttcact tgatgataca atgaacactt ataagtgaag tgatactatc 961 cagttactgc cggtttgaaa atatgcctgc aatctgagcc agtgctttaa tggcatgtca 1021 gacagaactt gaatgtgtca ggtgaccctg atgaaaacat agcatetcag gagatttcat 25 1081 gcctggtgct tccaaatatt gttgacaact gtgactgtac ccaaatggaa agtaactcat 1141 ttgttaaaat tatcaatatc taatatatat gaataaagtg taagttcaca act (SEQ ID NO: 17)

MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLG
ILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNK
KKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFQ
GRRASQ (SEQ ID NO: 18)

30

13

U.S. Patent Nos. 5,770,191 and 6,120,762, which are incorporated herein by reference in their entirety, describe several C-terminal fragments of IFN-gamma that may be encoded by the polynucleotide(s) carried by the particles of the invention. Other interferons that may be encoded by polynucleotides within the particles of the invention are described in U.S. patent publications 2005-0054052-A1; 2005-0054053-A1; 2005-0025742-A1; and 2005-0084478-A1; which are incorporated herein by reference in their entirety.

5

10

15

20

25

30

Interferon regulatory factor-1 (IRF-1) is an interferon-inducible molecule (e.g., an interferon-stimulated gene product) (Pizzoferrato, F. et al., Cancer Res., 2004, 64(22):8381-8388; Pack, S.Y. et al., Eur. J. Biochem., 2004, 271(21):4222-4228). The nucleotide sequence encoding human IRF-1 is provided herein as SEQ ID NO: 31. Particles of the invention may contain this polynucleotide, degenerate sequences encoding the same polypeptide, or biologically active fragments thereof, for example.

2'5' oligoadenylate synthetase (2-5 AS) is an interferon-inducible molecule. In some embodiments, the particles of the invention comprise a polynucleotide encoding 2-5 AS or at least one catalytically active fragment thereof selected from the group consisting of the p40, p69, and p100 subunit. Such 2-5 AS subunits may be one or more splice variants, such as the 42kDa, 46kDa, 69kDa, and/or 71kDa variant. For example, the particles can comprise one or more nucleotide sequences encoding polypeptides comprising one more amino acid sequences set forth herein as SEQ ID NOs: 2, 4, 5, 6, 8, 10, 12, 13, 14, 15, or 16, or catalytically active fragments of these amino acids. In some embodiments, the particles comprise one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 14, 15, 16, and 18, or a catalytically active fragment thereof.

As indicated above, the particle used in the compositions and methods of the invention comprise polynucleotides encoding an interferon, an interferon-inducible molecule, or both. For example, the particle can contain a polynucleotide encoding an interferon and 2-5 AS; encoding an interferon and IRF-1; encoding 2-5 AS and IRF-1; or encoding an interferon, 2-5 AS, and IRF-1. Combinations of an interferon and interferon-inducible molecules can be encoded by polynucleotides within a single particle or multiple different particles.

14

The nucleotide sequences encoding interferon and/or an interferon-inducible molecule used in the subject invention include "homologous" or "modified" nucleotide sequences. Modified nucleic acid sequences will be understood to mean any nucleotide sequence obtained by mutagenesis according to techniques well known to persons skilled in the art, and exhibiting modifications in relation to the normal sequences. For example, mutations in the regulatory and/or promoter sequences for the expression of a polypeptide that result in a modification of the level of expression of a polypeptide according to the invention provide for a "modified nucleotide sequence". Likewise, substitutions, deletions, or additions of nucleic acids to the polynucleotides of the invention provide for "homologous" or "modified" nucleotide sequences. In various embodiments, "homologous" or "modified" nucleic acid sequences have substantially the same biological or serological activity as the native (naturally occurring) interferon and/or interferon-inducible polypeptide. A "homologous" or "modified" nucleotide sequence will also be understood to mean a splice variant of the polynucleotides of the instant invention or any nucleotide sequence encoding a "modified polypeptide" as defined below.

5

10

15

20

25

30

A homologous nucleotide sequence, for the purposes of the present invention, encompasses a nucleotide sequence having a percentage identity with the bases of the nucleotide sequences of between at least (or at least about) 20.00% to 99.99% (inclusive). The aforementioned range of percent identity is to be taken as including, and providing written description and support for, any fractional percentage, in intervals of 0.01%, between 20.00% and 99.99%. These percentages are purely statistical and differences between two nucleic acid sequences can be distributed randomly and over the entire sequence length.

In various embodiments, homologous sequences exhibiting a percentage identity with the bases of the nucleotide sequences of the present invention can have 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent identity with the polynucleotide sequences of the instant invention. Homologous nucleic acid sequences and amino acid sequences include mammalian homologs of the human interferon and/or interferon-inducible molecule

15

nucleic acid sequences and amino acid sequences, including homologs of biologically active fragments, such as biologically active subunits.

Both protein and nucleic acid sequence homologies may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman *Proc. Natl. Acad. Sci. USA*, 1988, 85(8):2444-2448; Altschul *et al. J. Mol. Biol.*, 1990, 215(3):403-410; Thompson *et al. Nucleic Acids Res.*, 1994, 22(2):4673-4680; Higgins *et al. Methods Enzymol.*, 1996, 266:383-402; Altschul *et al. J. Mol. Biol.*, 1990, 215(3):403-410; Altschul *et al. Nature Genetics*, 1993, 3:266-272).

5

10

15

20

25

30

Nucleotide sequences encoding polypeptides with enhanced interferon activity or interferon-inducible molecule activity (such as 2-5 AS catalytic activity and/or IRF-1 activity) can be obtained by "gene shuffling" (also referred to as "directed evolution", and "directed mutagenesis"), and used in the compositions and methods of the present invention. Gene shuffling is a process of randomly recombining different sequences of functional genes (recombining favorable mutations in a random fashion) (U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; and 5,837,458). Thus, protein engineering can be accomplished by gene shuffling, random complex permutation sampling, or by rational design based on three-dimensional structure and classical protein chemistry (Cramer *et al.*, *Nature*, 391:288-291, 1998; and Wulff *et al.*, *The Plant Cell*, 13:255-272, 2001)

Identity and similarity of related nucleic acid molecules and polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; York (1988); Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; York (1993); Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Jersey (1994); Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; York (1991); and Carillo *et al.*, *SIAM J. Applied Math.*, 1988, 48:1073.

The particles, methods, and compositions of the present invention can utilize biologically active fragments of nucleic acid sequences encoding interferon and/or

16

interferon-inducible molecules. Representative fragments of the polynucleotide sequences according to the invention will be understood to mean any polynucleotide fragment having at least 8 or 9 consecutive nucleotides, preferably at least 12 consecutive nucleotides, and still more preferably at least 15 or at least 20 consecutive nucleotides of the sequence from which it is derived. The upper limit for such fragments is the total number of nucleotides found in the full-length sequence (or, in certain embodiments, of the full length open reading frame (ORF) identified herein).

5

10

15

20

25

30

In other embodiments, fragments can comprise consecutive nucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, and up to one nucleotide less than the full-length interferon and/or 2-5 AS coding sequences (or, in some embodiments, up to the full length of nucleotides in the open reading frame (ORF)).

In some embodiments, fragments comprise biologically active subunits (such as the p40 subunit of 2-5 AS (e.g., 40kDa, 42kDa, 46kDa, or other splice variant), p69 subunit of 2-5 AS (e.g., 69 kDa, 71 kDa, or other splice variant), p100 subunit of 2-5 AS, or combinations thereof).

It is also well known in the art that restriction enzymes can be used to obtain biologically active fragments of nucleic acid sequences, such as those encoding interferon and/or interferon-inducible molecules. For example, *Bal*31 exonuclease can be conveniently used for time-controlled limited digestion of DNA (commonly referred to as "erase-a-base" procedures). See, for example, Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York; Wei *et al.* [1983] *J. Biol. Chem.* 258:13006-13512.

Optionally, each particle of the invention further comprises a lipid component that is complexed with the chitin and polynucleotide components of the particle. Since efficient gene expression *in vivo* requires both complex formation for cell uptake and prevention of nucleotide degradation and complex dissociation for transcription by RNA polymerase, a combination of a chitin component and lipid component (such as chitosan

and liposomes, respectively) may lead to increased gene delivery and expression *in vivo*. Therefore, this embodiment of the particle combines these two different carrier systems (also referred to herein interchangeably as "chliposomes", "chlipids", "chitosan-lipid nanoparticles" or "CLNs") to significantly increase polynucleotide transfection and expression. Preferably, the components of the chlipid are oriented such that the polynucleotide is surrounded by a lipid monolayer, with polynucleotide-lipid inverted cylindrical micelles arranged in a hexagonal lattice. Methods for producing CLNs containing polynucleotides encoding interferon-gamma are described in Mohapatra *et al.* international publication WO 2004/074314 A2, which is hereby incorporated herein in its entirety.

The present invention further includes a method for producing the particles of the invention by mixing (e.g., complexing) a polynucleotide and a chitin component, such as chitosan or a chitosan derivative, to form a particle comprising a binary complex of the polynucleotide and the chitin component. Optionally, the method further comprises mixing (complexing) a lipid with the polynucleotide and chitin component to form a particle (CLN) comprising a multiplex of the polynucleotide, the chitin component, and the lipid. Typically, the particles of the present invention range in size from the nanometer range (e.g., less than one micrometer; nanoparticles) to the micrometer size range (e.g., about one micrometer or larger). Methods for producing chitosan-based DNA particles are described in Mohapatra, S.S. Pediatr. Infect. Dis. J., 2003, 22(2 suppl.):S100-S103: Kumar, M. et al., Hum. Gene Ther., 2002, 13(12):1415-1425; Kumar et al., Genetic Vaccines and Therapy, 2003, 1:3; and Mohapatra et al., international publication no. WO 2004/074314 A2; each of which are incorporated herein by reference in their entirety.

The type of reaction vessel or substrate utilized for producing the particles of the present invention, or the size of the vessel or substrate, is not critical. Any vessel or substrate capable of holding or supporting the reactants so as to allow the reaction to take place can be used. It should be understood that, unless expressly indicated to the contrary, the terms "adding", "contacting", "mixing", "reacting", "combining" and grammatical variations thereof, are used interchangeably to refer to the mixture of reactants of the method of the present invention (such as plasmid DNA or a non-

18

polynucleotide agent such as chitosan or a chitosan derivative, lipid, and so forth), and the reciprocal mixture of those reactants, one with the other (i.e., vice-versa), in any order.

5

10

15

20

25

30

It will be readily apparent to those of ordinary skill in the art that a number of general parameters can influence the efficiency of transfection or polynucleotide delivery. These include, for example, the concentration of polynucleotide to be delivered, the concentration of the chitin component (such as chitosan or a chitosan derivative), and the concentration of lipid (for chlipids of the present invention). For in vitro delivery, the number of cells transfected, the medium employed for delivery, the length of time the cells are incubated with the particles of the invention, and the relative amount of particles can influence delivery efficiency. For example, a 1:5 ratio of polynucleotide to lipid, 1:5 ratio of polynucleotide to chitosan, and 20% serum is suitable. These parameters can be optimized for particular cell types and conditions. Such optimization can be routinely conducted by one of ordinary skill in the art employing the guidance provided herein and knowledge generally available to those skilled in the art. It will also be apparent to those of ordinary skill in the art that alternative methods, reagents, procedures and techniques other than those specifically detailed herein can be employed or readily adapted to produce the particles and compositions of the invention. Such alternative methods, reagents, procedures and techniques are within the spirit and scope of this invention.

In accordance with the present invention, the polynucleotides carried by the particles are conjugated with a chitin component, such as chitosan or chitosan derivatives. For example, DNA chitosan nanospheres can be generated, as described by Roy, K. et al. (Nat Med, 1999, 5:387). Chitosan allows increased bioavailability of the nucleic acid sequences because of protection from degradation by serum nucleases in the matrix and thus has great potential as a mucosal gene delivery system. Chitosan also has many beneficial effects, including anticoagulant activity, wound-healing properties, and immunostimulatory activity, and is capable of modulating immunity of the mucosa and bronchus-associated lymphoid tissue.

The term "chitosan", as used herein, will be understood by those skilled in the art to include all derivatives of chitin, or poly-N-aceryl-D-glucosamine (including all polyglucosamine and oligomers of glucosamine materials of different molecular weights), in which the greater proportion of the N-acetyl groups have been removed through hydrolysis. Generally, chitosans are a family of cationic, binary hetero-polysaccharides

19

composed of (1→4)-linked 2-acetamido-2-deoxy-β-D-glucose (GlcNAc, A-unit) and 2amino-2-deoxy-\(\beta\)-D-glucose, (GlcN; D-unit) (Varum K.M. et al., Carbohydr. Res., 1991, 217:19-27; Sannan T. et al., Macromol. Chem., 1776, 177:3589-3600). Preferably, the chitosan has a positive charge. Chitosan, chitosan derivatives or salts (e.g., nitrate, phosphate, sulphate, hydrochloride, glutamate, lactate or acetate salts) of chitosan may be used and are included within the meaning of the term "chitosan". As used herein, the term "chitosan derivatives" are intended to include ester, ether or other derivatives formed by bonding of acyl and/or alkyl groups with OH groups, but not the NH2 groups, of chitosan. Examples are O-alkyl ethers of chitosan and 0-acyl esters of chitosan. Modified chitosans, particularly those conjugated to polyethylene glycol, are included in this definition. Low and medium viscosity chitosans (for example CL113, G210 and CL110) may be obtained from various sources, including PRONOVA Biopolymer, Ltd. (UK); SEIGAGAKU America Inc. (Maryland, USA); MERON (India) Pvt, Ltd. (India); VANSON Ltd. (Virginia, USA); and AMS Biotechnology Ltd. (UK). derivatives include those which are disclosed in Roberts, Chitin Chemistry, MacMillan Press Ltd., London (1992). Optimization of structural variables such as the charge density and molecular weight of the chitosan for efficiency of polynucleotide delivery and expression is contemplated and encompassed by the present invention.

5

10

15

20

25

30

The chitosan (or chitosan derivative or salt) used preferably has a molecular weight of 4,000 Dalton or more, preferably in the range 25,000 to 2,000,000 Dalton, and most preferably about 50,000 to 300,000 Dalton. Chitosans of different low molecular weights can be prepared by enzymatic degradation of chitosan using chitosanase or by the addition of nitrous acid. Both procedures are well known to those skilled in the art and are described in various publications (Li et al., Plant Physiol. Biochem., 1995, 33: 599-603; Allan and Peyron, Carbohydrate Research, 1995, 277:257-272; Damard and Cartier, Int. J. Biol. Macromol., 1989, 11: 297-302). Preferably, the chitosan is water-soluble and may be produced from chitin by deacetylation to a degree of greater than 40%, preferably between 50% and 98%, and more preferably between 70% and 90%.

The lipid component utilized for the particles, compositions, and methods of the present invention is preferably a phospholipid or cationic lipid. Cationic lipids are amphipathic molecules, containing hydrophobic moieties such as cholesterol or alkyl side chains and a cationic group, such as an amine. Phospholipids are amphipathic molecules

20

containing a phosphate group and fatty acid side chains. Phospholipids can have an overall negative charge, positive charge, or neutral charge, depending on various substituents present on the side chains. Typical phospholipid hydrophilic groups include phosphatidyl choline, phosphatidylglycerol, and phosphatidyl ethanolamine moieties. Typical hydrophobic groups include a variety of saturated and unsaturated fatty acid moieties. The lipids used in the present invention include cationic lipids that form a complex with the genetic material (e.g., polynucleotide), which is generally polyanionic, and the chitosan or chitosan derivative. The lipid may also bind to polyanionic proteoglycans present on the surface of cells. The cationic lipids can be phospholipids or lipids without phosphate groups.

5

10

15

20

25

30

A variety of suitable cationic lipids are known in the art, such as those disclosed in International Publication No. WO 95/02698, the disclosure of which is herein incorporated by reference in its entirety. Exemplified structures of cationic lipids useful in the particles of the present invention are provided in Table 1 of International Generally, any cationic lipid, either monovalent or Publication No. WO 95/02698. polyvalent, can be used in the particles, compositions and methods of the present invention. Polyvalent cationic lipids are generally preferred. Cationic lipids include saturated and unsaturated allyl and alicyclic ethers and esters of amines, amides or derivatives thereof. Straight-chain and branched alkyl and alkene groups of cationic lipids can contain from 1 to about 25 carbon atoms. Preferred straight-chain or branched alkyl or alkene groups have six or more carbon atoms. Alicyclic groups can contain from about 6 to 30 carbon atoms. Preferred alicyclic groups include cholesterol and other steroid groups. Cationic lipids can be prepared with a variety of counterions (anions) including among others: chloride, bromide, iodide, fluoride, acetate, trifluoroacetate, sulfate, nitrite, and nitrate.

Transfection efficiency can be increased by using a lysophosphatide in particle Preferred lysophosphatides include lysophosphatidylcholines such as Iformation. oleoyllysophosphatidylcholine and lysophosphatidylethanolamines. Well known may be used include DOTMA (dioleyloxypropyl lysophosphatides which trimethylammonium chloride/DOPE (i.e., LIPOFECTIN, GIBCO/BRL, Gaithersburg, dimethylpropanaminium (dioleyloxy sperminecarboxamidoethyl DOSPA, Md.), trifuoroacetate)/DOPE (i.e., LIPOFECTAMINE), LIPOFECTAMINE 2000, and DOGS

21

(dioctadecylamidospermine) (*i.e.*, TRANSFECTAM), and are all commercially available. Additional suitable cationic lipids structurally related to DOTMA are described in U.S. Patent No. 4,897,355, which is herein incorporated by reference in its entirety.

TRANSFECTAM belongs to a group of cationic lipids called lipopolamines (also referred to as second-generation cationic lipids) that differ from the other lipids used in gene transfer mostly by their spermine head group. The polycationic spermine head group promotes the formation of lipoplexes with better-defined structures (e.g., 50 to 100 nm) (Remy J.S. et al., "Gene Transfer with Lipospermines and Polyethylenimines", Adv. Drug Deliv. Rev., 1998, 30:85-95).

5

10

15

20

25

30

Another useful group of cationic lipids related to DOTMA and DOTAP that may be utilized are commonly called DORI-ethers or DORI-esters, such as (DL-1-O-oleyl-2oleyl-3-dimethylaminopropyl-β-hydroxyethylammonium or DL-1-oleyl-2-O oleyl-3dimethyl-aminopropyl-β-hydroxyethylammonium). DORI lipids differ from DOTMA and DOTAP in that one of the methyl groups of the trimethylammonium group is replaced with a hydroxyethyl group. The oleoyl groups of DORI lipids can be replaced with other alkyl or alkene groups, such as palmitoyl or stearoyl groups. The hydroxyl group of the DORI-type lipids can be used as a site for further functionalization, for example for esterification to amines, like carboxyspermine. Additional cationic lipids which can be employed in the particles, compositions, and methods of the present invention include those described in International Publication No. WO 91/15501, which is herein incorporated by reference in its entirety. Cationic sterol derivatives, like 3 β [N-(N',N'-dimethylaminoethane)carbamoyl] cholesterol (DC-Chol) in which cholesterol is linked to a trialkyammonium group, can also be employed in the present invention. DC-Chol is reported to provide more efficient transfection and lower toxicity than DOTMAcontaining liposomes for some cell lines. DC-Chol polyamine variants such as those described in International Publication No. WO 97/45442 may also be used. Polycationic lipids containing carboxyspermine are also useful in the delivery vectors or complexes of EP-A-304111 describes carboxyspermine containing cationic lipids this invention. including 5-carboxyspermylglycine dioctadecyl-amide (DOGS), as referenced above, and dipalmitoylphosphatidylethanolamine 5-carboxyspermylamide (DPPES). Additional cationic lipids can be obtained by replacing the octadecyl and palmitoyl groups of DOGS and DPPES, respectively, with other alkyl or alkene groups. Cationic lipids can

22

optionally be combined with non-cationic co-lipids, preferably neutral lipids, to form the chlipids of the invention. One or more amphiphilic compounds can optionally be incorporated in order to modify the particle's surface property.

Suitable cationic lipids include esters of the Rosenthal Inhibitor (RI) (DL-2,3-distearoyloxypropyl(dimethyl)-β-hydroxyethylammoniumbromide), as described in U.S. Patent No. 5,264,618, the contents of which is hereby incorporated by reference in its entirety. These derivatives can be prepared, for example, by acyl and alkyl substitution of 3-dimethylaminopropane diol, followed by quaternization of the amino group. Analogous phospholipids can be similarly prepared.

5

10

15

20

25

30

The polynucleotides (and particles containing them) are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight, and other factors known to medical practitioners. The therapeutically or pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. A therapeutically or pharmaceutically effective amount of polynucleotide (such as an IFN-encoding and/or IFN-inducible molecule-encoding polynucleotide) is that amount necessary to provide an effective amount of the polynucleotide, or the corresponding polypeptide(s) when expressed in vivo. An effective amount of an agent, such as a polynucleotide or nonpolynucleotide agent, or particles comprising such polynucleotide or non-polynucleotide agents, can be an amount sufficient to prevent, treat, reduce and/or ameliorate the symptoms and/or underlying causes of any cell proliferation disorder, such as lung cancer. In some instances, an "effective amount" is sufficient to eliminate the symptoms of the pathologic condition and, perhaps, overcome the condition itself. In the context of the present invention, the terms "treat" and "therapy" and the like refer to alleviate, slow the progression, prophylaxis, attenuation, or cure of an existing condition. The term "prevent", as used herein, refers to putting off, delaying, slowing, inhibiting, or otherwise stopping, reducing, or ameliorating the onset of such conditions. The therapeutic methods of the invention include prevention and/or treatment of a cell proliferation disorder.

In accordance with the present invention, a suitable single dose size is a dose that is capable of preventing or alleviating (reducing or eliminating) a symptom in a patient

23

when administered one or more times over a suitable time period. One of skill in the art can readily determine appropriate single dose sizes for systemic administration based on the size of a mammal and the route of administration.

In one embodiment, the cells or subject to which the particles of the invention are administered is not suffering from an RNA virus infection, such as those disclosed in Mohapatra *et al.*, international publication WO 03/092618 A2 and U.S. patent publication 2004-0009152-A1, which are incorporated herein by reference in their entirety. In another embodiment, the cells or subject to which the particles of the invention are administered is not suffering from a respiratory RNA virus infection. In another embodiment, the cells or subject to which the particles of the invention are administered is not suffering from a respiratory syncytial virus (RSV) infection.

5

10

15

20

25

30

Following administration of particles to a subject, the subject's physiological condition can be monitored in various ways well known to the skilled practitioner familiar with the hallmarks of cancer progression, or alternatively by monitoring the effects of administration of the particles on the amount and/or biological activity of the interferon and/or interferon-inducible molecule *in vivo*. Optionally, the therapeutic methods of the invention include identifying a subject suffering from a cell proliferation disorder, such as lung cancer or other cancer. Identification of the subject may include medical diagnosis of the disorder by a licensed clinician.

Mammalian species which benefit from the disclosed particles, compositions, and methods include, and are not limited to, apes, chimpanzees, orangutans, humans, monkeys; domesticated animals (e.g., pets) such as dogs, cats, guinea pigs, hamsters, Vietnamese pot-bellied pigs, rabbits, and ferrets; domesticated farm animals such as cows, buffalo, bison, horses, donkey, swine, sheep, and goats; exotic animals typically found in zoos, such as bear, lions, tigers, panthers, elephants, hippopotamus, rhinoceros, giraffes, antelopes, sloth, gazelles, zebras, wildebeests, prairie dogs, koala bears, kangaroo, opossums, raccoons, pandas, hyena, seals, sea lions, elephant seals, otters, porpoises, dolphins, and whales.

As used herein, the term "patient", "subject", and "host" are used herein interchangeably and intended to include such human and non-human mammalian species and cells of those species. For example, the term "host" includes one or more host cells, which may be prokaryotic (such as bacterial cells) or eukaryotic cells (such as human or

24

non-human mammalian cells), and may be in an *in vivo* or *in vitro* state. After particles of the invention are administered to cells *in vitro*, the cells may be administered to a subject. For example, the particles of the invention can be administered to a subject's cells *ex vivo*, followed by administration of the cells to the subject. In those cases wherein the polynucleotide utilized is a naturally occurring nucleic acid sequence, the polynucleotide encoding the polypeptide product can be administered to subjects of the same species or different species from which the nucleic acid sequence naturally exists, for example. When the subject is a human or the target cells are human, it is preferred that polynucleotides encoding human interferons and/or interferon-inducible molecules are utilized. However, mammalian homologs may also be used, for example.

5

10

15

20

25

30

The particles of the present invention (and compositions containing them) can be administered to a subject by any route that results in delivery and/or expression of the polynucleotide (such as plasmid DNA) or delivery of other non-polynucleotide agents carried by the particles at the desired site or sites. For example, the particles can be administered intravenously (I.V.), intramuscularly (I.M.), subcutaneously (S.C.), intradermally (I.D.), orally, intranasally, etc.

Examples of intranasal administration can be by means of a spray, drops, powder or gel and also described in U.S. Patent No. 6,489,306, which is incorporated herein by reference in its entirety. One embodiment of the present invention is the administration of the invention as a nasal spray. Alternate embodiments include administration through any oral or mucosal routes such as oral, sublingual, intravaginal or intraanal administration, and even eye drops. However, other means of drug administrations such as subcutaneous, intravenous, and transdermal are well within the scope of the present invention.

In various embodiments, the cell proliferation disorder may be cancer of a mucous membrane, such as adenocarcinoma or other cancer of the lung, respiratory tract, stomach, epithelium, *etc*. As used herein, a "lung cancer" includes either a primary lung tumor (for example, bronchogenic carcinoma or bronchial carcinoid) or a metastasis from a primary tumor of another organ or tissue (for example, breast, colon, ovary, prostate, kidney, thyroid, stomach, peritoneum, cervix, rectum, testis, bone, or melanoma).

In preferred embodiments, for cell proliferation disorders of the respiratory tract such as the lung, the particles of the invention are administered through inhalation in a

25

form such as an aerosol, a nebula, a mist, an atomized sample, liquid drops, *etc*. The particles are preferably delivered to the target respiratory tract tissue with a pharmacokinetic profile that results in the delivery of an effective dose of the polynucleotide carried by the particles. In preferred embodiments, at least 1%, more preferably at least 5%, even more preferably at least 10%, still more preferably at least 20%, and most preferably at least 30% or more of the administered particles preferably undergo apical to basolateral transcytosis from the pulmonary lumen.

5

10

15

20

25

30

In certain embodiments, the tumor in a subject is a primary tumor, such as that of the lung; however, the tumor in a subject may be a secondary tumor, such as a pulmonary metastasis from a primary tumor that is not of the lung. In various embodiments, the primary tumor is selected from the group consisting of a sarcoma, an adenocarcinoma, a choriocarcinoma, and a melanoma. In other embodiments, the tumor is a colon adenocarcinoma, a breast adenocarcinoma, an Ewing's sarcoma, or an osteosarcoma. For example, the primary tumor may be a renal cell carcinoma and the secondary tumor a tumor of the lung. In various embodiments, the clinical presentation of the pulmonary, metastasis is a solitary metastasis, a cannonball, a lymphangitis carcinoimatosa, or a pleural effusion. A "primary" tumor is the original tumor in a subject. A "secondary" tumor is a cancer that has metastasized from the organ in which it first appeared to another organ.

Cell proliferation disorders include but are not limited to solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, adenocarcenomas, and leukemias.

Cancers of any organ can be treated, such as cancers of the colon, pancreas, breast, prostate, bone, liver, kidney, lung, testes, skin, pancreas, stomach, colorectal cancer, renal cell carcinoma, hepatocellular carcinoma, melanoma, *etc*.

Examples of breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma. Examples of brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma,

26

5

10

15

20

25

30

medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor. Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer. Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus. Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers. Tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, and urethral cancers. Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma. Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular Skin cancers include, but are not limited to, squamous cell cholangiocarcinoma. carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and nonmelanoma skin cancer. Head-and-neck cancers include, but are not limited to, laryngeal, hypopharyngeal, nasopharyngeal, and/or oropharyngeal cancers, and lip and oral cavity cancer. Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and lymphoma of the central nervous system. Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, rhabdomyosarcoma. Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. In addition to reducing the proliferation of tumor cells and inducing apoptosis, the particles of the invention can also cause tumor regression, e.g., a decrease in the size of a tumor, or in the extent of cancer in the body.

In addition to chemotherapeutic agents, the methods and compositions of the subject invention can incorporate treatments and agents utilizing, for example, angiogenesis inhibitors (Thalidomide, Bevacizumab), Bcl-2 antisense oligonucleotides (G3139), a PSA based vaccine, a PDGF receptor inhibitor (Gleevec), microtubule stabilizers (Epothilones), and a pro-apoptotic agent (Perifosine). Thus, the particles of the invention can be administered to a subject in combination (simultaneously or consecutively) with other agents useful for treating cell proliferation disorders (including polynucleotides encoding such agents) or other disorders. Likewise, the pharmaceutical

27

compositions of the subject invention can include such agents (including polynucleotides encoding such agents).

5

10

15

20

25

30

The term "polynucleotide", as used herein, refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes doublestranded and single-stranded DNA, as well as double-stranded and single-stranded RNA. Thus, the term includes DNA, RNA, or DNA-DNA, DNA-RNA, or RNA-RNA hybrids, or protein nucleic acids (PNAs) formed by conjugating bases to an amino acid backbone. It also includes modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide. The nucleotides may be synthetic, or naturally derived, and may contain genes, portions of genes, or other useful polynucleotides. embodiment, the polynucleotide comprises DNA containing all or part of the coding sequence for a polypeptide, or a complementary sequence thereof, such as interferon and/or IFN-inducible molecule. An encoded polypeptide may be intracellular, i.e., retained in the cytoplasm, nucleus, or in an organelle, or may be secreted by the cell. For secretion, the natural signal sequence present in a polypeptide may be retained. When the polypeptide or peptide is a fragment of a protein, a signal sequence may be provided so that, upon secretion and processing at the processing site, the desired protein will have the Specific examples of coding sequences of interest for use in natural sequence. accordance with the present invention include the polypeptide-coding sequences disclosed herein. The polynucleotides may also contain, optionally, one or more expressible marker genes for expression as an indication of successful transfection and expression of the nucleic acid sequences contained therein.

According to the present invention, an isolated nucleic acid molecule or nucleic acid sequence is a nucleic acid molecule or sequence that has been removed from its natural milieu. As such, "isolated" does not necessarily reflect the extent to which the nucleic acid molecule has been purified.

The terms "polypeptide" and "protein" are used interchangeably herein and indicate a molecular chain of amino acids of any length linked through peptide bonds. Thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. The terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. In addition, protein

28

fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide.

5

10

15

20

25

30

The particles of the present invention are useful as vectors for the delivery of polynucleotides encoding interferon (such as IFN-gamma) and/or an interferon-inducible molecule (such as 2-5 AS or IRF-1) to hosts in vitro or in vivo. The term "vector" is used to refer to any molecule (e.g., nucleic acid or plasmid) usable to transfer a polynucleotide, such as coding sequence information (e.g., nucleic acid sequence encoding a protein or other polypeptide), to a host cell. A vector typically includes a replicon in which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment. The term includes expression vectors, cloning vectors, and the like. Thus, the term includes gene expression vectors capable of delivery/transfer of exogenous nucleic acid sequences into a host cell. The term "expression vector" refers to a vector that is suitable for use in a host cell (e.g., a subject's cell, tissue culture cell, cells of a cell line, etc.) and contains nucleic acid sequences which direct and/or control the expression of exogenous nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing, if introns are present. Nucleic acid sequences can be modified according to methods known in the art to provide optimal codon usage for expression in a particular expression system. The vector of the present invention may include elements to control targeting, expression and transcription of the nucleic acid sequence in a cell selective manner as is known in the art. The vector can include a control sequence, such as a promoter for controlling transcription of the exogenous material and can be either a constitutive or inducible promoter to allow selective transcription. The expression vector can also include a selection gene.

Each particle of the invention comprises a polynucleotide that is a coding sequence for an interferon, IFN-inducible molecule, or both. A "coding sequence" is a polynucleotide sequence that is transcribed into mRNA and/or translated into a polypeptide. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences. Variants or analogs may be prepared by the deletion of a portion of the coding sequence, by insertion of a sequence, and/or by substitution of one

29

or more nucleotides within the sequence. For example, the particles of the present invention may be used to deliver coding sequences for interferon gamma, or variants or analogs thereof. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art (See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, 1989; DNA Cloning, Vols. I and II, D.N. Glover ed., 1985). Optionally, the polynucleotides used in the particles of the present invention, and composition and methods of the invention that utilize such particles, can include non-coding sequences.

5

10

15

20

25

30

The term "operably-linked" is used herein to refer to an arrangement of flanking control sequences wherein the flanking sequences so described are configured or assembled so as to perform their usual function. Thus, a flanking control sequence operably-linked to a coding sequence may be capable of effecting the replication, transcription and/or translation of the coding sequence under conditions compatible with the control sequences. For example, a coding sequence is operably-linked to a promoter when the promoter is capable of directing transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it Thus, for example, intervening untranslated yet transcribed functions correctly. sequences can be present between a promoter sequence and the coding sequence, and the promoter sequence can still be considered "operably-linked" to the coding sequence. Each nucleotide sequence coding for a polypeptide will typically have its own operablylinked promoter sequence. The promoter can be a constitutive promoter, or an inducible promoter to allow selective transcription. Optionally, the promoter can be a cell-specific or tissue-specific promoter. Promoters can be chosen based on the cell-type or tissue-type that is targeted for delivery or treatment, for example.

Suitable promoters include any that are known in the art or yet to be identified that will cause expression of interferon-encoding nucleic acid sequences or IFN-inducible molecule-encoding nucleic acid sequences in mammalian cells. Suitable promoters and other regulatory sequences can be selected as is desirable for a particular application. The promoters can be inducible, tissue-specific, or event-specific, as necessary. For example, the cytomegalovirus (CMV) promoter (Boshart *et al.*, *Cell*, 1985, 41:521-530) and SV40 promoter (Subramani *et al.*, *Mol. Cell. Biol.*, 1981, 1:854-864) have been found to be suitable, but others can be used as well. Optionally, the polynucleotide used in the

30

particles of the subject invention includes a sequence encoding a signal peptide upstream of the interferon-encoding and/or IFN-inducible molecule-encoding sequence, thereby permitting secretion of the interferon and/or IFN-inducible molecule from a host cell. Also, various promoters may be used to limit the expression of the polypeptide in specific cells or tissues, such as lung cells.

5

10

15

20

25

30

A tissue-specific and/or event-specific promoter or transcription element that responds to the target microenviroment and physiology can also be utilized for increased transgene expression at the desired site. There has been an immense amount of research activity directed at strategies for enhancing the transcriptional activity of weak tissuespecific promoters or otherwise increasing transgene expression with vectors. It is possible for such strategies to provide enhancement of gene expression equal to one or two orders of magnitude, for example (see Nettelbeck et al., Gene Ther., 1998, 5(12):1656-1664 and Qin et al., Hum. Gene Ther., 1997, 8(17):2019-2019). Examples of cardiac-specific promoters are the ventricular form of MLC-2v promoter (see, Zhu et al., Mol. Cell Biol., 1993, 13:4432-4444, Navankasattusas et al., Mol. Cell Biol., 1992, 12:1469-1479, 1992) and myosin light chain-2 promoter (Franz et al., Circ. Res., 1993, 73:629-638). The E-cadherin promoter directs expression specific to epithelial cells (Behrens et al., PNAS, 1991, 88:11495-11499), while the estrogen receptor (ER) 3 gene promoter directs expression specifically to the breast epithelium (Hopp et al., J. Mammary Gland Biol. Neoplasia, 1998, 3:73-83). The human C-reactive protein (CRP) gene promoter (Ruther et al., Oncogene 8:87-93, 1993) is a liver-specific promoter. An example of a muscle-specific gene promoter is human enolase (ENO3) (Peshavaria et al., Biochem. J., 1993, 292(Pt 3):701-704). A number of brain-specific promoters are available such as the thy-1 antigen and gamma-enolase promoters (Vibert et al., Eur. J. Biochem. 181:33-39, 1989). The prostate-specific antigen promoter provides prostate tissue specificity (Pang et al., Gene Ther., 1995, 6(11):1417-1426; Lee et al., Anticancer Res., 1996, 16(4A):1805-1811). The surfactant protein B promoter provides lung specificity (Strayer et al., Am. J. Respir. Cell Mol. Biol., 1998, 18(1):1-11). Any of the aforementioned promoters may be selected for targeted or regulated expression of the interferon-encoding and/or IFN-inducible protein-encoding polynucleotide.

The particles of the present invention can be targeted through various means. As indicated above, tissue-specific promoters or event-specific promoters may be utilized

31

with polynucleotides encoding interferon and/or IFN-inducible molecules to further optimize and localize expression at target sites, such as within diseased tissues (e.g., cancer cells or tissues containing cancer cells). Robson et al. review various methodologies and vectors available for delivering and expressing a polynucleotide in vivo for the purpose of treating cancer (Robson, T. Hirst, D.G., J. Biomed. and Biotechnol., 2003, 2003(2):110-137, which is hereby incorporated by reference herein in its entirety). Among the various targeting techniques available, transcriptional targeting using tissue-specific and event-specific transcriptional control elements is discussed. For example, Table 1 at page 112 of the Robson et al. publication lists several tissue-specific promoters useful in cancer therapy. Tables 2-4 of the Robson et al. publication list tumor-specific promoters, tumor environment-specific promoters, and exogenously controlled inducible promoters, many of which were available at the time the patent The successful delivery and expression of the p53 tumor application was filed. suppressor gene in vivo has been documented (Horowitz, J. Curr. Opin. Mol. Ther., 1999, 1(4):500-509; Von Gruenigen, V.E. et al. Int. J. Gynecol. Cancer, 1999, 9(5):365-372; Fujiwara, T. et al., Mol. Urol., 2000, 4(2):51-54, respectively).

5

10

15

20

25

30

Many techniques for delivery of drugs and proteins are available in the art to reduce the effects of enzymatic degradation, to facilitate cell uptake, and to reduce any potential toxicity to normal (undiseased) cells, etc. Such methods and reagents can be utilized for administration of particles of the invention and their polynucleotide cargo to cells in vitro or in vivo. For example, peptides known as "cell penetrating peptides" (CPP) or "protein transduction domains" (PTD) have an ability to cross the cell membrane and enter the cell. PTDs can be linked to a cargo moiety such as a drug, peptide, or full-length protein, and can transport the moiety across the cell membrane. One well characterized PTD is the human immunodeficient virus (HIV)-1 Tat peptide (see, for example, Frankel et al., U.S. Patent Nos. 5,804,604; 5,747,641; 6,674,980; 5,670,617; and 5,652,122; Fawell, S. et al., Proc. Natl. Acad. Sci. U.S.A., 1994, 91:664-668). Peptides such as the homeodomain of Drosophila antennapedia (ANTp) and arginine-rich peptides display similar properties (Derossi, D. et al., J. Biol. Chem., 1994, 269:10444-10450; Derossi, D. et al., Trends Cell Biol., 1998, 8:84-87; Rojas, M. et al., Nat. Biotechnol., 1998, 16:370-375; Futaki, S. et al., J. Biol. Chem., 2001, 276:5836-5840). VP22, a tegument protein from Herpes simplex virus type 1 (HSV-1), also has the

32

ability to transport proteins across a cell membrane (Elliot et al., Cell, 1997, 88:223-233; Schwarze S.R. et al., Trends Pharmacol. Sci., 2000, 21:45-48). A common feature of these carriers is that they are highly basic and hydrophilic (Schwarze S.R. et al., Trends Cell Biol., 2000, 10:290-295). Coupling of these carriers to marker proteins such as betagalactosidase has been shown to confer efficient internalization of the marker protein into cells. More recently, chimeric, in-frame fusion proteins containing these carriers have been used to deliver proteins to a wide spectrum of cell types both in vitro and in vivo. For example, VP22-p53 chimeric protein retained its ability to spread between cells and its pro-apoptotic activity, and had a widespread cytotoxic effect in p53 negative human osteosarcoma cells in vitro (Phelan, A. et al., Nature Biotechnol., 1998, 16:440-443). Intraperitoneal injection of the beta-galactosidase protein fused to the HIV-1 Tat peptide resulted in delivery of the biologically active fusion protein to all tissues in mice, including the brain (Schwarze S.R. et al., Science, 1999, 285:1569-1572).

5

10

15

20

25

30

Liposomes of various compositions can also be used for site-specific delivery of proteins and drugs (Witschi, C. et al., Pharm. Res., 1999, 16:382-390; Yeh, M.K. et al., Pharm. Res., 1996, 1693-1698). The interaction between the liposomes and their cargo usually relies on hydrophobic interactions or charge attractions, particularly in the case of cationic lipid delivery systems (Zelphati, O. et al., J. Biol. Chem., 2001, 276:35103-35110). Tat peptide-bearing liposomes have also been constructed and used to deliver cargo directly into the cytoplasm, bypassing the endocytotic pathway (Torchilin V.P. et al., Biochim. Biophys. Acta-Biomembranes, 2001, 1511:397-411; Torchilin V.P. et al., Proc. Natl. Acad. Sci. USA, 2001, 98:8786-8791). When encapsulated in sugar-grafted liposomes, pentamidine isethionate and a derivative have been found to be more potent in comparison to normal liposome-encapsulated drug or to the free drug (Banerjee, G. et al., J. Antimicrob. Chemother., 1996, 38(1):145-150). A thermo-sensitive liposomal taxol formulation (heat-mediated targeted drug delivery) has been administered in vivo to tumor-bearing mice in combination with local hyperthermia, and a significant reduction in tumor volume and an increase in survival time was observed compared to the equivalent dose of free taxol with or without hyperthermia (Sharma, D. et al., Melanoma Res., 1998, 8(3):240-244). Topical application of liposome preparations for delivery of insulin, IFN-alpha, IFN-gamma, and prostaglandin E1 have met with some success (Cevc G. et al., Biochim. Biophys, Acta, 1998, 1368:201-215; Foldvari M. et al., J. Liposome

33

Res., 1997, 7:115-126; Short S.M. et al., Pharm. Res., 1996, 13:1020-1027; Foldvari M. et al., Urology, 1998, 52(5):838-843; U.S. Patent No. 5,853,755).

5

10

15

20

25

30

Antibodies represent another targeting device that may make particle uptake tissue-specific or cell-specific (Mastrobattista, E. et al., Biochim. Biophys. Acta, 1999, 1419(2):353-363; Mastrobattista, E. et al., Adv. Drug Deliv. Rev., 1999, 40(1-2):103-127). The liposome approach offers several advantages, including the ability to slowly release encapsulated drugs and proteins, the capability of evading the immune system and proteolytic enzymes, and the ability to target tumors and cause preferentially accumulation in tumor tissues and their metastases by extravasation through their leaky neovasculature. Other carriers have also been used to deliver anti-cancer drugs to neoplastic cells, such as polyvinylpyrrolidone nanoparticles and maleylated bovine serum albumin (Sharma, D. et al., Oncol. Res., 1996, 8(7-8):281-286; Mukhopadhyay, A. et al., FEBS Lett., 1995, 376(1-2):95-98). Thus, using targeting and encapsulation technologies, which are very versatile and amenable to rational design and modification, delivery of particles of the invention to desired cells can be further facilitated.

As indicated above, the particles of the present invention can include a lipid component, such as a liposome. According to the present invention, a liposome comprises a lipid composition that is capable of fusing with the plasma membrane of a cell, thereby allowing the liposome to deliver a nucleic acid molecule and/or a protein composition into a cell. Some preferred liposomes include those liposomes commonly used in gene delivery methods known to those of skill in the art. Some preferred liposome delivery vehicles comprise multilamellar vesicle (MLV) lipids and extruded lipids, although the invention is not limited to such liposomes. Methods for preparation of MLVs are well known in the art. "Extruded lipids" are also contemplated. Extruded lipids are lipids that are prepared similarly to MLV lipids, but which are subsequently extruded through filters of decreasing size, as described in Templeton et al., Nature Biotech., 1997, 15:647-652, which is incorporated herein by reference in its entirety. Small unilamellar vesicle (SUV) lipids can also be used for preparing particles of the present invention. Other preferred liposome delivery vehicles comprise liposomes having a polycationic lipid composition (i.e., cationic liposomes). For example, cationic liposome compositions include, but are not limited to, any cationic liposome complexed with cholesterol, and without limitation, include DOTMA and cholesterol, DOTAP and

34

cholesterol, DOTIM and cholesterol, and DDAB and cholesterol. Liposomes utilized in the present invention can be any size, including from about 10 to 1000 nanometers (nm), or any size in between.

5

10

15

20

25

30

A liposome delivery vehicle can be modified to target a particular site in a mammal, thereby targeting and making use of an interferon-encoding and/or IFNinducible molecule-encoding nucleic acid molecule of the present invention at that site. Suitable modifications include manipulating the chemical formula of the lipid portion of the delivery vehicle. Manipulating the chemical formula of the lipid portion of the delivery vehicle can elicit the extracellular or intracellular targeting of the delivery vehicle. For example, a chemical can be added to the lipid formula of a liposome that alters the charge of the lipid bilayer of the liposome so that the liposome fuses with particular cells having particular charge characteristics. In some embodiments, a liposome can be directed to a particular target cell or tissue by using a targeting agent, such as an antibody, soluble receptor or ligand, incorporated with the liposome, to target a particular cell or tissue to which the targeting molecule can bind. Targeting liposomes are described, for example, in Ho et al., Biochemistry, 1986, 25: 5500-6; Ho et al., J Biol Chem, 1987a, 262: 13979-84; Ho et al., J Biol Chem, 1987b, 262: 13973-8; and U.S. Patent No. 4,957,735 to Huang et al., each of which is incorporated herein by reference in its entirety). In one embodiment, if avoidance of the efficient uptake of injected liposomes by reticuloendothelial system cells due to opsonization of liposomes by plasma proteins or other factors is desired, hydrophilic lipids, such as gangliosides (Allen et al., FEBS Lett, 1987, 223: 42-6) or polyethylene glycol (PEG)-derived lipids (Klibanov et al., FEBS Lett, 1990, 268: 235-7), can be incorporated into the bilayer of a conventional liposome to form the so-called sterically-stabilized or "stealth" liposomes (Woodle et al., Biochim Biophys Acta, 1992, 1113: 171-99). Variations of such liposomes are described, for example, in U.S. Patent No. 5,705,187 to Unger et al., U.S. Patent No. 5,820,873 to Choi et al., U.S. Patent No. 5,817,856 to Tirosh et al.; U.S. Patent No. 5,686,101 to Tagawa et al.; U.S. Patent No. 5,043,164 to Huang et al., and U.S. Patent No. 5,013,556 to Woodle et al., all of which are incorporated herein by reference in their entireties).

The size of the particle provides another means for targeting the particles of the invention to cells or tissues. For example, relatively small particles of the invention can be made to efficiently target ischemic tissue and tumor tissue, as described in U.S. Patent

35

No. 5,527,538, and U.S. Patent Nos. 5,019,369, 5,435,989 and 5,441,745, the contents of which are hereby incorporated by reference in their entirety.

The particles of the invention can be targeted according to the mode of administration. For example, lung or other respiratory epithelial tissue can be targeted by intranasal administration, cervical cells can be targeted by intravaginal administration, and prostate tumors can be targeted by intrarectal administration. Skin cancer can be targeted by topical administration. Depending on location, tumors can be targeted locally, such as by injection, into the tumor mass.

5

10

15

20

25

30

Particles of the invention can be targeted by incorporating a ligand such as an antibody, a receptor, or other compound known to target particles such as liposomes or other vesicles to various sites. The ligands can be attached to cationic lipids used to form the particles of the present invention, or to a neutral lipid such as cholesterol used to stabilize the particle. Ligands that are specific for one or more specific cellular receptor sites are attached to a particle to form a delivery vehicle that can be targeted with a high degree of specificity to a target cell population of interest.

Suitable ligands for use in the present invention include, but are not limited to, sugars, proteins such as antibodies, hormones, lectins, major histocompatibility complex (MHC), and oligonucleotides that bind to or interact with a specific site. An important criteria for selecting an appropriate ligand is that the ligand is specific and is suitably bound to the surface of the particles in a manner which preserves the specificity. For example, the ligand can be covalently linked to the lipids used to prepare the particles. Alternatively, the ligand can be covalently bound to cholesterol or another neutral lipid, where the ligand-modified cholesterol is used to stabilize the lipid monolayer or bilayer.

The terms "transfection" and "transformation" are used interchangeably herein to refer to the insertion of an exogenous polynucleotide into a host, irrespective of the method used for the insertion, the molecular form of the polynucleotide that is inserted, or the nature of the host (e.g., prokaryotic or eukaryotic). The insertion of a polynucleotide per se and the insertion of a plasmid or vector comprising the exogenous polynucleotide are included. The exogenous polynucleotide may be directly transcribed and translated by the host or host cell, maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be stably integrated into the host genome. The terms "administration"

36

and "treatment" are used herein interchangeably to refer to transfection of hosts *in vitro* or *in vivo*, using particles of the present invention.

The term "wild-type" (WT), as used herein, refers to the typical, most common or conventional form as it occurs in nature.

5

10

15

20

25

30

Thus, the present invention includes methods of gene therapy whereby polynucleotides encoding the desired gene product (an interferon, such as interferongamma, an IFN-inducible molecule, or both) are delivered to a subject, and the polynucleotide is expressed in vivo. The term "gene therapy", as used herein, includes the transfer of genetic material (e.g., polynucleotides) of interest into a host to treat or prevent a genetic or acquired disease or condition phenotype, or to otherwise express the genetic material such that the encoded product is produced within the host. The genetic material of interest can encode a product (e.g., a protein, polypeptide, peptide, or functional RNA) whose production in vivo is desired. For example, in addition to interferon and/or an IFN-inducible molecule, the genetic material can encode a hormone, receptor, enzyme, polypeptide or peptide, of therapeutic and/or diagnostic value. For a review see, in general, the text "Gene Therapy" (Advances in Pharmacology 40, Academic Press, 1997). The genetic material may encode a product normally found within the species of the intended host, or within a different species. For example, if the polynucleotide encodes interferon-gamma, the cytokine may be human interferongamma, or that of another mammal, for example, regardless of the intended host. Preferably, the polynucleotide encodes a product that is normally found in the species of the intended host. Alternatively, the genetic material may encode a novel product.

Two basic approaches to gene therapy have evolved: (1) ex vivo and (2) in vivo gene therapy. The methods of the subject invention encompass either or both. In ex vivo gene therapy, host cells are removed from a patient and, while being cultured, are treated in vitro. Generally, a functional replacement gene is introduced into the cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the host/patient.

In *in vivo* gene therapy, target host cells are not removed from the subject, rather the gene to be transferred is introduced into the cells of the recipient organism *in situ*, that

37

is within the recipient. Alternatively, if the host gene is defective, the gene is repaired *in situ*.

The particle of the present invention is capable of delivery/transfer of heterologous nucleic acid sequences into a prokaryotic or eukaryotic host cell *in vitro* or *in vivo*. The particle may include elements to control targeting, expression and transcription of the nucleic acid sequence in a cell selective manner as is known in the art. It should be noted that often the 5'UTR and/or 3'UTR of the gene may be replaced by the 5'UTR and/or 3'UTR of other expression vehicles.

5

10

15

20

25

30

Optionally, the particles of the invention may have biologically active agents other than polynucleotides as a component of the complex (either instead of, or in addition to, polynucleotides). Such biologically active agents include, but are not limited to, substances such as proteins, polypeptides, antibodies, antibody fragments, lipids, carbohydrates, and chemical compounds such as pharmaceuticals. The substances can be therapeutic agents, diagnostic materials, and/or research reagents.

The present invention includes pharmaceutical compositions comprising an effective amount of particles of the invention and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the subject invention can be formulated according to known methods for preparing pharmaceutically useful compositions. As used herein, the phrase "pharmaceutically acceptable carrier" means any of the standard pharmaceutically acceptable carriers. The pharmaceutically acceptable carrier can include diluents, adjuvants, and vehicles, as well as implant carriers, and inert, non-toxic solid or liquid fillers, diluents, or encapsulating material that does not react with the active ingredients of the invention. Examples include, but are not limited to, phosphate buffered saline, physiological saline, water, and emulsions, such as oil/water emulsions. The carrier can be a solvent or dispersing medium containing, for example, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

The pharmaceutically acceptable carrier can be one adapted for a particular route of administration. For example, if the particles of the present invention are intended to be administered to the respiratory epithelium, a carrier appropriate for oral or intranasal administration can be used.

38

Formulations containing carriers are described in a number of sources which are well known and readily available to those skilled in the art. For example, Remington's Pharmaceutical Sciences (Martin E.W., 1995, Easton Pennsylvania, Mack Publishing Company, 19th ed.) describes formulations which can be used in connection with the subject invention. Formulations suitable for parenteral administration include, for example, aqueous sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and nonaqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unitdose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the condition of the sterile liquid carrier, for example, water for injections, prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powder, granules, tablets, etc. It should be understood that in addition to the ingredients particularly mentioned above, the formulations of the subject invention can include other agents conventional in the art having regard to the type of formulation in question.

5

10

15

20

25

30

As used herein, the terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, e.g., hepatic carcinoma, bladder cancer, colorectal cancer, endometrial carcinoma, kidney cancer, and thyroid cancer.

Other non-limiting examples of cancers are basal cell carcinoma, biliary tract cancer; bone cancer; brain and CNS cancer; choriocarcinoma; connective tissue cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intraepithelial neoplasm; larynx cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; melanoma; myeloma; neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); peritoneal cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular

39

cancer; uterine cancer; cancer of the urinary system, as well as other carcinomas and sarcomas.

5

10

15

20

25

30

As used herein, the term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. For example, a particular cancer may be characterized by a solid mass tumor. The solid tumor mass, if present, may be a primary tumor mass. A primary tumor mass refers to a growth of cancer cells in a tissue resulting from the transformation of a normal cell of that tissue. In most cases, the primary tumor mass is identified by the presence of a cyst, which can be found through visual or palpation methods, or by irregularity in shape, texture or weight of the tissue. However, some primary tumors are not palpable and can be detected only through medical imaging techniques such as X-rays (e.g., mammography), or by needle aspirations. The use of these latter techniques is more common in early detection. Molecular and phenotypic analysis of cancer cells within a tissue will usually confirm if the cancer is endogenous to the tissue or if the lesion is due to metastasis from another site.

As used herein, the term "metastasis" refers to the process by which cancer cells are spread to distant parts of the body, such as from one organ and/or tissue to another not directly connected with it. The term is also used herein to refer to a tumor that develops through the metastatic process. Thus, as used herein, the term "metastasis" refers to neoplastic cell growth (e.g., tumor cell growth) in an unregulated fashion and spread to distal tissues and organs of the body. As used herein, the phrase "inhibiting metastasis" refers to the particles slowing and/or preventing metastasis or the spread of neoplastic cells to a site remote from the primary growth area.

The term "anti-cancer activity", in reference to the particles of the invention, is intended to mean an activity which is able to substantially inhibit, slow, interfere, suppress, prevent, delay and/or arrest a cancer and/or a metastasis thereof (such as initiation, growth, spread, and/or progression thereof of such cancer and/or metastasis).

As used herein, the term "growth inhibitory amount" refers to an amount which inhibits growth of a target cell, such as a tumor cell, either *in vitro* or *in vivo*, irrespective of the mechanism by which cell growth is inhibited. In a preferred embodiment, the growth inhibitory amount inhibits growth of the target cell in cell culture by greater than

40

about 20%, preferably greater than about 50%, most preferably greater than about 75% (e.g., from about 75% to about 100%).

The therapeutic methods of the invention can be advantageously combined with at least one additional therapeutic technique, including but not limited to chemotherapy, radiation therapy, surgery (e.g., surgical excision of cancerous or pre-cancerous cells), or any other therapy known to those of skill in the art of the treatment and management of cancer, such as administration of an anti-cancer agent.

5

10

15

20

25

30

As used herein, the term "anti-cancer agent" refers to a substance or treatment that inhibits the function of cancer cells, inhibits their formation, and/or causes their destruction *in vitro* or *in vivo*. Examples include, but are not limited to, cytotoxic agents (e.g., 5-fluorouracil, TAXOL) and anti-signaling agents (e.g., the PI3K inhibitor LY).

As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells *in vitro* and/or *in vivo*. The term is intended to include radioactive isotopes (*e.g.*, At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², and radioactive isotopes of Lu), chemotherapeutic agents, toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, and antibodies, including fragments and/or variants thereof.

As used herein, the term "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer, such as, for example, taxanes, e.g., paclitaxel (TAXOL, BRISTOL-MYERS SQUIBB Oncology, Princeton, N.J.) and doxetaxel (TAXOTERE, Rhone-Poulenc Rorer, Antony, France), chlorambucil, vincristine, vinblastine, antiestrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston), and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, etc.

As used herein, the term "anti-signaling agent" refers to agents that interfere with cancer cell malignancy by inhibiting specific aberrant signal transduction circuits in the cell *in vitro* and/or *in vivo*. The PI3K inhibitor LY is an example of an anti-signalling agent.

The terms "comprising", "consisting of" and "consisting essentially of" are defined according to their standard meaning. The terms may be substituted for one

41

another throughout the instant application in order to attach the specific meaning associated with each term.

As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a particle" includes more than one such particle, a reference to "a polynucleotide" includes more than one such polynucleotide, a reference to "a polypeptide" includes more than one such polypeptide, a reference to "a host cell" includes more than one such host cell, a reference to an interferon or IFN-inducible molecule includes more than one such interferon or IFN-inducible molecule, and so forth.

5

10

15

20

25

Standard molecular biology techniques known in the art and not specifically described were generally followed as in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York (1989), and in Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989) and in Perbal, A Practical Guide to Molecular Cloning, John Wiley & Sons, New York (1988), and in Watson *et al.*, Recombinant DNA, Scientific American Books, New York and in Birren *et al.* (eds) Genome Analysis: A Laboratory Manual Series, Vols. 1-4 Cold Spring Harbor Laboratory Press, New York (1998) and methodology as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659; and 5,272,057; and incorporated herein by reference. Polymerase chain reaction (PCR) was carried out generally as in PCR Protocols: A Guide To Methods And Applications, Academic Press, San Diego, Calif. (1990). *In situ* (In-cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni *et al.*, *Blood*, 1996, 87:3822).

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

30 Example 1—pIFN-y induces apoptosis of HEp-2 carcinoma cells

To determine the effect of overexpression of pIFN-γ on proliferation of A549 lung epithelial cells, cells were transfected with either pIFN-γ or empty vector, pVAX

42

(control). Cell cycle analysis was performed using propidium iodide (PI) staining and flow cytometry 48 hours after transfection. No significant difference was observed between control and pIFN-γ-transfected cells in S1, Go-G1 and G2-M stages of the cell cycle (data not shown). However, an analysis of apoptosis using fluorescence microscopy cells transfected with pIFN-γ exhibited significantly higher apoptosis compared to cells transfected with either the control plasmid or a plasmid encoding pVAX (shown in Figure 1).

Cells were seeded into 4-well slide dishes at 104 cells per well and allowed to grow to 75% confluency. Cells were treated for 20 hours with 1000 U/ml IFN-γ. After 24 hours, cells were fixed with 4% paraformaldehyde in PBS for 25 minutes at 4°C and then permeabilized. Apoptotic cells were identified using a fluorescein-based, terminal nucleotidyl end-labeling kit (PROMEGA TUNEL Apoptosis Assay) that adds fluorescein conjugated dUTP to the 3'-hydroxyl ends of DNA fragments arising from apoptosis. After the reaction, the cells were rinsed in 2x saline citrate buffer and the nuclei were stained with DAPI. Stained cells were examined by immuno-fluorescence microscopy to determine the extent of apoptosis.

Figure 2 demonstrates the detection of p27kip expression and PARP cleavage in IFN-gamma treated HEp-2 cells. Total cell extracts of HEp-2 cells (1x10⁶) treated as above were prepared after 24 and 48 hours of treatment and proteins were subjected to SDS-PAGE and western blotting was done with a monoclonal antibody to p27kip1 (A) or an antibody to PARP (B). The lanes are as follows: 1) Untreated cells, 2) IFN-gamma 100u/ml, 3) IFN-gamma 1000u/ml, 4) IFN-beta 100u/ml, 5) IFN-beta 1000u/ml, 6) untreated cells, 7) IFN-gamma 100u/ml, 8) IFN-gamma 1000u/ml, 9) IFN-beta 100u/ml, and 10) IFN-beta 1000u/ml.

The apoptosis was confirmed by analysis of PARP cleavage in these cells 48 hours after transfection, which was significantly more prominent in pIFN- γ transfected cells (Figure 2). Thus, pIFN- γ induces apoptosis of lung adenocarcinoma cells. Together, these studies indicate that pIFN- γ is an inducer of apoptosis in A549 lung adenocarcinoma cells.

5

10

15

20

43

Example 2—Microarray analysis of Chitosan -pIFNgamma treated lungs

Using MU11KsubA and B chips (Affymetrix), which contain probes interrogating about 11,000 murine genes and ESTs (Unigene, Build-4), as well as EST clusters from TIGR (1.0 Beta), we have identified a total of 126 differentially expressed genes whose expression level is altered in the CIN treated mouse lung in the range of –10.6- to 152.4-fold. A noteworthy observation is the up-regulation of the expression of a number of IFN-inducible genes, immune response related genes, and genes involved in signal transduction, including STAT1 and STAT4.

10 Table 1. GENE EXPRESSION ANALYSIS IN BALB/c LUNG BY MICROARRAY

Category of Genes	Max. Fold	Genes						
	Change							
IFN-regulated	12	IFN-induced 15 KDa protein, IFN-activable protein 204, Eukaryotic initiation factor 5, Mx protein, MIG, IP-10, Interferon regulatory factor (mirf7), interferonactivatable protein, IFN-induced protein 6-16 precursor, IFN-induced guanylate-binding protein, HLA- associated protein i (phapi) 2'-5' oilgo A synthetase						
Immune-related	8.4	T-cell specific protein, RegIII gamma protein, MHC class II, MIP, Down regulatory protein (rpt-1r) of interlukin-2, T-cell receptor alpha-chain precursor, Immune-responsive gene 1 (Irg1), High affinity IgG receptor, MHC, class III antigene factor B, MEL-14, Lymphotoxin-beta, C-11, Rantes, MAMA Serine protease, Proteasome subunit (Imp7)						
Signal transduction	10.8*	PDGF, GTPase IGTP, Glucocorticoid-attenuated response gene 16, Stat1, purine nucleotide binding protein, G-protein-like LRG-47, ras-related protein ora2, GTP binding protein (IRG-47), Stat 4, cathespin s precursor, Oct binding factor 1 (OBF-1), FYN binding protein, High mobility group 2						

The RNA was isolated from BALB/c lungs following 5 days of CIN treatment. The mouse chips A and B, a total of 11,000 genes, were scanned. The asterisk indicates the fold increase was uncertain, as no expression was observed in control lungs. The genes are listed in no particular order.

44

Example 3—Chitosan-conjugated pIFN-γ plasmid prevents metastasis of lung tumors in nude mice

BALB/c nude mice were injected intravenously with 5 X 10⁶ A549 cells, then treated one day afterwards and at weekly intervals with pIFN-γ or control plasmid. After 4 weeks, mice were examined for lung histology. The control animals showed tumors, whereas no tumors were seen in the pIFN-γ-treated group (Figure 3). These results indicate that pIFN-γ has the potential to decrease tumor metastasis.

5

10

15

20

25

30

The results indicated in Figure 3 were obtained when BALB/c nude mice were injected with A549 cells (5 x 10⁶ cells/mouse) intravenously and one group treated with pIFN-gamma and another group with pVAX as control. The lungs of control mice showed numerous lung nodules in contrast to mice treated with pIFN-gamma, which showed very few tumors. The lungs were removed from mice treated with nanoparticles carrying empty plasmid pVAX (control) or with pIFN-gamma (Rx) and H & E stained. The lungs of control mice showed numerous lung nodules with typical tumor cell morphology in contrast to mice treated with pIFN-gamma, which showed very few tumors.

Example 4—Development of thermogel from modified chitosan that provides sustained release

Using depolymerization methods, four novel chitosan derivative was synthesized. The products were separated by capillary gel electrophoresis. The plot shows the separation of 2 low molecular weight components (Figure 4A). Nanogene-042(NG042) is a unique low molecular weight chitosan-based carrier, which has a particle size of 155 nm (major peak, with some aggregates at 335 nm), a zeta potential of about +20 mV with typical oligomeric structure, as identified by atomic force microscopy, and significant heat-stable properties for gene transfer, with both *in vitro* and *in vivo* expression (Figures 4B and 4C). Lyophilzed and resuspended NG042 particles retain functionality at ambient temperatures of 23° to 55° C. Nanogene complexes of pGL3 (firefly luciferase, Promega) was lyophilized, reconstituted with water and treated for 24 hours at RT (23° C), 42° C, 55° C, and -20° C. A549 cells were plated and transfected with the above complexes. Uptake and expression of DNA was allowed to occur for 24 hours. Luciferase activity

45

was determined by using Promega's Dual Assay kit. Readings were normalized to relative luminiscence units (RLU) per mg protein.

Another carrier, Nanogene-044 (NG044), is soluble in water and supports sustained gene expression *in vivo* (Figure 5A). It also exhibits thermo-gelling properties, *i.e.*, it is liquid at room temperature and forms a gel at temperatures above 37°C (Figure 5B). NG045 is a 1000-dalton oligomeric chitosan that is water soluble and shows sustained drug delivery following

5

10

15

20

25

30

NG044 was found to form a gel upon reacting with 2-glycerol phosphate, while NG042, another depolymerized chitosan does not.

To establish length of gene expression, Nanogene 044 (NG044) particles were complexed with DNA (5:1) encoding green fluorescent protein and a hydrogel was formed. The hydrogel was administered intranasally to groups of mice (n=4). Mice were sacrificed on the indicated days and broncho-alveolar lavage cells were examined by fluorescent microscopy. Another group received NG044 with pEGFP without gelling (Control). Gene expression in the mouse lung was measured by EGFP expression in BAL cells 10 and 20 days after administration. The results at day 10 were similar (not shown) for control and hydrogel, whereas after 20 days, mice given hydrogel continued EGFP show expression and no expression was detected in control mice.

Overall, the notion of intranasal chitosan nanoparticles carrying pIFN- γ for the treatment of cancer is based on the preliminary results that pIFN- γ may induce epithelial cell production of NO, which is known to possess anti-tumor effects, apoptosis of carcinoma cells, and abrogation of lung nodule formation in a murine model of lung metastasis. It will be seen that the objects set forth above, and those made apparent from the foregoing description, are efficiently attained and since certain changes may be made in the above construction without departing from the scope of the invention, it is intended that all matters contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All patents, patent applications, provisional applications, and publications (including information associated with sequence accession numbers) referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

46

CLAIMS

I claim:

- 1. A method for treating a cell proliferation disorder in a subject, comprising administering a therapeutically effective amount of particles to the subject, wherein the particles comprise: a polynucleotide encoding an interferon, an interferon-inducible molecule, or both; and a chitin-containing component associated with the polynucleotide, wherein the polynucleotide is expressed in the subject and cell proliferation is reduced.
- 2. The method of claim 1, wherein the interferon is selected from the group consisting of alpha interferon, beta interferon, gamma interferon, omega interferon, and lambda interferon, or a biologically active fragment or derivative thereof.
 - 3. The method of claim 1, wherein the interferon is gamma interferon.
 - 4. The method of claim 1, wherein the interferon is a hybrid interferon.
- 5. The method of claim 1, wherein the interferon inducible molecule comprises interferon regulatory factor-1 (IRF-1).
- 6. The method of claim 1, wherein the interferon-inducible molecule comprises 2'-5' oligoadenylate synthetase, interferon regulatory factor-1 (IRF-1), or both.
- 7. The method of claim 1, wherein the interferon-inducible molecule comprises a catalytically active subunit of 2'-5' oligoadenylate synthetase selected from the group consisting of p40, p69, and p100 subunit.
- 8. The method of claim 1, wherein the 2'-5' oligoadenylate synthetase comprises at least one splice variant selected from the group consisting of 40kDa, 42kDa, 46kDa, 69 kDa, and 71 kDa.

- 9. The method of claim 1, wherein the chitin-containing component comprises chitosan or a chitosan derivative.
- 10. The method of claim 1, wherein the particles further comprise a lipid component associated with the chitin-containing component and the polynucleotide.
- 11. The method of claim 1, wherein the cell proliferation disorder is a cancer of the respiratory tract.
 - 12. The method of claim 1, wherein the cell proliferation disorder is lung cancer.
- 13. The method of claim 1, wherein the particles are administered to the subject via a mucosal route.
- 14. The method of claim 1, wherein the particles are administered to the subject intranasally.
- 15. The method of claim 1, wherein the particles are administered to the subject as a spray, drops, powder, gel, or a combination of two or more of the foregoing.
 - 16. The method of claim 1, wherein the subject is human.
- 17. The method of claim 1, wherein the subject is suffering from a cell proliferation disorder.
- 18. The method of claim 1, wherein the subject has been diagnosed with the cell proliferation disorder prior to said administering.
- 19. A method of inducing apoptosis in a cancer cell, comprising contacting a target cancer cell *in vitro* or *in vivo* with an effective amount of particles comprising: a polynucleotide encoding an interferon, an interferon-inducible molecule, or both; and a

48

chitin-containing component associated with the polynucleotide, wherein the polynucleotide is expressed in the cancer cell and apoptosis is induced.

- 20. The method of claim 19, wherein the interferon is selected from the group consisting of alpha interferon, beta interferon, gamma interferon, omega interferon, and lambda interferon, or a biologically active fragment or derivative thereof.
- 21. The method of claim 19, wherein the interferon-inducible molecule comprises 2'-5' oligoadenylate synthetase, interferon regulatory factor-1 (IRF-1), or both.
- 22. The method of claim 19, wherein the cancer cell is a respiratory epithelial cell.
- 23. A particle comprising a polynucleotide encoding an interferon, an interferoninducible molecule, or both; and a chitin-containing component associated with the polynucleotide.
- 24. The particle of claim 23, wherein said chitin-containing component comprises chitosan or a chitosan derivative.
- 25. The particle of claim 23, wherein said particle further comprises a lipid component associated with the chitin-containing component and the polynucleotide.
- 26. The particle of claim 23, wherein said particle comprises a polynucleotide encoding said interferon and said interferon-inducible molecule.
- 27. The particle of claim 23, wherein said particle comprises a polynucleotide encoding said interferon and 2'-5' oligoadenylate synthetase.
- 28. The particle of claim 23, wherein said particle comprises a polynucleotide encoding said interferon and interferon regulatory factor-1 (IRF-1).

- 29. The particle of claim 23, wherein said particle comprises a polynucleotide encoding 2'-5' oligoadenylate synthetase and interferon regulatory factor-1 (IRF-1).
- 30. The particle of claim 23, wherein said particle comprises a polynucleotide encoding said interferon, 2'-5' oligoadenylate synthetase, and interferon regulatory factor-1 (IRF-1).
- 31. The particle of claim 23, wherein said polynucleotide comprises one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, and 31.

1/9




FIG. 1




FIG. 2




FIG. 3




FIG. 4A




FIG. 4B

5/9

AFM analysis




FIG. 4C




FIG. 4D




FIG. 5A

8/9

Thermogelling




FIG. 5B




FIG. 5C

1

SEQUENCE LISTING

```
<110> University of South Florida
       Mohapatra, Shyam
<120> Nanogene Therapy For Cell Proliferation Disorders
<130> USF-216PTCZ
<150> 60/565,756
<151> 2004-04-27
<160> 31
<170> PatentIn version 3.3
<210> 1
<211> 1203
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)..(1203)
<300>
<301> Aissouni, Y., et al.
<302> The cleavage/polyadenylation activity triggered by a U-rich motif
        sequence
<303> J. Biol. Chem.
<304> 277
<304> 277
<305> 39
<306> 35808-35814
<307> 2002
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Behera, A.K., et al. <302> 2'-5' Oligoadenylate synthesis plays a critical role in
        interferon-gamma inhibition
<303> J. Biol. Chem. <304> 277
<305> 28
<306> 25601-25608
<307> 2002
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Sarker, S.N., et al.
<302> Identification of the substrate-binding sites of
       2'-5'-oligoadenylate synthetase
<303> J. Biol. Chem.
<304> 277
<305> 27
<306> 24321-24330
<307> 2002
```

```
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Hovnanian, A., et al.
<302> The human 2',5'-oligoadenylate synthetase locus is composed of
      three distinct genes
<303> Genomics
<304> 52
<305> 3
<306> 267-277
<307> 1998
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Renault, B., et al.
<302> A sequence-ready physical map of a region of 12q24.1
<303> Genomics
<304> 45
<305> 2
<306> 271-278
<307> 1997
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Nechiporuk, T., et al.
<302> A high-resolution PAC and BAC map of the SCA2 region
<303> Genomics
<304> 44
<305> 3
<306> 321-329
<307> 1997
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Wathelet, M.G., et al.
<302> Cloning and chromosomal location of human genes inducible by type
       I interferon
<303> Somat. Cell Mol. Genet.
<304> 14
<305> 5
<306> 415-426
<307> 1988
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Rutherford, M.N., et al.
<302> Interferon-induced binding of nuclear factors to promoter
      elements of the 2-5A synthetase gene
<303> EMBO J.
<304> 7
<305> 3
<306> 751-759
<307> 1988
<308> NCBI/NM_016816
```

```
<309> 2003-04-06
<300>
<301> Wathelet, M.G., et al.
<302> New inducers revealed by the promoter sequence analysis of two
       interferon-activated human genes
<303> Eur. J. Biochem.
<304> 169
<305> 2
<306> 313-321
<307> 1987
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Benech, P., et al.
<302> Interferon-responsive regulatory elements in the promoter of the
       human 2',5'-oligo(A) synthetase gene
<303> Mol. Cell. Biol.
<304> 7
<305> 12
<306> 4498-4504
<307> 1987
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<300>
<301> Hovanessian, A.G., et al.
<302> Identification of 69-kd and 100-kd forms of 2-5A synthetase
<303> EMBO J.
<304> 6
<305> 5
<306> 1273-1280
<307> 1987
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Williams, B.R., et al.
<302> Interferon-regulated human 2-5A synthetase gene maps to
       chromosome
<303> Somat. Cell Mol. Genet.
<304> 12
<305> 4
<306> 403-408
<307> 1986
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Shiojiri, S., et al.
<302> Structure and expression of a cloned cDNA for human (2'~5')
       oligoadenylate synthetase
<303> J. Biochem.
<304> 99
<305> 5
<306> 1455-1464
<307> 1986
<308> NCBI/NM 016816
```

```
<309> 2003-04-06
<300>
<301> Wathelet, M., et al.
<302> Full-length sequence and expression of the 42 kDa 2-5A synthetase
<303> FEBS Lett.
<304> 196
<305> 1
<306> 113-120
<307> 1986
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Benech, P., et al.
<302> Structure of two forms of the interferon-induced (2'-5') oligo A
      synthetase of human cells
<303> EMBO J.
<304> 4
<305> 9
<306> 2249-2256
<307> 1985
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Saunders, M.E., et al.
<302> Human 2-5A synthetase: characterization of a novel cDNA and
       corresponding gene structure
<303> EMBO J.
<304> 4
<305> 7
<306> 1761-1768
<307> 1985
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Merlin, G., et al.
<302> Molecular cloning and sequence of partial cDNA for
       interferon-induced (2'-5')oligo(A_ synthetase mRNA from human
       cells
<303> Proc. Natl. Acad. Sci. U.S.A. <304> 80
<305> 16
<306> 4904-4908
<307> 1983
<308> NCBI/NM_016816
<309> 2003-04-06
<400> 1
atg atg gat ctc aga aat acc cca gcc aaa tct ctg gac aag ttc att
                                                                         48
Met Met Asp Leu Arg Asn Thr Pro Ala Lys Ser Leu Asp Lys Phe Ile
gaa gac tat ctc ttg cca gac acg tgt ttc cgc atg caa atc gac cat
                                                                        96
Glu Asp Tyr Leu Leu Pro Asp Thr Cys Phe Arg Met Gln Ile Asp His
                                 25
                                                      30
```

_		_			tgt Cys			_	_	_		_	_		144
					tgt Cys										192
					ctc Leu 70										240
		_			acc Thr			_	_	_			 		288
					att Ile										33 <i>6</i>
				_	aag Lys		_	_							384
	_			_	ttc Phe	_	_	_	_		_		 		432
_	_				ctg Leu 150										480
	-				aac Asn										528
_		_	_	_	aaa Lys									_	576
					ctg Leu										624
	_		_		cac His							_			672
					tat Tyr 230										720
	_		_	_	aaa Lys						_				768
					gtc Val										816

aca aag tat Thr Lys Tyr 275			_	_	5 5	864
agg cag ctc Arg Gln Leu 290			Ile Leu A			912
aca gga aac Thr Gly Asn 305						960
caa gag gct Gln Glu Ala						800
ggg tcc cca Gly Ser Pro					_	056
gac gat gag Asp Asp Glu 355			_			104
gga aca cat Gly Thr His 370			His Arg P		-	152
gca gca tcc Ala Ala Ser 385	_					200
tga					12	203
<210> 2						
<211> 400 <212> PRT	sapiens					
<400> 2						
Met Met Asp 1	Leu Arg Asn 5	Thr Pro Ala	Lys Ser Le	eu Asp Lys	Phe Ile 15	
Glu Asp Tyr	Leu Leu Pro 20	Asp Thr Cys 25	Phe Arg Me	et Gln Ile 30	Asp His	
Ala Ile Asp :	Ile Ile Cys	Gly Phe Leu 40	Lys Glu A	rg Cys Phe 45	Arg Gly	
Ser Ser Tyr :	Pro Val Cys	Val Ser Lys 55	Val Val Ly		Ser Ser	

Gly 65	Lys	Gly	Thr	Thr	Leu 70	Arg	Gly	Arg	Ser	Asp 75	Ala	Asp	Leu	Val	Val 80

- Phe Leu Ser Pro Leu Thr Thr Phe Gln Asp Gln Leu Asn Arg Arg Gly 85 90 95
- Glu Phe Ile Gln Glu Ile Arg Arg Gln Leu Glu Ala Cys Gln Arg Glu 100 105 110
- Arg Ala Leu Ser Val Lys Phe Glu Val Gln Ala Pro Arg Trp Gly Asn 115 120 125
- Pro Arg Ala Leu Ser Phe Val Leu Ser Ser Leu Gln Leu Gly Glu Gly 130 135 140
- Val Glu Phe Asp Val Leu Pro Ala Phe Asp Ala Leu Gly Gln Leu Thr 145 150 155 160
- Gly Ser Tyr Lys Pro Asn Pro Gln Ile Tyr Val Lys Leu Ile Glu Glu 165 170 175
- Cys Thr Asp Leu Gln Lys Glu Gly Glu Phe Ser Thr Cys Phe Thr Glu 180 185 190
- Leu Gln Arg Asp Phe Leu Lys Gln Arg Pro Thr Lys Leu Lys Ser Leu 195 200 205
- Ile Arg Leu Val Lys His Trp Tyr Gln Asn Cys Lys Lys Leu Gly 210 215 220
- Lys Leu Pro Pro Gln Tyr Ala Leu Glu Leu Leu Thr Val Tyr Ala Trp 225 230 235 240
- Glu Arg Gly Ser Met Lys Thr His Phe Asn Thr Ala Gln Gly Phe Arg 245 250 255
- Thr Val Leu Glu Leu Val Ile Asn Tyr Gln Gln Leu Cys Ile Tyr Trp 260 265 270
- Thr Lys Tyr Tyr Asp Phe Lys Asn Pro Ile Ile Glu Lys Tyr Leu Arg 275 280 285
- Arg Gln Leu Thr Lys Pro Arg Pro Val Ile Leu Asp Pro Ala Asp Pro 290 295 300

8

Thr Gly Asn Leu Gly Gly Gly Asp Pro Lys Gly Trp Arg Gln Leu Ala Gln Glu Ala Glu Ala Trp Leu Asn Tyr Pro Cys Phe Lys Asn Trp Asp 325 330 Gly Ser Pro Val Ser Ser Trp Ile Leu Leu Ala Glu Ser Asn Ser Thr 340 345 Asp Asp Glu Thr Asp Asp Pro Arg Thr Tyr Gln Lys Tyr Gly Tyr Ile 360 Gly Thr His Glu Tyr Pro His Phe Ser His Arg Pro Ser Thr Leu Gln 375 Ala Ala Ser Thr Pro Gln Ala Glu Glu Asp Trp Thr Cys Thr Ile Leu 390 395 <210> 3 <211> 1207 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (1)..(1206) <300> <301> Benech et al. <302> Structure of two forms of the interferon-induced (2'-5') oligo A synthetase human cells based on cDNAs and gene sequences <303> EMBO J. <304> 4 <305> 9 <306> 2249-2256 <307> 1985 <308> NM_016816 <309> 2003-04-06 <400> 3 atg atg gat ctc aga aat acc cca gcc aaa tct ctg gac aag ttc att 48 Met Met Asp Leu Arg Asn Thr Pro Ala Lys Ser Leu Asp Lys Phe Ile gaa gac tat ctc ttg cca gac acg tgt ttc cgc atg caa atc gac cat 96 Glu Asp Tyr Leu Leu Pro Asp Thr Cys Phe Arg Met Gln Ile Asp His 20 gcc att gac atc atc tgt ggg ttc ctg aag gaa agg tgc ttc cga ggt 144 Ala Ile Asp Ile Ile Cys Gly Phe Leu Lys Glu Arg Cys Phe Arg Gly

9

WO 2005/105136 PCT/US2005/014626

										ggt Gly			192
										gac Asp			240
							_			aat Asn		_	288
			_			_				tgt Cys			336
										cgc Arg 125			384
	_		_	_	_	_	_		_	ctc Leu	 		432
										ggt Gly			480
	_								_	ctc Leu			528
										tgc Cys			576
										ctc Leu 205			624
										aag Lys			672
_	_		_	_	_			_	_	gtc Val	_		720
										caa Gln			768
										tgc Cys			816
	_		_						_	aag Lys	_		864

10

275		280	285		
agg cag ctc acg Arg Gln Leu Thr 290					912
aca gga aac ttg Thr Gly Asn Leu 305		_			960
caa gag gct gag Gln Glu Ala Glu			Cys Phe Lys		1008
ggg tcc cca gtg Gly Ser Pro Val 340	Ser Ser Trp				1056
gac gat gag acc Asp Asp Glu Thr 355					1104
gga aca cat gag Gly Thr His Glu 370					1152
gca gca tcc acc Ala Ala Ser Thr 385					1200
tga atg c Met					1207
<210> 4 <211> 400 <212> PRT <213> Homo sap	iens				
<400> 4					
Met Met Asp Leu 1	Arg Asn Thr 5	Pro Ala Lys 10	Ser Leu Asp	Lys Phe Ile 15	
Glu Asp Tyr Leu 20	Leu Pro Asp	Thr Cys Phe 25	Arg Met Gln	Ile Asp His	
Ala Ile Asp Ile 35	Ile Cys Gly	Phe Leu Lys 40	Glu Arg Cys 45	Phe Arg Gly	
Ser Ser Tyr Pro 50	Val Cys Val 55	Ser Lys Val	Val Lys Gly 60	Gly Ser Ser	

Gly Lys Gly Thr Thr Leu Arg Gly Arg Ser Asp Ala Asp Leu Val Val

65	5									75					
Phe	Leu	Ser	Pro	Leu 85	Thr	Thr	Phe	Gln	Asp 90	Gln	Leu	Asn	Arg	Arg 95	Gly
Glu	Phe	Ile	Gln 100	Glu	Ile	Arg	Arg	Gln 105	Leu	Glu	Ala	Cys	Gln 110	Arg	Glu
Arg	Ala	Leu 115	Ser	Val	Lys	Phe	Glu 120	Val	Gln	Ala	Pro	Arg 125	Trp	Gly	Asn
Pro	Arg 130	Ala	Leu	Ser	Phe	Val 135	Leu	Ser	Ser	Leu	Gln 140	Leu	Gly	Glu	Gly
Val 145	Glu	Phe	Asp	Val	Leu 150	Pro	Ala	Phe	Asp	Ala 155	Leu	Gly	Gln	Leu	Thr 160
Gly	Ser	Tyr	Lys	Pro 165	Asn	Pro	Gln	Ile	Tyr 170	Val	Lys	Leu	Ile	Glu 175	Glu
Cys	Thr	Asp	Leu 180	Gln	Lys	Glu	Gly	Glu 185	Phe	Ser	Thr	Cys	Phe 190	Thr	Glu
Leu	Gln	Arg 195	Asp	Phe	Leu	Lys	Gln 200	Arg	Pro	Thr	Lys	Leu 205	Lys	Ser	Leu
Ile	Arg 210	Leu	Val	Lys	His	Trp 215	Tyr	Gln	Asn	Cys	Lys 220	Lys	Lys	Leu	Gly
Lys 225	Leu	Pro	Pro	Gln	Tyr 230	Ala	Leu	Glu	Leu	Leu 235	Thr	Val	Tyr	Ala	Trp 240
Glu	Arg	Gly	Ser	Met 245	Lys	Thr	His	Phe	Asn 250	Thr	Ala	Gln	Gly	Phe 255	Arg
Thr	Val	Leu	Glu 260	Leu	Val	Ile	Asn	Tyr 265	Gln	Gln	Leu	Cys	Ile 270	Tyr	Trp
Thr	Lys	Tyr 275	Tyr	Asp	Phe	Lys	Asn 280	Pro	Ile	Ile	Glu	Lys 285	Tyr	Leu	Arg
Arg	Gln 290	Leu	Thr	Lys	Pro	Arg 295	Pro	Val	Ile	Leu	Asp 300	Pro	Ala	Asp	Pro

12

Thr Gly Asn Leu Gly Gly Gly Asp Pro Lys Gly Trp Arg Gln Leu Ala 305 310 Gln Glu Ala Glu Ala Trp Leu Asn Tyr Pro Cys Phe Lys Asn Trp Asp Gly Ser Pro Val Ser Ser Trp Ile Leu Leu Ala Glu Ser Asn Ser Thr Asp Asp Glu Thr Asp Asp Pro Arg Thr Tyr Gln Lys Tyr Gly Tyr Ile Gly Thr His Glu Tyr Pro His Phe Ser His Arg Pro Ser Thr Leu Gln 375 Ala Ala Ser Thr Pro Gln Ala Glu Glu Asp Trp Thr Cys Thr Ile Leu 390 395 <210> 5 <211> 2064 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (1)..(2064) <300> <301> Hovnanian, A., et al. <302> The human 2', 5'-oligoadenylate synthetase locus is comosed of three distinct genes <303> Genomics <304> 52 <304> 52 <305> 3 <306> 267-277 <307> 1998 <308> NCBI/NM_002535 <309> 2003-04-03 <300> <301> Marie, I. and Hovanessian, A.G. <302> The 69-kDa 2-5A synthetase is composed of two homologous and adjacent functional domains <303> J. Biol. Chem. <304> 267 <305> 14 <306> 9933-9939 <307> 1992 <308> NCBI/NM 002535 <309> 2003-04-03

<300>

```
<301> Marie, I., et al.
<302> Differential expression and distinct structure of 69- and 100-kDa
        forms of 2-5A synthetase
<303> J. Biol. Chem.
<304> 265
<305> 30
<306> 18601-18607
<307> . 1990
<308> NCBI/NM 002535
<309> 2003-04-03
<300>
<301> Marie, I., et al.
<302> Preparation and characterization of polyclonal antibodies
       specific for the 69 and 100 k-dalton forms of human 2-5A
       synthetase
<303> Biochem. Biophys. Res. Commun.
<304> 160
<305> 2
<306> 580~587
<307> 1989
<308> NCBI/NM_002535
<309> 2003-04-03
<300>
<301> Hovanessian, A.G., et al.
<302> Characterization of 69- and 100-kDa forms of 2-5A-synthetase from
       interferon-treated human cells
<303> J. Biol. Chem.
<304> 263
<305> 10
<306> 4959
<307> 1988
<308> NCBI/NM_002535
<309> 2003-04-03
<300>
<301> Hovanessian, A.G., et al.
<302> Identification of 69-kd and 100-kd forms of 2-5A synthesase
<303> EMBO J.
<304> 6
<305> 5
<306> 1273-1280
<307> 1987
<308> NCBI/NM_002535
<309> 2003-04-03
<400> 5
atg gga aat ggg gag tcc cag ctg tcc tcg gtg cct gct cag aag ctg
                                                                          48
Met Gly Asn Gly Glu Ser Gln Leu Ser Ser Val Pro Ala Gln Lys Leu
                 5
                                                                          96
ggt tgg ttt atc cag gaa tac ctg aag ccc tac gaa gaa tgt cag aca
Gly Trp Phe Ile Gln Glu Tyr Leu Lys Pro Tyr Glu Glu Cys Gln Thr
             20
ctg atc gac gag atg gtg aac acc atc tgt gac gtc tgc agg aac ccc
                                                                         144
Leu Ile Asp Glu Met Val Asn Thr Ile Cys Asp Val Cys Arg Asn Pro
        35
                                                   45
```

					gga Gly							192
		_	_		aac Asn							240
					cag Gln							288
					aag Lys							336
 _					atc Ile 120	_	_		_			384
					cag Gln							432
					aat Asn							480
					gat Asp							528
_	_	_		_	ctc Leu							576
					atc Ile 200							624
					gat Asp							672
					gcc Ala							720
					gtc Val							768
					tat Tyr							816
					ctg Leu							864

	275					280					285					
cca gta Pro Val 290	. Ile	_	_		_	_						_		_		912
aaa ata Lys Ile 305																960
tct ccc Ser Pro																1008
cct gca Pro Ala				_							_					1056
aag gaq Lys Gli	,		_				_				_		_	_		1104
gct gtt Ala Val 370	Asn			_					_				_			1152
tca aca Ser Thi	_	_		_		_										1200
aca gct Thr Ala																1248
tca cti Ser Lei		_												_		1296
aag gaa Lys Glu																1344
gag cti Glu Lei 450	ı Glu															1392
ctg ago Leu Sei 465															;	1440
gat gte Asp Val															;	1488
aca cco Thr Pro	_		_	_											;	1536
tcg gad	ctc	ccg	gga	gga	gag	ttt	tct	acc	tgt	ttc	aca	gtc	ctg	cag	;	1584

16

Ser As	sp Leu 515		Gly	Gly	Glu	Phe 520	Ser	Thr	Cys	Phe	Th <i>r</i> 525	Val	Leu	Gln	
cga aa Arg As			_							_	_			_	1632
ctg gt Leu Va 545	~ ~						_	_			_	_		~	1680
ggg to Gly Se	~			_		_	_	~ ~	_					_	1728
tgg ga			Ser												1776
cgg ac Arg Th		Leu													1824
tgg aa Trp Ly 61						_	_					_			1872
ctg ag Leu Se 625	-														1920
ccc ac Pro Th						_	_		_	_				-	1968
gac aa Asp Ly	_	_	_	_						-		_	_		2016
act go Thr Gl		Pro												taa	2064
<210><211><212><213>	6 687 PRT Homo	sap:	iens												
<400> Met Gl	6 Ly Asn	Gly	Glu	Ser	Gln	Leu	Ser	Ser	Val	Pro	Ala	Gln	Lys	Leu	
1			5		:			10					15		

Gly Trp Phe Ile Gln Glu Tyr Leu Lys Pro Tyr Glu Glu Cys Gln Thr 20 25 30

Leu	Ile	Asp 35	Glu	Met	Val	Asn	Thr 40	Ile	Cys	Asp	Val	Cys 45	Arg	Asn	Pro
Glu	Gln 50	Phe	Pro	Leu	Val	Gln 55	Gly	Val	Ala	Ile	Gly 60	Gly	Ser	Tyr	Glγ
Arg 65	Lys	Thr	Val	Leu	Arg 70	Gly	Asn	Ser	Asp	Gly 75	Thr	Leu	Val	Leu	Phe 80
Phe	Ser	Asp	Leu	Lys 85	Gln	Phe	Gln	Asp	Gln 90	Lys	Arg	Ser	Gln	Arg 95	Asp
Ile	Leu	Asp	Lys 100	Thr	Gly	Asp	Lys	Leu 105	Lys	Phe	Cys	Leu	Phe 110	Thr	Lys
Trp	Leu	Lуs 115	Asn	Asn	Phe	Glu	Ile 120	Gln	Lys	Ser	Leu	Asp 125	Gly	Ser	Thr
Ile	Gln 130	Val	Phe	Thr	Lys	Asn 135	Gln	Arg	Ile	Ser	Phe 140	Glu	Val	Leu	Ala
Ala 145	Phe	Asn	Ala	Leu	Ser 150	Leu	Asn	Asp	Asn	Pro 155	Ser	Pro	Trp	Ile	Туг 160
Arg	Glu	Leu	Lys	Arg 165	Ser	Leu	Asp	Lys	Thr 170	Asn	Ala	Ser	Pro	Gly 175	Glu
Phe	Ala	Val	Cys 180	Phe	Thr	Glu	Leu	Gln 185	Gln	Lys	Phe	Phe	Asp 190	Asn	Arg
Pro	Gly	Lys 195	Leu	Lys	Asp		Ile 200		Leu	Ile	Lys	His 205	Trp	His	Gln
Gln	Cys 210	Gln	Lys	Lys	Ile	Lys 215	Asp	Leu	Pro	Ser	Leu 220	Ser	Pro	Tyr	Ala
Leu 225	Glu	Leu	Leu	Thr	Val 230	Tyr	Ala	Trp	Glu	Gln 235	Gly	Cys	Arg	Lys	Asp 240
Asn	Phe	Asp	Ile	Ala 245	Glu	Gly	Val	Arg	Thr 250	Val	Leu	Glu	Leu	Ile 255	Lys
Cys	Gln	Glu	Lys 260	Leu	Cys	Ile	Tyr	Trp 265	Met	Val	Asn	Tyr	Asn 270	Phe	Glu

Asp	Glu	Thr 275	Ile	Arg	Asn	Ile	Leu 280	Leu	His	Gln	Leu	Gln 285	Ser	Ala	Arg
Pro	Val 290	Ile	Leu	Asp	Pro	Val 295	Asp	Pro	Thr	Asn	Asn 300	Val	Ser	Gly	Asp
Lys 305	Ile	Cys	Trp	Gln	Trp 310	Leu	Lys	Lys	Glu	Ala 315	Gln	Thr	Trp	Leu	Thr 320
Ser	Pro	Asn	Leu	Asp 325	Asn	Glu	Leu	Pro	Ala 330	Pro	Ser	Trp	Asn	Val 335	Leu
Pro	Ala	Pro	Leu 340	Phe	Thr	Thr	Pro	Gly 345	His	Leu	Leu	Asp	Lуs 350	Phe	Ile
Lys	Glu	Phe 355	Leu	Gln	Pro	Asn	160	Cys	Phe	Leu	Glu	Gln 365	Ile	Asp	Ser
Ala	Val 370	Asn	Ile	Ile	Arg	Thr 375	Phe	Leu	Lys	Glu	Asn 380	Cys	Phe	Arg	Gln
Ser 385	Thr	Ala	Lys	Ile	Gln 390	Ile	Val	Arg	Gly	Gly 395	Ser	Thr	Ala	Lys	Gly 400
Thr	Ala	Leu	Lys	Thr 405	Gly	Ser	Asp	Ala	Asp 410	Leu	Val	Val	Phe	His 415	Asn
Ser	Leu	Lys	Ser 420	Tyr	Thr	Ser	Gln	Lys 425	Asn	Glu	Arg	His	Lуз 430	Ile	Val
Lys	Glu	Ile 435	His	Glu	Gln	Leu	Lys 440	Ala	Phe	Trp	Arg	Glu 445	Lys	Glu	Glu
Glu	Leu 450	Glu	Val	Ser	Phe	Glu 455	Pro	Pro	Lys	Trp	Lys 460	Ala	Pro	Arg	Val
Leu 465	Ser	Phe	Ser	Leu	Lys 470	Ser	Lys	Val	Leu	Asn 475	Glu	Ser	Val	Ser	Phe 480
Asp	Val	Leu	Pro	Ala 485	Phe	Asn	Ala	Leu	Gly 490	Gln	Leu	Ser	Ser	Gly 495	Ser
Thr	Pro	Ser	Pro 500	Glu	Val	Tyr	Ala	Gly 505	Leu	Ile	Asp	Leu	Tyr 510	Lys	Ser

Ser Asp Leu Pro Gly Gly Glu Phe Ser Thr Cys Phe Thr Val Leu Gln 515 520 525

Arg Asn Phe Ile Arg Ser Arg Pro Thr Lys Leu Lys Asp Leu Ile Arg 530 540

Leu Val Lys His Trp Tyr Lys Glu Cys Glu Arg Lys Leu Lys Pro Lys 545 550 555 560

Gly Ser Leu Pro Pro Lys Tyr Ala Leu Glu Leu Leu Thr Ile Tyr Ala 565 570 575

Trp Glu Gln Gly Ser Gly Val Pro Asp Phe Asp Thr Ala Glu Gly Phe
580 585 590

Arg Thr Val Leu Glu Leu Val Thr Gln Tyr Gln Gln Leu Gly Ile Phe 595 600 605

Trp Lys Val Asn Tyr Asn Phe Glu Asp Glu Thr Val Arg Lys Phe Leu 610 620

Leu Ser Gln Leu Gln Lys Thr Arg Pro Val Ile Leu Asp Pro Gly Glu 625 630 635 640

Pro Thr Gly Asp Val Gly Gly Gly Asp Arg Trp Cys Trp His Leu Leu 645 650 655

Asp Lys Glu Ala Lys Val Arg Leu Ser Ser Pro Cys Phe Lys Asp Gly 660 665 670

Thr Gly Asn Pro Ile Pro Pro Trp Lys Val Pro Val Lys Val Ile 675 680 685

<210> 7

<211> 2186

<212> DNA

<213> Homo sapiens

<300>

<301> Marie, I. and Hovanessian, A.G.

<302> The 69-kDa 2-5A synthetase is composed of two homologous and adjacent functional domains

<303> J. Biol. Chem.

<304> 267

<305> 14

<306> 9933-9939

20

<307> 1992 <308> (unknown) <309> 2003-04-03

<400> 7 60 atgggaaatg gggagtccca gctgtcctcg gtgcctgctc agaagctggg ttggtttatc caggaatacc tgaagcccta cgaagaatgt cagacactga tcgacgagat ggtgaacacc 120 atctgtgacg tctgcaggaa ccccgaacag ttccccctgg tgcagggagt ggccataggt 180 ggctcctatg gacggaaaac agtcttaaga ggcaactccg atggtaccct tgtccttttc 240 ttcagtgact taaaacaatt ccaggatcag aagagaagcc aacgtgacat cctcgataaa 300 actggggata agctgaagtt ctgtctgttc acgaagtggt tgaaaaacaa tttcgagatc 360 cagaagtccc ttgatgggtc caccatccag gtgttcacaa aaaatcagag aatctctttc 420 gaqqtqctqq ccqccttcaa cqctctqaqc ttaaatqata atcccaqccc ctqqatctat 480 cgagagctca aaagatcctt ggataagaca aatgccagtc ctggtgagtt tgcagtctgc 540 ttcactgaac tccagcagaa gttttttgac aaccgtcctg gaaaactaaa ggatttgatc 600 ctcttgataa agcactggca tcaacagtgc cagaaaaaaa tcaaggattt accctcgctg 660 teteegtatg ceetggaget gettaeggtg tatgeetggg aacaggggtg cagaaaagae 720 aactttgaca ttgctgaagg cgtcagaacg gttctggagc tgatcaaatg ccaggagaag 780 ctgtgtatct attggatggt caactacaac tttgaagatg agaccatcag gaacatcctg 840 ctgcaccagc tccaatcagc gaggccagta atcttggatc cagttgaccc aaccaataat 900 960 gtgagtggag ataaaatatg ctggcaatgg ctgaaaaaag aagctcaaac ctggttgact totoccaaco tggataatga gttacotgca coatottgga atgtoctgco tgcaccacto 1020 ttcacgaccc caggccacct tctggataag ttcatcaagg agtttctcca gcccaacaaa 1080 tgcttcctag agcagattga cagtgctgtt aacatcatcc gtacattcct taaagaaaac 1140 tgcttccgac aatcaacagc caagatccag attgtccggg gaggatcaac cgccaaaggc 1200 acagetetga agaetggete tgatgeegat etegtegtgt tecataaete aettaaaage 1260 tacacctccc aaaaaaacga gcggcacaaa atcgtcaagg aaatccatga acagctgaaa 1320 gccttttgga gggagaagga ggaggagctt gaagtcagct ttgagcctcc caagtggaag 1380 gctcccaggg tgctgagctt ctctctgaaa tccaaagtcc tcaacgaaag tgtcagcttt 1440 gatgtgcttc ctgcctttaa tgcactgggt cagctgagtt ctggctccac acccagcccc 1500 gaggtttatg cagggctcat tgatctgtat aaatcctcgg acctcccggg aggagagttt 1560 tctacctgtt tcacagtcct gcagcgaaac ttcattcgct cccggcccac caaactaaag 1620

gatttaattc	gcctggtgaa	gcactggtac	aaagagtgtg	aaaggaaact	gaagccaaag	1680
gggtctttgc	ccccaaagta	tgccttggag	ctgctcacca	tctatgcctg	ggagcagggg	1740
agtggagtgc	cggattttga	cactgcagaa	ggtttccgga	cagtcctgga	gctggtcaca	1800
caatatcagc	agctcggcat	cttctggaag	gtcaattaca	actttgaaga	tgagaccgtg	1860
aggaagtttc	tactgagcca	gttgcagaaa	accaggcctg	tgatcttgga	cccaggcgaa	1920
cccacaggtg	acgtgggtgg	aggggaccgt	tggtgttggc	atcttctgga	caaagaagca	1980
aaggttaggt	tatcctctcc	ctgcttcaag	gatgggactg	gaaacccaat	accaccttgg	2040
aaagtgccga	caatgcagac	accaggaagt	tgtggagcta	ggattccatc	ctattgtcaa	2100
tgagatgttg	tcatccagaa	gccatagaat	cctgaataat	aattctaaaa	gaaacttctg	2160
gagatcatct	ggcaatcgct	tttaaa				2186

<210> 8

<211> 727

<212> PRT

<213> Homo sapiens

<400> 8

Met Gly Asn Gly Glu Ser Gln Leu Ser Ser Val Pro Ala Gln Lys Leu 1 5 10 15

Gly Trp Phe Ile Gln Glu Tyr Leu Lys Pro Tyr Glu Glu Cys Gln Thr $20 \\ 25 \\ 30$

Leu Ile Asp Glu Met Val Asn Thr Ile Cys Asp Val Cys Arg Asn Pro 35 40 45

Glu Gln Phe Pro Leu Val Gln Gly Val Ala Ile Gly Gly Ser Tyr Gly 50 55 60

Arg Lys Thr Val Leu Arg Gly Asn Ser Asp Gly Thr Leu Val Leu Phe 65 70 75 80

Phe Ser Asp Leu Lys Gln Phe Gln Asp Gln Lys Arg Ser Gln Arg Asp 85 90 95

Ile Leu Asp Lys Thr Gly Asp Lys Leu Lys Phe Cys Leu Phe Thr Lys
100 105 110

Trp Leu Lys Asn Asn Phe Glu Ile Gln Lys Ser Leu Asp Gly Ser Thr 115 120 125

Ile	Gln 130	Val	Phe	Thr	Lys	Asn 135	Gln	Arg	Ile	Ser	Phe 140	Glu	Val	Leu	Ala
Ala 145	Phe	Asn	Ala	Leu	Ser 150	Leu	Asn	Asp	Asn	Pro 155	Ser	Pro	Trp	Ile	Tyr 160
Arg	Glu	Leu	Lys	Arg 165	Ser	Leu	Asp	Lys	Thr 170	Asn	Ala	Ser	Pro	Gly 175	Glu
Phe	Ala	Val	Cys 180	Phe	Thr	Glu	Leu	Gln 185	Gln	Lys	Phe	Phe	Asp 190	Asn	Arg
Pro	Gly	Lys 195	Leu	Lys	Asp	Leu	Ile 200	Leu	Leu	Ile	Lys	His 205	Trp	His	Gln
Gln	Cys 210	Gln	Lys	Lys	Ile	Lys 215	Asp	Leu	Pro	Ser	Leu 220	Ser	Pro	Tyr	Ala
Leu 225	Glu	Leu	Leu	Thr	Val 230	Tyr	Ala	Trp	Glu	Gln 235	Gly	Cys	Arg	Lys	Asp 240
Asn	Phe	Asp	Ile	Ala 245	Glu	Gly	Val	Arg	Thr 250	Val	Leu	Glu	Leu	Ile 255	Lys
Cys	Gln	Glu	Lys 260	Leu	Cys	Ile	Tyr	Trp 265	Met	Val	Asn	Tyr	Asn 270	Phe	Glu
Asp	Glu	Thr 275	Ile	Arg	Asn	Ile	Leu 280	Leu	His	Gln	Leu	Gln 285	Ser	Ala	Arg
Pro	Val 290	Ile	Leu	Asp	Pro	Val 295	Asp	Pro	Thr	Asn	Asn 300	Val	Ser	Gly	Asp
Lys 305	Ile	Cys	Trp	Gln	Trp 310	Leu	Lys	Lys	Glu	Ala 315	Gln	Thr	Trp	Leu	Thr 320
Ser	Pro	Asn	Leu	Asp 325	Asn	Glu	Leu	Pro	Ala 330	Pro	Ser	Trp	Asn	Val 335	Leu
Pro	Ala	Pro	Leu 340	Phe	Thr	Thr	Pro	Gly 345	His	Leu	Leu	Asp	Lys 350	Phe	Ile
Lys	Glu	Phe 355	Leu	Gln	Pro	Asn	Lys 360	Cys	Phe	Leu	Glu	Gln 365	Ile	Asp	Ser

Ala Val Asn Ile Ile Arg Thr Phe Leu Lys Glu Asn Cys Phe Arg Gln 375 Ser Thr Ala Lys Ile Gln Ile Val Arg Gly Gly Ser Thr Ala Lys Gly 395 Thr Ala Leu Lys Thr Gly Ser Asp Ala Asp Leu Val Val Phe His Asn Ser Leu Lys Ser Tyr Thr Ser Gln Lys Asn Glu Arg His Lys Ile Val 420 Lys Glu Ile His Glu Gln Leu Lys Ala Phe Trp Arg Glu Lys Glu Glu Glu Leu Glu Val Ser Phe Glu Pro Pro Lys Trp Lys Ala Pro Arg Val 455 Leu Ser Phe Ser Leu Lys Ser Lys Val Leu Asn Glu Ser Val Ser Phe 475 470 Asp Val Leu Pro Ala Phe Asn Ala Leu Gly Gln Leu Ser Ser Gly Ser 485 490 Thr Pro Ser Pro Glu Val Tyr Ala Gly Leu Ile Asp Leu Tyr Lys Ser 505 Ser Asp Leu Pro Gly Gly Glu Phe Ser Thr Cys Phe Thr Val Leu Gln Arg Asn Phe Ile Arg Ser Arg Pro Thr Lys Leu Lys Asp Leu Ile Arg 535 Leu Val Lys His Trp Tyr Lys Glu Cys Glu Arg Lys Leu Lys Pro Lys 545 550 555 Gly Ser Leu Pro Pro Lys Tyr Ala Leu Glu Leu Leu Thr Ile Tyr Ala 565 570 Trp Glu Gln Gly Ser Gly Val Pro Asp Phe Asp Thr Ala Glu Gly Phe 580 585 590

Arg Thr Val Leu Glu Leu Val Thr Gln Tyr Gln Gln Leu Gly Ile Phe

24

600 605 595 Trp Lys Val Asn Tyr Asn Phe Glu Asp Glu Thr Val Arg Lys Phe Leu 620 615 Leu Ser Gln Leu Gln Lys Thr Arg Pro Val Ile Leu Asp Pro Gly Glu 635 630 Pro Thr Gly Asp Val Gly Gly Gly Asp Arg Trp Cys Trp His Leu Leu 650 645 Asp Lys Glu Ala Lys Val Arg Leu Ser Pro Cys Phe Lys Asp Gly 660 665 Thr Gly Asn Pro Ile Pro Pro Trp Lys Val Pro Thr Met Gln Thr Pro 680 675 Gly Ser Cys Gly Ala Arg Ile His Pro Ile Val Asn Glu Met Phe Ser 695 690 Ser Arg Ser His Arg Ile Leu Asn Asn Ser Lys Arg Asn Phe Thr 705 710 715 Arg Ser Ser Gly Asn Arg Phe 725 <210> 9 <211> 3264 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (1)..(3264) <300> <301> Rebouillat, D., et al. <302> The 100-kDa 2',5'-oligoadenylate synthetase catalyzing preferentially the synthesis of dimeric pppA2'p5'A molecules <303> J. Biol. Chem. <304> 274 <305> 3 <306> 1557-1565 <307> 1999 <308> NCBI/AF 063613 <309> 1999-05-04

<300>

<301> Rebouillat, D. and Hovanessian, A.G.

<302 <303 <304 <305 <306 <308 <308	3 > 8 4 > 6 5 > 6 7 > 3 3 > 1	Directory Paste D D 1998 NCBI 1999	Lttedeur /AF_(06363	7-Maş		98) I	Oept .	of A	Aids	and	Reti	rovin	cuses	s, In	stitut
	gac	9 ttg Leu														48
		ctg Leu														96
		gcc Ala 35														144
gct Ala	gct Ala 50	gcc Ala	ccg Pro	cgg Arg	gtg Val	ctg Leu 55	aaa Lys	act Thr	gtc Val	aag Lys	gga Gly 60	ggc gly	tcc Ser	tcg Ser	ggc	192
cgg Arg 65	ggc	aca Thr	gct Ala	ctc Leu	aag Lys 70	ggt Gly	ggc Gly	tgt Cys	gat Asp	tct Ser 75	gaa Glu	ctt Leu	gtc Val	atc Ile	ttc Phe 80	240
		tgc Cys														288
atc Ile	ctc Leu	agt Ser	gag Glu 100	atg Met	cgg Arg	gca Ala	tcg Ser	ctg Leu 105	gaa Glu	tcc Ser	tgg Trp	tgg Trp	cag Gln 110	aac Asn	cca Pro	336
		ggt Gly 115														384
		ttc Phe														432
		gtg Val														480
		aag Lys														528
		gag Glu														576

PCT/US2005/014626

									ttg Leu			624
									aag Lys 220			672
_	_	_	_	_	_	_			gcc Ala	 	_	 720
									ctc Leu			768
									ttc Phe			816
									ttg Leu			864
_	_			_			-		gac Asp 300			912
									cat His			960
									gjà aaa			1008
									gct Ala			1056
									aag Lys			1104
									380 GJA aaa			1152
									gca Ala			1200
									ccc Pro			1248
									ccc Pro			1296

											tgc Cys					1344
											ggc Gly 460					1392
ggc Gly 465	aca Thr	gac Asp	cta Leu	agg Arg	gat Asp 470	ggc	tgt Cys	gat Asp	gtt Val	gaa Glu 475	ctc Leu	atc Ile	atc Ile	ttc Phe	ctc Leu 480	1440
											cgc Arg					1488
											tgg Trp					1536
											gtg Val					1584
cag Gln	ttc Phe 530	cag Gln	ctg Leu	gtg Val	tcc Ser	aca Thr 535	gcc Ala	ctg Leu	aag Lys	agc Ser	tgg Trp 540	acg Thr	gat Asp	gtt Val	agc Ser	1632
											agt Ser					1680
cca Pro	aat Asn	ccc Pro	cag Gln	gtc Val 565	tac Tyr	tcg Ser	agg Arg	ctc Leu	ctc Leu 570	acc Thr	agt Ser	gly	tgc Cys	cag Gln 575	gag Glu	1728
											agg Arg					1776
att Ile	cgc Arg	cct Pro 595	gtc Val	aag Lys	ctg Leu	aag Lys	aac Asn 600	ctg Leu	att Ile	ctg Leu	ctg Leu	gtg Val 605	aag Lys	cac His	tgg Trp	1824
tac Tyr	cgc Arg 610	cag Gln	gtt Val	gcg Ala	gct Ala	cag Gln 615	aac Asn	aaa Lys	gga Gly	aaa Lys	gga Gly 620	cca Pro	gcc Ala	cct Pro	gcc Ala	1872
											acc Thr					1920
gag Glu	cag Gln	ggc	tgc Cys	agg Arg 645	cag Gln	gat Asp	tgt Cys	ttc Phe	aac Asn 650	atg Met	gcc Ala	caa Gln	gly ggc	ttc Phe 655	cgg Arg	1968
											ctc Leu					2016

	660	66	55	670	
	_		ca gcc atg aga ro Ala Met Arg	-	
	_	_	ig gtc ctg gac eu Val Leu Asp 700		
		Gly Ser Tr	gg gag ctg ttg cp Glu Leu Leu 715		
			it ctg agt aga ne Leu Ser Arg 730		
			cc ctc ctt tac la Leu Leu Tyr 15		
			aa ttt ctc cag lu Phe Leu Gln		
			t gat acc atc al Asp Thr Ile 780		
		Asn Ser Pr	cc atc aaa gtg co Ile Lys Val 795		
			ca gct ctg cga nr Ala Leu Arg 810		
			gc ttc agc cag ys Phe Ser Gln 25		_
			cc gag atc cga er Glu Ile Arg		
			ag gtc aag ttt Lu Val Lys Phe 860		
		Leu Ser Ph	cc tca ctg aca ne Ser Leu Thr 875		
			eg ctg cca gcc al Leu Pro Ala 890		
ggc cag ctg	gtc tct ggc	tcc agg cc	cc agc tct caa	gtc tac gtc	gac 2736

Gly Gln Leu Val Ser Gly Ser Arg Pro Ser Ser Gln Val Tyr Val Asp 900 905 910	
ctc atc cac agc tac agc aat gcg ggc gag tac tcc acc tgc ttc aca Leu Ile His Ser Tyr Ser Asn Ala Gly Glu Tyr Ser Thr Cys Phe Thr 915 920 925	2784
gag cta caa cgg gac ttc atc atc tct cgc cct acc aag ctg aag agc Glu Leu Gln Arg Asp Phe Ile Ile Ser Arg Pro Thr Lys Leu Lys Ser 930 935 940	2832
ctg atc cgg ctg gtg aag cac tgg tac cag cag tgt acc aag atc tcc Leu Ile Arg Leu Val Lys His Trp Tyr Gln Gln Cys Thr Lys Ile Ser 945 950 955 960	2880
aag ggg aga ggc tcc cta ccc cca cag cac ggg ctg gaa ctc ctg act Lys Gly Arg Gly Ser Leu Pro Pro Gln His Gly Leu Glu Leu Leu Thr 965 970 975	2928
gtg tat gcc tgg gag cag ggc ggg aag gac tcc cag ttc aac atg gct Val Tyr Ala Trp Glu Gln Gly Gly Lys Asp Ser Gln Phe Asn Met Ala 980 985 990	2976
gag ggc ttc cgc acg gtc ctg gag ctg gtc acc cag tac cgc cag ctc Glu Gly Phe Arg Thr Val Leu Glu Leu Val Thr Gln Tyr Arg Gln Leu 995	3024
tgt atc tac tgg acc atc aac tac aac gcc aag gac aag act gtt Cys Ile Tyr Trp Thr Ile Asn Tyr Asn Ala Lys Asp Lys Thr Val 1010 1015 1020	3069
gga gac ttc ctg aaa cag cag ctt cag aag ccc agg cct atc atc Gly Asp Phe Leu Lys Gln Gln Leu Gln Lys Pro Arg Pro Ile Ile 1025	3114
ctg gat ccg gct gac ccg aca ggc aac ctg ggc cac aat gcc cgc Leu Asp Pro Ala Asp Pro Thr Gly Asn Leu Gly His Asn Ala Arg 1040 1045 1050	3159
tgg gac ctg ctg gcc aag gaa gct gca gcc tgc aca tct gcc ctg Trp Asp Leu Leu Ala Lys Glu Ala Ala Ala Cys Thr Ser Ala Leu 1055 1060 1065	3204
tgc tgc atg gga cgg aat ggc atc ccc atc cag cca tgg cca gtg Cys Cys Met Gly Arg Asn Gly Ile Pro Ile Gln Pro Trp Pro Val 1070 1075 1080	3249
aag gct gct gtg tga Lys Ala Ala Val 1085	3264

<400> 10

<210> 10 <211> 1087 <212> PRT <213> Homo sapiens

Met 1	Asp	Leu	Tyr	Ser 5	Thr	Pro	Ala	Ala	Ala 10	Leu	Asp	Arg	Phe	Val 15	Ala
Arg	Arg	Leu	Gln 20	Pro	Arg	Lys	Glu	Phe 25	Val	Glu	Lys	Ala	Arg 30	Arg	Ala
Leu	Gly	Ala 35	Leu	Ala	Ala	Ala	Leu 40	Arg	Glu	Arg	Gly	Gly 45	Arg	Leu	Gly
Ala	Ala 50	Ala	Pro	Arg	Val	Leu 55	Lys	Thr	Val	Lys	Gly 60	Gly	Ser	Ser	Gly
Arg 65	Gly	Thr	Ala	Leu	Lys 70	Gly	Gly	Cys	Asp	Ser 75	Glu	Leu	Val	Ile	Phe 80
Leu	Asp	Cys	Phe	Lys 85	Ser	Tyr	Val	Asp	Gln 90	Arg	Ala	Arg	Arg	Ala 95	Glu
Ile	Leu	Ser	Glu 100	Met	Arg	Ala	Ser	Leu 105	Glu	Ser	Trp	Trp	Gln 110	Asn	Pro
Val	Pro	Gly 115	Leu	Arg	Leu	Thr	Phe 120	Pro	Glu	Gln	Ser	Val 125	Pro	Gly	Ala
Leu	Gln 130	Phe	Arg	Leu	Thr	Ser 135	Val	Asp	Leu	Glu	Asp 140	Trp	Met	Asp	Val
Ser 145	Leu	Val	Pro	Ala	Phe 150	Asn	Val	Leu	Gly	Gln 155	Ala	Gly	Ser	Ala	Val 160
Lys	Pro	Lys	Pro	Gln 165	Val	Tyr	Ser	Thr	Leu 170	Leu	Asn	Ser	Gly	Cys 175	Gln
Gly	Gly	Glu	His 180	Ala	Ala	Cys	Phe	Thr 185	Glu	Leu	Arg	Arg	Asn 190	Phe	Val
Asn	Ile	Arg 195	Pro	Ala	Lys	Leu	Lys 200	Asn	Leu	Ile	Leu	Leu 205	Val	Lys	His
Trp	Tyr 210	His	Gln	Val	Сув	Leu 215	Gln	Gly	Leu	Trp	Lys 220	Glu	Thr	Leu	Pro
Pro 225	Val	Tyr	Ala	Leu	Glu 230	Leu	Leu	Thr	Ile	Phe 235	Ala	Trp	Glu	Gln	Gly 240

- Cys Lys Lys Asp Ala Phe Ser Leu Gly Glu Gly Leu Arg Thr Val Leu 245 250 255
- Gly Leu Ile Gln Gln His Gln His Leu Cys Val Phe Trp Thr Val Asn 260 265 270
- Tyr Gly Phe Glu Asp Pro Ala Val Gly Gln Phe Leu Gln Arg His Val 275 280 285
- Lys Arg Pro Arg Pro Val Ile Leu Asp Pro Ala Asp Pro Thr Trp Asp 290 295 300
- Leu Gly Asn Gly Ala Ala Trp His Trp Asp Leu His Ala Gln Glu Ala 305 310 315 320
- Ala Ser Cys Tyr Asp His Pro Cys Phe Leu Arg Gly Met Gly Asp Pro 325 330 335
- Val Gln Ser Trp Lys Gly Pro Gly Leu Pro Arg Ala Gly Cys Ser Gly 340 345 350
- Leu Gly His Pro Ile Gln Leu Asp Pro Asn Gln Lys Thr Pro Glu Asn 355 360 365
- Ser Lys Ser Leu Asn Ala Val Tyr Pro Arg Ala Gly Ser Lys Pro Pro 370 380
- Ser Cys Pro Ala Pro Gly Pro Thr Ala Glu Pro Ala Ser Tyr Pro Ser 385 390 395 400
- Val Pro Gly Met Ala Leu Asp Leu Ser Gln Ile Pro Thr Lys Glu Leu 405 410 415
- Asp Arg Phe Ile Gln Asp His Leu Lys Pro Ser Pro Gln Phe Gln Glu 420 425 430
- Gln Val Lys Lys Ala Ile Asp Ile Ile Leu Arg Cys Leu His Glu Asn 435 440 445
- Cys Val His Lys Ala Ser Arg Val Ser Lys Gly Gly Ser Phe Gly Arg 450 455 460
- Gly Thr Asp Leu Arg Asp Gly Cys Asp Val Glu Leu Ile Ile Phe Leu 465 470 475 480

Asn	Cys	Phe	Thr	Asp 485	Tyr	Lys	Asp	Gln	Gly 490	Pro	Arg	Arg	Ala	Glu 495	Ile
Leu	Asp	Glu	Met 500	Arg	Ala	His	Val	Glu 505	Ser	Trp	Trp	Gln	Asp 510	Gln	Val
Pro	Ser	Leu 515	Ser	Leu	Gln	Phe	Pro 520	Glu	Gln	Asn	Val	Pro 525	Glu	Ala	Leu
Gln	Phe 530	Gln	Leu	Val	Ser	Thr 535	Ala	Leu	Lys	Ser	Trp 540	Thr	Asp	Val	Ser
Leu 545	Leu	Pro	Ala	Phe	Asp 550	Ala	Val	Gly	Gln	Leu 555	Ser	Ser	Gly	Thr	Lys 560
Pro	Asn	Pro	Gln	Val 565	Tyr	Ser	Arg	Leu	Leu 570	Thr	Ser	Gly	Cys	Gln 575	Glu
Gly	Glu	His	Lys 580	Ala	Cys	Phe	Ala	Glu 585	Leu	Arg	Arg	Asn	Phe 590	Met	Asn
Ile	Arg	Pro 595	Val	Lys	Leu	ГЛЗ	Asn 600	Leu	Ile	Leu	Leu	Val 605	Lys	His	Trp
Tyr	Arg 610	Gln	Val	Ala	Ala	Gln 615	Asn	Lys	Gly	Lys	Gly 620	Pro	Ala	Pro	Ala
Ser 625	Leu	Pro	Pro	Ala	Tyr 630	Ala	Leu	Glu	Leu	Leu 635	Thr	Ile	Phe	Ala	Trp 640
Glu	Gln	Gly	Cys	Arg 645	Gln	Asp	Cys	Phe	Asn 650	Met	Ala	Gln	Gly	Phe 655	Arg
Thr	Val	Leu	Gly 660	Leu	Val	Gln	Gln	His 665	Gln	Gln	Leu	Cys	Val 670	Tyr	Trp
Thr	Val	Asn 675	Tyr	Ser	Thr	Glu	Asp 680	Pro	Ala	Met	Arg	Met 685	His	Leu	Leu
Gly	Gln 690	Leu	Arg	Lys	Pro	Arg 695	Pro	Leu	Val	Leu	Asp 700	Pro	Ala	Asp	Pro
Thr	Trn	Λαn	τ7a l	G] w	шie	G] v	Ser	Trn	Gl 11	T. 611	T.611	ת דת	G] n	G] 11	מות

33

705 710 715 720 Ala Ala Leu Gly Met Gln Ala Cys Phe Leu Ser Arg Asp Gly Thr Ser 725 730 Val Gln Pro Trp Asp Val Met Pro Ala Leu Leu Tyr Gln Thr Pro Ala 745 Gly Asp Leu Asp Lys Phe Ile Ser Glu Phe Leu Gln Pro Asn Arg Gln Phe Leu Ala Gln Val Asn Lys Ala Val Asp Thr Ile Cys Ser Phe Leu Lys Glu Asn Cys Phe Arg Asn Ser Pro Ile Lys Val Ile Lys Val Val 795 Lys Gly Gly Ser Ser Ala Lys Gly Thr Ala Leu Arg Gly Arg Ser Asp 805 810 Ala Asp Leu Val Val Phe Leu Ser Cys Phe Ser Gln Phe Thr Glu Gln 820 825 Gly Asn Lys Arg Ala Glu Ile Ile Ser Glu Ile Arg Ala Gln Leu Glu 835 840 Ala Cys Gln Glu Arg Gln Phe Glu Val Lys Phe Glu Val Ser Lys 850 855 Trp Glu Asn Pro Arg Val Leu Ser Phe Ser Leu Thr Ser Gln Thr Met 865 870 Leu Asp Gln Ser Val Asp Phe Asp Val Leu Pro Ala Phe Asp Ala Leu Gly Gln Leu Val Ser Gly Ser Arg Pro Ser Ser Gln Val Tyr Val Asp 900 905 Leu Ile His Ser Tyr Ser Asn Ala Gly Glu Tyr Ser Thr Cys Phe Thr 915 920 Glu Leu Gln Arg Asp Phe Ile Ile Ser Arg Pro Thr Lys Leu Lys Ser 930 935

34

Leu Ile Arg Leu Val Lys His Trp Tyr Gln Gln Cys Thr Lys Ile Ser

Lys Gly Arg Gly Ser Leu Pro Pro Gln His Gly Leu Glu Leu Leu Thr

Val Tyr Ala Trp Glu Gln Gly Gly Lys Asp Ser Gln Phe Asn Met Ala 980 985

Glu Gly Phe Arg Thr Val Leu Glu Leu Val Thr Gln Tyr Arg Gln Leu

Cys Ile Tyr Trp Thr Ile Asn Tyr Asn Ala Lys Asp Lys Thr Val 1015

Gly Asp Phe Leu Lys Gln Gln Leu Gln Lys Pro Arg Pro Ile Ile 1030 1035

Leu Asp Pro Ala Asp Pro Thr Gly Asn Leu Gly His Asn Ala Arg 1045 1050

Trp Asp Leu Leu Ala Lys Glu Ala Ala Cys Thr Ser Ala Leu 1055 1060 1065

Cys Cys Met Gly Arg Asn Gly Ile Pro Ile Gln Pro Trp Pro Val 1075 1070 1080

Lys Ala Ala Val 1085

<210> 11

<211> 1104 <212> DNA

<213> Mus musculus

<220>

<221> CDS <222> (1)..(1104)

<300>

<301> Coccia, E.M., et al.

<302> A full-length murine 2-5A synthetase cDNA transfected in NIH-3T3 cells

<303> Virology

<304> 179

<305> 1

<306> 228-233

<307> 1990

35

PCT/US2005/014626

<308		NCBI 1993		,											
_	gag	11 cac His			_			_		_	_	_	_		48
		gat Asp				_					_	_	_		96
	_	gtc Val 35	_	_		_		_	_		_	-			144
		gcc Ala													192
		aaa Lys													240
		ctt Leu													288
		ttc Phe	_	_		_			_			_			336
	_	cgt Arg 115	_	_	_			_	_	_					384
	-	cgg Arg	_	_		_	_	_	_			_		_	432
		gag Glu													480
		tcc Ser								_					528
		acc Thr													576
		cag Gln 195					_	_			_	_	_		624
		cgc Arg													672

36

		o Gln Tyr	Ala Leu Gl	ag ttg ctc act lu Leu Leu Thr 35	
<u>-</u> -				tc aac aca gcc he Asn Thr Ala	
				at cag cat ctt yr Gln His Leu 270	
	_	_		ag gag gtc tcc ln Glu Val Ser 285	
				tg atc ctg gac al Ile Leu Asp 300	
		l Ala Gly		ca gag ggc tgg ro Glu Gly Trp 15	
				ac cca tgt ttt yr Pro Cys Phe	
		l Ser Ser		tg ccg acg gtg al Pro Thr Val 350	
_				ca tgt atc ctg ar Cys Ile Leu 365	_
<210> 12 <211> 367 <212> PRT <213> Mus	musculus		,		
<400> 12					
Met Glu His 1	Gly Leu Ar 5	g Ser Ile	Pro Ala Tr 10	cp Thr Leu Asp	Lys Phe 15
Ile Glu Asp	Tyr Leu Le 20	-	Thr Thr Ph 25	ne Gly Ala Asp 30	Val Lys
Ser Ala Val	Asn Val Va	l Cys Asp 40	Phe Leu Ly	ys Glu Arg Cys 45	Phe Gln

Gly Ala Ala His Pro Val Arg Val Ser Lys Val Val Lys Gly Gly Ser 50 55 60

Ser 65	Gly	Lys	Gly	Thr	Thr 70	Leu	Lys	Gly	Arg	Ser 75	Asp	Ala	Asp	Leu	Val 80
Val	Phe	Leu	Asn	Asn 85	Leu	Thr	Ser	Phe	Glu 90	Asp	Gln	Leu	Asn	Arg 95	Arg
Gly	Glu	Phe	Ile 100	Lys	Glu	Ile	Lys	Lys 105	Gln	Leu	Tyr	Glu	Val 110	Gln	His
Glu	Arg	Arg 115	Phe	Arg	Val	Lys	Phe 120	Glu	Val	Gln	Ser	Ser 125	Trp	Trp	Pro
Asn	Ala 130	Arg	Ser	Leu	Ser	Phe 135	Lys	Leu	Ser	Ala	Pro 140	His	Leu	His	Gln
Glu 145	Val	Glu	Phe	Asp	Val 150	Leu	Pro	Ala	Phe	Asp 155	Val	Leu	Gly	His	Val 160
Asn	Thr	Ser	Ser	Lуs 165	Pro	Asp	Pro	Arg	Ile 170	Tyr	Ala	Ile	Leu	Ile 175	Glu
Glu	Cys	Thr	Ser 180	Leu	Gly	Lys	Asp	Gly 185	Glu	Phe	Ser	Thr	Cys 190	Phe	Thr
Glu	Leu	Gln 195	Arg	Asn	Phe	Leu	Lys 200	Gln	Arg	Pro	Thr	Lys 205	Leu	Lys	Ser
Leu	Ile 210	Arg	Leu	Val	Lys	His 215	Trp	Tyr	Gln	Leu	Cys 220	Lys	Glu	Lys	Leu
Gly 225	Lys	Pro	Leu	Pro	Pro 230	Gln	Tyr	Ala	Leu	Glu 235	Leu	Leu	Thr	Val	Phe 240
Ala	Trp	Glu	Gln	Gly 245	Asn	Gly	Cys	Tyr	Glu 250	Phe	Asn	Thr	Ala	Gln 255	Gly
Phe	Arg	Thr	Val 260	Leu	Glu	Leu	Val	Ile 265	Asn	Tyr	Gln	His	Leu 270	Arg	Ile
Tyr	Trp	Thr 275	Lys	Tyr	Tyr	Asp	Phe 280	Gln	His	Gln	Glu	Val 285	Ser	Lys	Tyr
Leu	His	Arg	Gln	Leu	Arg	Lys	Ala	Arg	Pro	Val	Ile	Leu	Asp	Pro	Ala

38

290 295 300 Asp Pro Thr Gly Asn Val Ala Gly Gly Asn Pro Glu Gly Trp Arg Arg 310 315 Leu Ala Glu Glu Ala Asp Val Trp Leu Trp Tyr Pro Cys Phe Ile Lys 325 330 Lys Asp Gly Ser Arg Val Ser Ser Trp Asp Val Pro Thr Val Val Pro 345 Val Pro Phe Glu Gln Val Glu Glu Asn Trp Thr Cys Ile Leu Leu 360 <210> 13 <211> 1590 <212> DNA <213> Homo sapiens <300> <301> Aissouni, Y. et al. <302> The cleavage/polyadenylation activity triggered by a U-rich motif sequence <303> J. Biol. Chem. <304> 277 <305> 39 <306> 35808-35814 <307> 2002 <308> NCBI/NM_016816 <309> 2003-04-06 <300> <301> Behera, A.K., et al. <302> 2'-5' Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition <303> J. Biol. Chem. <304> 277 <305> 28 <306> 25601-25608 <307> 2002 <308> NCBI/NM_016816 <309> 2003-04-06 <300> <301> Sarkar, S.N., et al. <302> Identification of the substrate-binding sites of 2'-5'-oligoadenylate synthetase <303> J. Biol. Chem. <304> 277 <305> 27 <306> 24321-24330 <307> 2002 <308> NCBI/NM 016816

<309> 2003-04-06

```
<300>
<301> Hovnanian, A., et al.
<302> The human 2',5'-oligoadenylate synthetase locus is composed of
       three distinct genes
<303> Genomics
<304> 52
<305> 3
<306> 267-277
<307> 1998
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Renault, B.
<302> A sequence-ready physical map of a region of 12q24.1
<303> Genomics
<304> 45
<305> 2
<306> 271-278
<307> 1997
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Nechiporuk, T., et al.
<302> A high-resolution PAC and BAC map of the SCA2 region
<303> Genomics
<304> 44
<305> 3
<306> 321-329
<307> 1997
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Wathelet, M.G., et al.
<302> Cloning and chromosomal location of human genes inducible by type
       I interferon
<303> Somat. Cell Mol. Genet.
<304> 14
<304> 14

<305> 5

<306> 415-426

<307> 1988

<308> NCBI/NM_016816

<309> 2003-04-06
<300>
<301> Rutherford, M.N., et al.
<302> Interferon-induced binding of nuclear factors to promoter
       elements of the 2-5A synthetase gene
<303> EMBO J.
<304> 7
<305> 3
<306> 751~759
<307> 1988
<308> NCBI/NM 016816
<309> 2003-04-06
```

```
<300>
<301> Wathelet, M.G., et al.
<302> New inducers revealed by the promoter sequence analysis of two
       interferon-activated human genes
<303> Eur. J. Biochem.
<304> 169
<305> 2
<306> 313-321
<307> 1987
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
<301> Benech, P., et al.
<302> Interferon-responsive regulatory elements in the promoter of the
       human 2',5'-oligo(A) synthetase gene
<303> Mol. Cell. Biol.
<304> 7
<305> 12
<306> 4498-4504
<307> 1987
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Hovanessian, A.G., et al.
<302> Identification of 69-kd and 100-kd forms of 2-5A sythetase
<303> EMBO J.
<304> 6
<305> 5
<306> 1273-1280
<307> 1987
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Williams, B.R., et al.
<302> Interferon-regulated human 2-5A synthetase gene maps to
       chromosome
<303> Somat. Cell Mol. Genet. <304> 12
<304> 12
<305> 4
<306> 403-408
<307> 1986
<308> NCBI/NM_016816
<309> 2003-04-06
<300>
<301> Shiojiri, S., et al.
<302> Structure and expression of a cloned cDNA
<303> J. Biochem.
<304> 99
<305> 5
<306> 1455-1464
<307> 1986
<308> NCBI/NM 016816
<309> 2003-04-06
<300>
```

41 <301> Wathelet, M., et al. <302> Full-length sequence and expression of the 42 kDa 2-5A synthetase <303> FEBS Lett. <304> 196 <305> 1 <306> 113-120 <307> 1986 <308> NCBI/NM 016816 <309> 2003-04-06 <300> <301> Benech, P., et al. <302> Structure of two forms of the interferon-induced (2'-5') oligo A synthetase <303> EMBO J. <304> 4 <305> 9 <306> 2249-2256 <307> 1985 <308> NCBI/NM_016816 <309> 2003-04-06 <300> <301> Saunders, M.E., et al. <302> Human 2-5A synthetase: characterization of a novel cDNA and corresponding gene structure <303> ЕМВО J. <304> 4 <305> 7 <306> 1761-1768 <307> 1985 <308> NCBI/NM_016816 <309> 2003-04-06 <300> <301> Merlin, G., et al. <302> Molecular cloning and sequence of partial cDNA for interferon-induced (2'-5') oligo(A) synthetase mRNA from human cells <303> Proc. Natl. Acad. Sci. U.S.A. <304> 80 <305> 16 <306> 4904-4908 <307> 1983 <308> NCBI/NM_016816 <309> 2003-04-06 <400> 13 gaggcagttc tgttgccact ctctctcctg tcaatgatgg atctcagaaa taccccagcc 60 aaatctctgg acaagttcat tgaagactat ctcttgccag acacgtgttt ccgcatgcaa 120 ategaceatg ceattgacat catetgtggg tteetgaagg aaaggtgett eegaggtage 180 tectacectg tgtgtgte caaggtggta aagggtgget ceteaggeaa gggeaceace 240 ctcagaggcc gatctgacgc tgacctggtt gtcttcctca gtcctctcac cacttttcag 300

gatcagttaa atcgccgggg agagttcatc caggaaatta ggagacagct ggaagcctgt

42

caaagagaga gagcactttc cgtgaagttt gaggtccagg ctccacgctg gggcaacccc 420 cgtgcgctca gcttcgtact gagttcgctc cagctcgggg agggggtgga gttcgatgtg 480 ctgcctgcct ttgatgccct gggtcagttg actggcagct ataaacctaa cccccaaatc 540 tatgtcaagc tcatcgagga gtgcaccgac ctgcagaaag agggcgagtt ctccacctgc 600 ttcacagaac tacagagaga cttcctgaag cagcgcccca ccaagctcaa gagcctcatc 660 cgcctagtca agcactggta ccaaaattgt aagaagaagc ttgggaagct gccacctcag 720 tatgccctgg agctcctgac ggtctatgct tgggagcgag ggagcatgaa aacacatttc 780 aacacagccc aaggatttcg gacggtcttg gaattagtca taaactacca gcaactctgc 840 atctactgga caaagtatta tgactttaaa aaccccatta ttgaaaagta cctgagaagg 900 cageteaega aaceeaggee tgtgateetg gaceeggegg accetacagg aaacttgggt 960 ggtggagacc caaagggttg gaggcagctg gcacaagagg ctgaggcctg gctgaattac 1020 ccatgcttta agaattggga tgggtcccca gtgagctcct ggattctgct ggctgaaagc 1080 aacagtacag acgatgagac cgacgatccc aggacgtatc agaaatatgg ttacattgga 1140 acacatgagt acceteattt eteteataga eccageaege tecaggeage atecaceeca 1200 caggcagaag aggactggac ctgcaccatc ctctgaatgc cagtgcatct tgggggaaag 1260 ggctccagtg ttatctggac cagttccttc attttcaggt gggactcttg atccagagaa 1320 gacaaagctc ctcagtgagc tggtgtataa tccaagacag aacccaagtc tcctgactcc 1380 tggccttcta tgccctctat cctatcatag ataacattct ccacagcctc acttcattcc 1440 acctattctc tgaaaatatt ccctgagaga gaacagagag atttagataa gagaatgaaa 1500 ttccagcctt gactttcttc tgtgcacctg atgggagggt aatgtctaat gtattatcaa 1560 taacaataaa aataaagcaa ataccaaaaa 1590

```
<210> 14
<211> 3068
<212> DNA
<213> Homo sapiens

<300>
<301> Hovnanian, A., et al.
<302> The human 2',5'-oligoadenylate synthetase locus is composed of three distinct genes
<303> Genomics
<304> 52
<305> 3
<306> 267-277
<307> 1998
```

<308> NCBI/NM_002535

<309> 2003-04-03

WO 2005/105136 PCT/US2005/014626

43 <309> 2003-04-03 <300> <301> Marie, I. and Hovanessian, A.G. <302> The 69-kDa 2-5A synthetase is composed of two homologous and adjacent functional domains <303> J. Biol. Chem. <304> 267 <305> 14 <306> 9933-9939 <307> 1992 <308> NCBI/NM 002535 <309> 2003-04-03 <300> <301> Marie, I., et al. <302> Differential expression and distinct structure of 69- and 100-kDa forms of 2-5A synthetase <303> J. Biol. Chem. <304> 265 <305> 30 <306> 18601-18607 <307> 1990 <308> NCBI/NM_002535 <309> 2003-04-03 <300> <301> Marie, I., et al. <302> Preparation and characterization of polyclonal antibodies <303> Biochem. Biophys. Res. Commun. <304> 160 <305> 2 <306> 580-587 <307> 1989 <308> NCBI/NM 002535 <309> 2003-04-03 <300> <301> Hovanessian, A.G., et al. <301> Hovanessian, A.G., et al.
<302> Characterization of 69- and 100-kDa forms of 2-5A-synthetase
<303> J. Biol. Chem.
<304> 263
<305> 10
<306> 4959
<307> 1988
<308> NCBI/NM_002535
<309> 2003-04-03 <300> <301> Hovanessian, A.G., et al. <302> Identification of 69-kd and 100-kd forms of 2-5A synthetase <303> EMBO J. <304> 6 <305> 5 <306> 1273-1280 <307> 1987 <308> NCBI/NM 002535

44

<400> 14 cggcagccag ctgagagcaa tgggaaatgg ggagtcccag ctgtcctcgg tgcctgctca б0 gaagctgggt tggtttatcc aggaatacct gaagccctac gaagaatgtc agacactgat 120 cgacgagatg gtgaacacca tetgtgacgt etgcaggaac ceegaacagt teeceetggt 180 gcagggagtg gccataggtg gctcctatgg acggaaaaca gtcttaagag gcaactccga 240 tggtaccctt gtccttttct tcagtgactt aaaacaattc caggatcaga agagaagcca 300 acgtgacatc ctcgataaaa ctggggataa gctgaagttc tgtctgttca cgaagtggtt 360 gaaaaacaat ttcgagatcc agaagtccct tgatgggtcc accatccagg tgttcacaaa 420 aaatcagaga atctctttcg aggtgctggc cgccttcaac gctctgagct taaatgataa 480 teccagecce tggatetate gagageteaa aagateettg gataagaeaa atgecagtee 540 tggtgagttt gcagtctgct tcactgaact ccagcagaag ttttttgaca accgtcctgg 600 aaaactaaag gatttgatcc tcttgataaa gcactggcat caacagtgcc agaaaaaaat 660 caaggattta ccctcgctgt ctccgtatgc cctggagctg cttacggtgt atgcctqgqa 720 acaggggtgc agaaaagaca actttgacat tgctgaaggc gtcagaacgg ttctggagct 780 gatcaaatgc caggagaagc tgtgtatcta ttggatggtc aactacaact ttgaagatga 840 gaccatcagg aacatcctgc tgcaccagct ccaatcagcg aggccagtaa tcttggatcc 900 agttgaccca accaataatg tgagtggaga taaaatatgc tggcaatggc tgaaaaaaga 960 ageteaaace tggttgaett eteceaacet ggataatgag ttaeetgeac catettggaa 1020 tgtcctgcct gcaccactct tcacgacccc aggccacctt ctggataagt tcatcaagga 1080 gtttctccag cccaacaaat gcttcctaga gcagattgac agtgctgtta acatcatccg 1140 tacatteett aaagaaaact getteegaca ateaacagee aagateeaga ttgteegggg 1200 aggatcaacc gccaaaggca cagctctgaa gactggctct gatgccgatc tcgtcgtgtt 1260 ccataactca cttaaaagct acacctccca aaaaaacgag cggcacaaaa tcgtcaagga 1320 aatccatgaa cagctgaaag ccttttggag ggagaaggag gaggagcttg aagtcagctt 1380 tgagcctccc aagtggaagg ctcccagggt gctgagcttc tctctgaaat ccaaagtcct 1440 caacgaaagt gtcagctttg atgtgcttcc tgcctttaat gcactgggtc agctgagttc 1500 tggctccaca cccagccccg aggtttatgc agggctcatt gatctgtata aatcctcgga 1560 cctcccggga ggagagtttt ctacctgttt cacagtcctg cagcgaaact tcattcgctc 1620 ccggcccacc aaactaaagg atttaattcg cctggtgaag cactggtaca aagagtgtga 1680 aaggaaactg aagccaaagg ggtctttgcc cccaaagtat gccttggagc tgctcaccat 1740

ctatgcctgg	gagcagggga	gtggagtgcc	ggattttgac	actgcagaag	gtttccggac	1800
agtcctggag	ctggtcacac	aatatcagca	gctcggcatc	ttctggaagg	tcaattacaa	1860
ctttgaagat	gagaccgtga	ggaagtttct	actgagccag	ttgcagaaaa	ccaggcctgt	1920
gatcttggac	ccaggcgaac	ccacaggtga	cgtgggtgga	ggggaccgtt	ggtgttggca	1980
tcttctggac	aaagaagcaa	aggttaggtt	atcctctccc	tgcttcaagg	atgggactgg	2040
aaacccaata	ccaccttgga	aagtgccggt	aaaagtcatc	taaaggaggc	gttgtctgga	2100
aatagccctg	taacaggctt	gaatcaaaga	acttctccta	ctgtagcaac	ctgaaattaa	2160
ctcagacaca	aataaaggaa	acccagctca	caggagctta	aacagctggt	cagcccccct	2220
aagcccccac	tacaagtgat	cctcaggcag	gtaaccccag	attcatgcac	tgtagggctg	2280
ggcgcagcat	ccctaggtct	ctacccagta	gatgccacta	gccctcctct	cccagtgaca	2340
accaaaagtc	ttcacatgtt	caaacgttcc	cctgggttca	cagatettte	tgcctttggc	2400
ttttggctcc	accctcttta	gctgttaatt	tgagtactta	tggccctgaa	agcggccacg	2460
gtgcctccag	atggcaggtt	tgcaatccaa	gcaggaagaa	ggaaaagata	cccaaaggtc	2520
aagaacacag	tgattttatt	agaagtttca	tccgcaaatt	ttcttccatt	tcattgctca	2580
gaatgtcatg	tggttacctg	taacttgaag	gtggctacaa	agatgactgt	ggaggtggtt	2640
gcacttgcca	cccaaggatg	tctgccacac	ctctccaagc	cctcctacct	accaagatat	2700
acctgatata	tccaccagat	atctcctcag	atatacttgg	ttctctccac	caggttcttt	2760
ctttaaagca	ggattctcaa	ctttgatact	tactcacatt	gggctagaca	gttctttgtt	2820
tggaggctct	cttgtgcatg	taggatgttg	agcagcatgt	gtggcctgta	cccagtacat	2880
gccacccagt	tgtgacaatt	aaaagtgtct	tgagacttta	tcatgtgtct	tctgccctag	2940
gtgagaaccc	ttgcactaca	ggaaccctac	acccaacctg	gggggaatgt	agggaagagg	3000
tgccaagcca	accgtggggt	tagctctaat	tattaagtta	tgcattataa	ataaatacca	3060
aaaaattg						3068

<210> 15 <211> 6270 <212> DNA

<213> Homo sapiens

<300>

<301> Rebouillat, D., et al. <302> The 100-kDa 2',5'-oligoadenylate synthetase catalyzing preferentially the synthesis of dimeric pppA2'p5'A molecules <303> J. Biol. Chem. <304> 274

<305> 3

46

<306> 1557-1565 <307> 1999 <308> NCBI/AF063613 <309> 1999-05-04 <300> <301> Rebouillat, D., and Hovanessian, A.G. <302> Direct Submission <303> Submitted (07-May-1998) Dept. of AIDS and Retroviruses, Institut <304> 0 <305> 0 <306> 0 <307> 1998 <308> NCBI/AF063613 <309> 1999-05-04 <400> 15 gecetgette ecettgeace tgegeeggge ggecatggae ttgtacagea eceeggeege 60 tgcgctggac aggttcgtgg ccagaaggct gcagccgcgg aaggagttcg tagagaaggc 120 geggegeget etgggegeec tggeegetge cetgagggag eqegggggee geeteggtge 180 tgctgccccg cgggtgctga aaactgtcaa gggaggctcc tcgggccggg gcacagctct 240 caagggtggc tgtgattctg aacttgtcat cttcctcgac tgcttcaaga gctatgtgga 300 ccagagggcc cgccgtgcag agatcctcag tgagatgcgg gcatcgctgg aatcctggtg 360 gcagaaccca gtccctggtc tgagactcac gtttcctgag cagagcgtgc ctggggccct 420 gcagttccgc ctgacatccg tagatcttga ggactggatg gatgttagcc tggtgcctgc 480 540 cctcctcaac agtggctgcc aagggggcga gcatgcggcc tgcttcacag agctgcggag 600 gaactttgtg aacattcgcc cagccaagtt gaagaaccta atcttgctgg tgaagcactg 660 gtaccaccag gtgtgcctac aggggttgtg gaaggagacg ctgcccccgg tctatgccct 720 ggaattgctg accatcttcg cctgggagca gggctgtaag aaggatgctt tcagcctagg 780 cgaaggcctc cgaactgtcc tgggcctgat ccaacagcat cagcacctgt gtgttttctg 840 gactgtcaac tatggetteg aggaceetge agttgggeag ttettgeage ggeaegttaa 900 gagacccagg cctgtgatcc tggacccagc tgaccccaca tgggacctgg ggaatggggc 960 agcctggcac tgggatttgc atgcccagga ggcagcatcc tgctatgacc acccatgctt 1020 tetgaggggg atgggggace cagtgeagte ttggaagggg cegggeette caegtgetgg 1080 atgeteaggt ttgggeeace ceateeaget agaceetaac cagaagacee etgaaaacag 1140 caagageete aatgetgtgt acceaagage agggageaaa eeteeeteat geecagetee 1200 tggccccact gcggagccag catcgtaccc ctctgtgccg ggaatggcct tggacctgtc 1260

47

PCT/US2005/014626

1320 tcagatcccc accaaggagc tggaccgctt catccaggac cacctgaagc cgagccccca gttccaggag caggtgaaaa aggccatcga catcatcttg cgctgcctcc atgagaactg 1380 tgttcacaag gcctcaagag tcagtaaagg gggctcattt ggccggggca cagacctaag 1440 ggatggctgt gatgttgaac tcatcatctt cctcaactgc ttcacggact acaaggacca 1500 ggggcccgc cgcgcagaga tccttgatga gatgcgagcg cacgtagaat cctggtggca 1560 ggaccaggtg cccagcctga gccttcagtt tcctgagcag aatgtgcctg aggctctgca 1620 1680 gttccagctg gtgtccacag ccctgaagag ctggacggat gttagcctgc tgcctgcctt cgatgctgtg gggcagctca gttctggcac caaaccaaat ccccaggtct actcgaggct 1740 cctcaccagt ggctgccagg agggcgagca taaggcctgc ttcgcagagc tgcggaggaa 1800 cttcatgaac attcgccctg tcaagctgaa gaacctgatt ctgctggtga agcactggta 1860 1920 ccgccaggtt gcggctcaga acaaaggaaa aggaccagcc cctgcctctc tgcccccagc ctatgccctg gagctcctca ccatctttgc ctgggagcag ggctgcaggc aggattgttt 1980 2040 caacatggcc caaggcttcc ggacggtgct ggggctcgtg caacagcatc agcagctctg tgtctactgg acggtcaact atagcactga ggacccagcc atgagaatgc accttcttgg 2100 ccagcttcga aaacccagac ccctggtcct ggaccccgct gatcccacct ggaacgtggg 2160 ccacggtagc tgggagctgt tggcccagga agcagcagcg ctggggatgc aggcctgctt 2220 tctgagtaga gacgggacat ctgtgcagcc ctgggatgtg atgccagccc tcctttacca 2280 aaccccagct ggggaccttg acaagttcat cagtgaattt ctccagccca accgccagtt 2340 cctggcccag gtgaacaagg ccgttgatac catctgttca tttttgaagg aaaactgctt 2400 ccggaattct cccatcaaag tgatcaaggt ggtcaagggt ggctcttcag ccaaaggcac 2460 agctctgcga ggccgctcag atgccgacct cgtggtgttc ctcagctgct tcagccagtt 2520 2580 cactgagcag ggcaacaagc gggccgagat catctccgag atccgagccc agctggaggc atgtcaacag gagcggcagt tcgaggtcaa gtttgaagtc tccaaatggg agaatccccg 2640 2700 cgtgctgagc ttctcactga catcccagac gatgctggac cagagtgtgg actttgatgt gctgccagcc tttgacgccc taggccagct ggtctctggc tccaggccca gctctcaagt 2760 2820 ctacgtcgac ctcatccaca gctacagcaa tgcgggcgag tactccacct gcttcacaga gctacaacgg gacttcatca tctctcgccc taccaagctg aagagcctga tccggctggt 2880 2940 gaagcactgg taccagcagt gtaccaagat ctccaagggg agaggctccc tacccccaca gcacgggctg gaactcctga ctgtgtatgc ctgggagcag ggcgggaagg actcccagtt 3000

caacatggct	gagggcttcc	gcacggtcct	ggagctggtc	acccagtacc	gccagctctg	3060
tatctactgg	accatcaact	acaacgccaa	ggacaagact	gttggagact	tcctgaaaca	3120
gcagcttcag	aagcccaggc	ctatcatcct	ggatccggct	gacccgacag	gcaacctggg	3180
ccacaatgcc	cgctgggacc	tgctggccaa	ggaagctgca	gcctgcacat	ctgccctgtg	3240
ctgcatggga	cggaatggca	tccccatcca	gccatggcca	gtgaaggctg	ctgtgtgaag	3300
ttgagaaaat	cagcggtcct	actggatgaa	gagaagatgg	acaccagccc	tcagcatgag	3360
gaaattcagg	gtcccctacc	agatgagaga	gattgtgtac	atgtgtgtgt	gagcacatgt	3420
gtgcatgtgt	gtgcacacgt	gtgcatgtgt	gtgttttagt	gaatctgctc	tcccagctca	3480
cacactcccc	tgcctcccat	ggcttacaca	ctaggatcca	gactccatgg	tttgacacca	3540
gcctgcgttt	gcagcttctc	tgtcacttcc	atgactctat	cctcatacca	ccactgctgc	3600
ttcccaccca	gctgagaatg	cccctcctc	cctgactcct	ctctgcccat	gcaaattagc	3660
tcacatcttt	cctcctgctg	caatccatcc	cttcctccca	ttggcctctc	cttgccaaat	3720
ctaaatactt	tatataggga	tggcagagag	ttcccatctc	atctgtcagc	cacagtcatt	3780
tggtactggc	tacctggagc	cttatcttct	gaagggtttt	aaagaatggc	caattagctg	3840
agaagaatta	tctaatcaat	tagtgatgtc	tgccatggat	gcagtagagg	aaagtggtgg	3900
tacaagtgcc	atgattgatt	agcaatgtct	gcactggata	tggaaaaaag	aaggtgcttg	3960
caggtttaca	gtgtatatgt	gggctattga	agagccctct	gagctcggtt	gctagcagga	4020
gagcatgccc	atattggctt	actttgtctg	ccacagacac	agacagaggg	agttgggaca	4080
tgcatgctat	ggggaccctc	ttgttggaca	cctaattgga	tgcctcttca	tgagaggcct	4140
ccttttcttc	accttttatg	ctgcactcct	cccctagttt	acacatcttg	atgctgtggc	4200
tcagtttgcc	ttcctgaatt	tttattgggt	ccctgttttc	tctcctaaca	tgctgagatt	4260
ctgcatcccc	acagcctaaa	ctgagccagt	ggccaaacaa	ccgtgctcag	cctgtttctc	4320
tetgeeetet	agagcaaggc	ccaccaggtc	catccaggag	gctctcctga	cctcaagtcc	4380
aacaacagtg	tccacactag	tcaaggttca	gcccagaaaa	cagaaagcac	tctaggaatc	4440
ttaggcagaa	agggatttta	tctaaatcac	tggaaaggct	ggaggagcag	aaggcagagg	4500
ccaccactgg	actattggtt	tcaatattag	accactgtag	ccgaatcaga	ggccagagag	4560
cagccactgc	tactgctaat	gccaccacta	cccctgccat	cactgcccca	catggacaaa	4620
actggagtcg	agacctaggt	tagattcctg	caaccacaaa	catccatcag	ggatggccag	4680
ctgccagagc	tgcgggaaga	cggatcccac	ctccctttct	tagcagaatc	taaattacag	4740
ccagacctct	ggctgcagag	gagtctgaga	catgtatgat	tgaatgggtg	ccaagtgcca	4800

gggggcggag	tccccagcag	atgcatcctg	gccatctgtt	gcgtggatga	gggagtgggt	4860
ctatctcaga	ggaaggaaca	ggaaacaaag	aaaggaagcc	actgaacatc	ccttctctgc	4920
tccacaggag	tgtcttagac	agcctgactc	tccacaaacc	actgttaaaa	cttacctgct	4980
aggaatgcta	gattgaatgg	gatgggaaga	gaattaaata	attattgtca	ttcttggaga	5040
gaggtgagca	accaagggaa	gctcctctga	ttcacctaga	acctgttctc	tgccgtcttt	5100
ggctcagcct	acagagacta	gagtaggtga	agggacagag	gacagggctt	ctaatacctg	5160
tgccatattg	acagceteca	tecetgtece	ccatcttggt	gctgaaccaa	cgctaagggc	5220
accttcttag	actcacctca	tcgatactgc	ctggtaatcc	aaagctagaa	ctctcaggac	5280
cccaaactcc	acctcttgga	ttggccctgg	ctgctgccac	acacatatcc	aagagctcag	5340
ggccagttct	ggtgggcagc	agagacctgc	tctgccaagt	tgtccagcag	cagagtggcc	5400
ctggcctggg	catcacaagc	cagtgatgct	cctgggaaga	ccaggtggca	ggtcgcagtt	5460
gggtaccttc	cattcccacc	acacagactc	tgggcctccc	cgcaaaatgg	ctccagaatt	5520
agagtaatta	tgagatggtg	ggaaccagag	caactcaggt	gcatgataca	aggagaggtt	5580
gtcatctggg	tagggcagag	aggagggctt	gctcatctga	acaggggtgt	atttcattcc	5640
aggccctcag	tctttggcaa	tggccaccct	ggtgttggca	tattggcccc	actgtaactt	5700
ttgggggctt	cccggtctag	ccacaccctc	ggatggaaag	acttgactgc	ataaagatgt	5760
cagttctccc	tgagttgatt	gataggctta	atggtcaccc	taaaaacacc	cacatatgct	5820
tttcgatgga	accagataag	ttgacgctaa	agttcttatg	gaaaaataca	cacgcaatag	5880
ctaggaaaac	acagggaaag	aagagttctg	agcagggcct	agtcttagcc	aatattaaaa	5940
catactatga	agcctctgat	acttaaacag	catggcgctg	gtacgtaaat	agaccaatgc	6000
agttaggtgg	ctctttccaa	gactctgggg	aaaaaagtag	taaaaagcta	aatgcaatca	6060
atcagcaatt	gaaagctaag	tgagagagcc	agagggcctc	cttggtggta	aaagagggtt	6120
gcatttcttg	cagccagaag	gcagagaaag	tgaagaccaa	gtccagaact	gaatcctaag	6180
aaatgcagga	ctgcaaagaa	attggtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtttaa	6240
tttttaaaaa	gtttttattc	ggaatccgcg				6270

<210> 16 <211> 1412 <212> DNA <213> Mus musculus

<300>

<301> Coccia, E.M., et al.

<302>	cell	Ls	murine 2-5A	synthetase	cDNA trans	fected in NI	H-3T3
<303> <304> <305>	179 1	ology					
<306>	228- 1990						
<308>		I/M33863					
<309>	1993	3-06-11					
<400>	16						
ccaggct	999	agacccagga	agctccagac	ttagcatgga	gcacggactc	aggagcatcc	60
cagccto	ggac	gctggacaag	ttcatagagg	attacctcct	tecegacace	acctttggtg	120
ctgatgt	caa	atcagccgtc	aatgtcgtgt	gtgatttcct	gaaggagaga	tgcttccaag	180
gtgctgo	cca	cccagtgagg	gtctccaagg	tggtgaaggg	tggctcctca	ggcaaaggca	240
ccacact	caa	gggcaggtca	gacgctgacc	tggtggtgtt	ccttaacaat	ctcaccagct	300
ttgagga	atca	gttaaaccga	cggggagagt	tcatcaagga	aattaagaaa	cagctgtacg	360
aggttca	ıgca	tgagagacgt	tttagagtca	agtttgaggt	ccagagttca	tggtggccca	420
acgcccc	ggtc	tctgagcttc	aagctgagcg	cccccatct	gcatcaggag	gtggagtttg	480
atgtgct	gcc	agcctttgat	gtcctgggtc	atgttaatac	ttccagcaag	cctgatccca	540
gaatcta	tgc	catcctcatc	gaggaatgta	cctccctggg	gaaggatggc	gagttctcta	600
cctgctt	cac	ggagctccag	cggaacttcc	tgaagcagcg	cccaaccaag	ctgaagagtc	660
tcatcco	gcct	ggtcaagcac	tggtaccaac	tgtgtaagga	gaagctgggg	aagccattgc	720
ctccaca	igta	cgccctagag	ttgctcactg	tctttgcctg	ggaacaaggg	aatggatgtt	780
atgagtt	caa	cacagcccag	ggcttccgga	ccgtcttgga	actggtcatc	aattatcagc	840
atcttcg	gaat	ctactggaca	aagtattatg	actttcaaca	ccaggaggtc	tccaaatacc	900
tgcacag	jaca	gctcagaaaa	gccaggcctg	tgatcctgga	cccagctgac	ccaacaggga	960
atgtggc	cgg	tgggaaccca	gagggctgga	ggcggttggc	tgaagaggct	gatgtgtggc	1020
tatggta	ccc	atgttttatt	aaaaaggatg	gttcccgagt	gageteetgg	gatgtgccga	1080
cggtggt	tcc	tgtacctttt	gagcaggtag	aagagaactg	gacatgtatc	ctgctgtgag	1140
cacagca	ıgca	cctgcccagg	agactgctgg	tcaggggcat	ttgctgctct	gctgcaggcc	1200
catgacc	cag	tgagggaggg	ccccacctgg	catcagactc	cgtgcttctg	atgcctgcca	1260
gccatgt	ttg	actcctgtcc	aatcacagcc	agccttcctc	aacagattca	gaaggagagg	1320
aaagaac	aca	cgcttggtgt	ccatctgtcc	acctgttgga	aggttctgtc	tgacaaagtc	1380
tgatcaa	caa	taaaccacag	caggtgccgt	ca			1412

<210> 17 <211> 1193 <212> DNA <213> Homo sapiens	
<400> 17 tgaagatcag ctattagaag agaaagatca gttaagtcct ttggacctga tcagcttgat	60
acaagaacta ctgatttcaa cttctttggc ttaattctct cggaaacgat gaaatataca	120
agttatatet tggettttea getetgeate gttttgggtt etettggetg ttactgecag	180
gacccatatg taaaagaagc agaaaacctt aagaaatatt ttaatgcagg tcattcagat	240
gtagcggata atggaactct tttcttaggc attttgaaga attggaaaga ggagagtgac	300
agaaaaataa tgcagagcca aattgtctcc ttttacttca aacttttaa aaactttaaa	360
gatgaccaga gcatccaaaa gagtgtggag accatcaagg aagacatgaa tgtcaagttt	420
ttcaatagca acaaaaagaa acgagatgac ttcgaaaagc tgactaatta ttcggtaact	480
gacttgaatg tccaacgcaa agcaatacat gaactcatcc aagtgatggc tgaactgtcg	540
ccagcagcta aaacagggaa gcgaaaaagg agtcagatgc tgtttcaagg tcgaagagca	600
tcccagtaat ggttgtcctg cctgcaatat ttgaatttta aatctaaatc tatttattaa	660
tatttaacat tatttatatg gggaatatat ttttagactc atcaatcaaa taagtattta	720
taatagcaac ttttgtgtaa tgaaaatgaa tatctattaa tatatgtatt atttataatt	780
cctatatcct gtgactgtct cacttaatcc tttgttttct gactaattag gcaaggctat	840
gtgattacaa ggctttatct caggggccaa ctaggcagcc aacctaagca agatcccatg	900
ggttgtgtgt ttatttcact tgatgataca atgaacactt ataagtgaag tgatactatc	960
cagttactgc cggtttgaaa atatgcctgc aatctgagcc agtgctttaa tggcatgtca	1020
gacagaactt gaatgtgtca ggtgaccctg atgaaaacat agcatctcag gagatttcat	1080
gcctggtgct tccaaatatt gttgacaact gtgactgtac ccaaatggaa agtaactcat	1140
ttgttaaaat tatcaatatc taatatatat gaataaagtg taagttcaca act	1193
<210> 18 <211> 166 <212> PRT <213> Homo sapiens	

<400> 18

Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu 1 5 10 15

52

Gly	Ser	Leu				Cys			Pro	_	Val	Lys	Glu 30	Ala	Glu	
Asn	Leu		Lys			Asn	Ala 40	Gly	His	Ser	Asp	Val 45	Ala	Asp	Asn	
Gly	Thr 50	Leu	Phe	Leu	Gly	Ile 55	Leu	Lys	Asn	Trp	Lys 60	Glu	Glu	Ser	Asp	
Arg	Lys	Ile	Met	Gln		Gln					_		Lys	Leu	Phe	

Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile

Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg 105

Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val 120

Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser 135

Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Gln 150 155 160

Gly Arg Arg Ala Ser Gln 165

<210> 19

<211> 838

<212> DNA <213> Homo sapiens

<400> 19

gagtetaact geaacettte gaageetttg etetggeaca acaggtagta ggegaeactq 60 gtcgtgttgt tgacatgacc aacaagtgtc tcctccaaat tgctctcctg ttgtgcttct 120 ccacgacage tetttecatg agetacaact tgettggatt cetacaaaga ageagcaatt 180 gtcagtgtca gaagctcctg tggcaattga atgggaggct tgaatactgc ctcaaggaca 240 ggaggaactt tgacatccct gaggagatta agcaqctgca qcaqttccaq aaqqaqqacq 300 ccgcagtgac catctatgag atgctccaga acatctttgc tattttcaqa caagattcat 360 cgagcactgg ctggaatgag actattgttg agaacctcct ggctaatgtc tatcatcaga 420

53

WO 2005/105136 PCT/US2005/014626

gaaaccatct gaagacagtc	ctggaagaaa	aactggagaa	agaagatttc	accaggggaa	480
aacgcatgag cagtctgcac	ctgaaaagat	attatgggag	gattctgcat	tacctgaagg	540
ccaaggagga cagtcactgt	gcctggacca	tagtcagagt	ggaaatccta	aggaactttt	600
acgtcattaa cagacttaca	ggttacctcc	gaaactgaag	atctcctagc	ctgtgcctct	660
gggacgggac aattgcttca	agcattcttc	aaccagcaga	tgctgtttaa	gtgactgatg	720
gcgaatgtac tgcatatgaa	aggacactag	aagattttga	aatttttatt	aaattatgag	780
gtatttttat ttatttaaat	tttattttgg	aaaataaatt	atttttggtg	caaaagtc	838
<210> 20 <211> 840 <212> DNA <213> Homo sapiens					
<400> 20 acattctaac tgcaaccttt	cgaagccttt	gctctggcac	aacaggtagt	aggcgacact	60
gttcgtgttg tcaacatgac	caacaagtgt	ctcctccaaa	ttgctctcct	gttgtgcttc	120
tecactacag etettecat	gagctacaac	ttgcttggat	tcctacaaag	aagcagcaat	180
tttcagtgtc agaagctcct	gtggcaattg	aatgggaggc	ttgaatactg	cctcaaggac	240
aggatgaact ttgacatccc	tgaggagatt	aagcagctgc	agcagttcca	gaaggaggac	300
geegeattga eeatetatga	gatgctccag	aacatctttg	ctattttcag	acaagattca	360
tctagcactg gctggaatga	gactattgtt	gagaacctcc	tggctaatgt	ctatcatcag	420
ataaaccatc tgaagacagt	cctggaagaa	aaactggaga	aagaagattt	caccagggga	480
aaactcatga gcagtctgca	cctgaaaaga	tattatggga	ggattctgca	ttacctgaag	540
gccaaggagt acagtcactg	tgcctggacc	atagtcagag	tggaaatcct	aaggaacttt	600
tacttcatta acagacttac	aggttacctc	cgaaactgaa	gatctcctag	cctgtgcctc	660
tgggactgga caattgcttc	aagcattctt	caaccagcag	atgctgttta	agtgactgat	720
ggctaatgta ctgcatatga	aaggacacta	gaagattttg	aaatttttat	taaattatga	780
gttattttta tttatttaaa	ttttattttg	gaaaataaat	tatttttggt	gcaaaagtca	840
<210> 21 <211> 588 <212> DNA <213> Homo sapiens <400> 21					60
atggccttcg tgctctctct	actcatggcc	ceggegeegg	cagetaegg	cccaggagga	60

а

WO 2005/105136 PCT/US2005/014626

54

tccctgggtt	gtgacctgtc	tcagaaccac	gtgctggttg	gcaggaagaa	cctcaggctc	120
ctggacgaaa	tgaggagact	ctcccctcac	ttttgtctgc	aggacagaaa	agacttcgct	180
ttaccccagg	aaatggtgga	gggcggccag	ctccaggagg	cccaggccat	ctctgtgctc	240
catgagatgc	tccagcagag	cttcaacctc	ttccacacag	agcactcctc	tgctgcctgg	300
gacaccaccc	tcctggagcc	atgccgcact	ggactccatc	agcagctgga	caacctggat	360
gcctgcctgg	ggcaggtgat	gggagaggaa	gactctgccc	tgggaaggac	gggccccacc	420
ctggctctga	agaggtactt	ccagggcatc	catgtctacc	tgaaagagaa	gggatacagc	480
gactgcgcct	gggaaaccgt	cagactggaa	atcatgagat	ccttctcttc	attaatcagc	540
ttgcaagaaa	ggttaagaat	gatggatgga	gacctgagct	caccttga		588
<210> 22 <211> 961 <212> DNA <213> Homo	o sapiens					
	ccttaggctc	acccatttca	accagtctag	cagcatctgc	aacatctaca	60
atggccttga	cctttgcttt	actggtggcc	ctcctggtgc	tcagctgcaa	gtcaagctgc	120
tctgtgggct	gtgatctgcc	tcaaacccac	agcctgggta	gcaggaggac	cttgatgctc	180
ctggcacaga	tgaggaaaat	ctctctttc	tcctgcttga	aggacagaca	tgactttgga	240
tttccccagg	aggagtttgg	caaccagttc	caaaaggctg	aaaccatccc	tgtcctccat	300
gagatgatcc	agcagatctt	caatctcttc	agcacaaagg	actcatctgc	tgcttgggat	360
gagaccctcc	tagacaaatt	ctacactgaa	ctctaccagc	agctgaatga	cctggaagcc	420
tgtgtgatac	agggggtggg	ggtgacagag	actcccctga	tgaaggagga	ctccattctg	480
gctgtgagga	aatacttcca	aagaatcact	ctctatctga	aagagaagaa	atacagccct	540
tgtgcctggg	aggttgtcag	agcagaaatc	atgagatett	tttctttgtc	aacaaacttg	600
caagaaagtt	taagaagtaa	ggaatgaaaa	ctggttcaac	atggaaatga	ttttcattaa	660
ttcgtatgcc	agctcacctt	tttatgatct	gccatttcaa	agactcatgt	ttctgctatg	720
accatgacac	gatttaaatc	tttttcaaat	gtttttagga	gtattaatca	acattgtatt	780
cagctcttaa	ggcactagtc	ccttacagag	gaccatgctg	actgatccat	tatctattta	840
aatatttta	aaatattatt	tatttaacta	tttataaaac	aacttatttt	tgttcatatt	900
acgtcatgtg	cacctttgca	cagtggttaa	tgtaataaaa	tatgttcttt	gtatttggta	960

<210><211><212><213>	23 737 DNA Homo	o sapiens					
<400> tacccac	23 cctc	aggtagccta	gtgatatttg	caaaatccca	atggcccggt	ccttttcttt	60
actgatg	gcc	gtgctggtac	tcagctacaa	atccatctgc	tatatgggat	gtgatctgcc	120
tcagaco	cac	agcctgcgta	ataggagggc	cttgatactc	ctggcacaaa	tgggaagaat	180
ctctcct	ttc	tcctgcttga	aggacagaca	tgaattcaga	ttcccggagg	aggagtttga	240
tggccac	cag	ttccagaaga	ctcaagccat	ctctgtcctc	catgagatga	tccagcagac	300
cttcaat	ctc	ttcagcacag	aggactcatc	tgctgcttgg	gaacagagcc	tcctagaaaa	360
attttcc	act	gaactttacc	agcaactgaa	tgacctggaa	gcatgtgtga	tacaggaggt	420
tggggtg	gaa	gagactcccc	tgatgaatga	ggacttcatc	ctggctgtga	ggaaatactt	480
ccaaaga	atc	actctttatc	taacagagaa	gaaatacagc	ccttgtgcct	gggaggttgt	540
cagagca	ıgaa	atcatgagat	ccttctcttt	ttcaacaaac	ttgaaaaaag	gattaaggag	600
gaaggat	tga	aaactggttc	atcatggaaa	tgattctcat	tgactaatgc	atcatctcac	660
actttca	tga	gttcttccat	ttcaaagact	cacttctata	accaccacaa	gttgaatcaa	720
aatttcc	aaa	tgttttc					737
	24 1933 DNA Homo	s sapiens					
<400> gatctgg	24 taa	acctgaagca	aatatagaaa	cctatagggc	ctgacttcct	acataaagta	60
aggaggg	rtaa	aaatggaggc	tagaataagg	gttaaaattt	tgcttctaga	acagagaaaa	120
tgatttt	ttt	catatatata	tgaatatata	ttatatatac	acatatatac	atatattcac	180
tatagtg	tgt	atacataaat	atataatata	tatattgtta	gtgtagtgtg	tgtctgatta	240
tttacat	gca	tatagtatat	acacttatga	ctttagtacc	cagacgtttt	tcatttgatt	300
aagcatt	cat	ttgtattgac	acagctgaag	tttactggag	tttagctgaa	gtctaatgca	360
aaattaa	tag	attgttgtca	tcctcttaag	gtcataggga	gaacacacaa	atgaaaacag	420
taaaaga	.aac	tgaaagtaca	gagaaatgtt	cagaaaatga	aaaccatgtg	tttcctatta	480
aaagcca	tgc	atacaagcaa	tgtcttcaga	aaacctaggg	tccaaggtta	agccatatcc	540
cagctca	.gta	aagccaggag	catcctcatt	tcccaatgqc	cctcctgttc	cctctactgg	600

56

WO 2005/105136 PCT/US2005/014626

cagccctagt	gatgaccagc	tatagccctg	ttggatctct	gggctgtgat	ctgcctcaga	660
accatggcct	acttagcagg	aacaccttgg	tgcttctgca	ccaaatgagg	agaatctccc	720
ctttcttgtg	tctcaaggac	agaagagact	tcaggttccc	ccaggagatg	gtaaaaggga	780
gccagttgca	gaaggcccat	gtcatgtctg	tcctccatga	gatgctgcag	cagatcttca	840
gcctcttcca	cacagagcgc	tcctctgctg	cctggaacat	gaccctccta	gaccaactcc	900
acactggact	tcatcagcaa	ctgcaacacc	tggagacctg	cttgctgcag	gtagtgggag	960
aaggagaatc	tgctggggca	attagcagcc	ctgcactgac	cttgaggagg	tacttccagg	1020
gaatccgtgt	ctacctgaaa	gagaagaaat	acagcgactg	tgcctgggaa	gttgtcagaa	1080
tggaaatcat	gaaatccttg	ttcttatcaa	caaacatgca	agaaagactg	agaagtaaag	1140
atagagacct	gggctcatct	tgaaatgatt	ctcattgatt	aatttgccat	ataacacttg	1200
cacatgtgac	tctggtcaat	tcaaaagact	cttatttcgg	ctttaatcac	agaattgact	1260
gaattagttc	tgcaaatact	ttgtcggtat	attaagccag	tatatgttaa	aaagacttag	1320
gttcaggggc	atcagtccct	aagatgttat	ttatttttac	tcatttattt	attcttacat	1380
tttatcatat	ttatactatt	tatattctta	tataacaaat	gtttgccttt	acattgtatt	1440
aagataacaa	aacatgttca	gctttccatt	tggttaaata	ttgtattttg	ttatttatta	1500
aattatttc	aaacaaact	tcttgaagtt	atttattcga	aaaccaaaat	ccaaacacta	1560
gttttctgaa	ccaaatcaag	gaatggacgg	taatatacac	ttacctattc	attcattcca	1620
tttacataat	atgtataaag	tgagtatcaa	agtggcatat	tttggaattg	atgtcaagca	1680
atgcaggtgt	actcattgca	tgactgtatc	aaaatatctc	atgtaaccaa	taaatatata	1740
cacttactat	gtatcccaca	aaaattaaaa	agttatttta	aaaaagaaat	acaggtgaat	1800
aaacacagtt	tctttccgtg	ttgaagagct	ttcattctta	caggaaaaga	aacagtaaag	1860
atgtaccaat	ttcgcttata	tgaaacacta	caaagataag	taaaagaaaa	tgatgttctc	1920
atactagaag	ctt					1933

<210> 25

tgggtgacag cctcagagtg tttcttctgc tgacaaagac cagagatcag gaatgaaact 60
agacatgact ggggactgca cgccagtgct ggtgctgatg gccgcagtgc tgaccgtgac 120
tggagcagtt cctgtcgcca ggctccacgg ggctctcccg gatgcaaggg gctgccacat 180

<211> 734

<212> DNA

<213> Homo sapiens

<400> 25

agcccagttc	aagtccctgt	ctccacagga	gctgcaggcc	tttaagaggg	ccaaagatgc	240
cttagaagag	tcgcttctgc	tgaaggactg	caggtgccac	tcccgcctct	tccccaggac	300
ctgggacctg	aggcagctgc	aggtgaggga	gcgccccatg	gctttggagg	ctgagctggc	360
cctgacgctg	aaggttctgg	aggccaccgc	tgacactgac	ccagccctgg	tggacgtctt	420
ggaccagccc	cttcacaccc	tgcaccatat	cctctcccag	ttccgggcct	gtatccagcc	480
tcagcccacg	gcagggccca	ggacccgggg	ccgcctccac	cattggctgt	accggctcca	540
ggaggcccca	aaaaaggagt	cccctggctg	cctcgaggcc	tctgtcacct	tcaacctctt	600
cegeeteete	acgcgagacc	tgaattgtgt	tgccagtggg	gacctgtgtg	tctgaccctc	660
ccaccagtca	tgcaacctga	gattttattt	ataaattagc	cacttgtctt	aatttattgc	720
cacccagtcg	ctat					734
	o sapiens					
<400> 26 gacatgaccg	gggactgcat	gccagtgctg	gtgctgatgg	ccgcagtgct	gaccgtgact	60
ggagcagttc	ctgtcgccag	geteegeggg	getetecegg	atgcaagggg	ctgccacata	120
gcccagttca	agtccctgtc	tccacaggag	ctgcaggcct	ttaagagggc	caaagatgcc	180
ttagaagagt	cgcttctgct	gaaggactgc	aagtgccgct	cccgcctctt	ccccaggacc	240
tgggacctga	ggcagctgca	ggtgagggag	cgccccgtgg	ctttggaggc	tgagctggcc	300
ctgacgctga	aggttctgga	ggccaccgct	gacactgacc	cagccctggg	ggatgtcttg	360
gaccagcccc	ttcacaccct	gcaccatatc	ctctcccagc	tccgggcctg	tatccagcct	420
cagcccacgg	cagggcccag	gacccggggc	cgcctccacc	attggctgca	ccggctccag	480
gaggccccaa	aaaaggagtc	ccctggctgc	ctcgaggcct	ctgtcacctt	caacctcttc	540
cgcctcctca	cgcgagacct	gaattgtgtt	gccagcgggg	acctgtgtgt	ctga	594
	o sapiens					
	gggactgcat	gccagtgctg	gtgctgatgg	ccgcagtgct	gaccgtgact	60
ggagcagttc	ctgtcgccag	gctccgcggg	gctctcccgg	atgcaagggg	ctgccacata	120

58

WO 2005/105136 PCT/US2005/014626

geccagttca agtecetgte t	tccacaggag	ctgcaggcct	ttaagagggc	caaagatgcc	180
ttagaagagt cgcttctgct g	gaaggactgc	aagtgccgct	cccgcctctt	ccccaggacc	240
tgggacctga ggcagctgca g	ggtgagggag	cgccccgtgg	ctttggaggc	tgagctggcc	300
ctgacgctga aggttctgga g	ggccaccgct	gacactgacc	cagccctggg	ggatgtcttg	360
gaccagcccc ttcacaccct g	gcaccatatc	ctctcccagc	tccgggcctg	tatccagcct	420
cagcccacgg cagggcccag g	gacccggggc	cgcctccacc	attggctgca	ccggctccag	480
gaggccccaa aaaaggagtc c	ccctggctgc	ctcgaggcct	ctgtcacctt	caacctcttc	540
cgcctcctca cgcgagacct g	gaattgtgtt	gccagcgggg	acctgtgtgt	ctga	594
<210> 28 <211> 856 <212> DNA <213> Homo sapiens <400> 28					
aattaccttt tcactttaca c	cacatcatct	tggattgccc	attttgcgtg	gctaaaaagc	60
agagccatgc cgctggggaa g	gcagttgcga	tttagccatg	gctgcagctt	ggaccgtggt	120
gctggtgact ttggtgctag g	gettggeegt	ggcaggccct	gtccccactt	ccaagcccac	180
cacaactggg aagggctgcc a	acattggcag	gttcaaatct	ctgtcaccac	aggagctagc	240
gagcttcaag aaggccaggg a	acgccttgga	agagtcactc	aagctgaaaa	actggagttg	300
cagctetect gtetteceeg g	ggaattggga	cctgaggctt	ctccaggtga	gggagcgccc	360
tgtggccttg gaggctgagc t	ggccctgac	gctgaaggtc	ctggaggccg	ctgctggccc	420
agccctggag gacgtcctag a	ccagcccct	tcacaccctg	caccacatcc	tctcccagct	480
ccaggcctgt atccagcctc a	ıgcccacagc	agggcccagg	ccccggggcc	gcctccacca	540
ctggctgcac cggctccagg a	ıggcccccaa	aaaggagtcc	gctggctgcc	tggaggcatc	600
tgtcaccttc aacctcttcc g	geeteeteae	gcgagacctc	aaatatgtgg	ccgatgggaa	660
cctgtgtctg agaacgtcaa c	ccaccctga	gtccacctga	caccccacac	cttatttatg	720
cgctgagccc tactccttcc t	taatttatt	tcctctcacc	ctttatttat	gaagctgcag	780
ccctgactga gacatagggc t	gagtttatt	gttttacttt	tatacattat	gcacaaataa	840
acaacaagga attgga					856

<210> 29 <211> 607 <212> DNA

<213> Artificial Sequence

<220> <223> Synt	thetic DNA e	encoding hur	man interfe	con-like per	ptide	
<400> 29 aattcaccgt	gcgtgttgac	tattttacct	ctggcggtga	taatgaaatc	aattgtgagc	60
ggataacaat	taaaaattaa	ggaggatcac	tatctgtgat	ttgccgcaga	ctcatagctt	120
cggcaaccga	acagcactca	tcctcttggc	ccaattggcc	caaatgggtc	gcatttccct	180
gttctcgtgc	cttaaagacc	gccacgattt	cgggtttcca	caggaagagt	ttgacggcaa	240
tcagttccaa	aaggctcagg	caatctcggt	tctgcatgag	atgattcagc	aaatcttcaa	300
cctgttctcc	actaaagact	cttcggctgc	ttggaacgaa	tccttgcttg	ataaattctc	360
cactgaactc	tatcagcaac	tgaacgtact	tgaagcttgc	gttatccagg	aggtaggcgt	420
tgaagagact	ccgcttatga	atgttgagtc	tatcctggct	gtatctaagt	attttcaccg	480
aattaccctc	tacctcagtg	agaagaaata	ttcaccgtgt	gcgtgggaaa	ttgtgagagc	540
cgaaatcatg	cgttccctga	ctcttctgac	caacctccag	gaacgcctgc	gtaataaaga	600
ctaatag						607
<220>	ificial Sequ chetic DNA e		nan interfe	con-like pep	otide	
<400> 30 aattcaccgt	gcgtgttgac	tattttacct	ctggcggtga	taatgaaatc	aattgtgagc	60
ggataacaat	tattacccaa	cttgaggaat	ttataatgtg	tgatttacca	caaacccata	120
gcttgggcaa	ccgaagagca	ctcatcctgt	tggcccaatt	ggcccaaatg	ggtcgcattt	180
ccctgttctc	gtgccttaaa	gaccgccacg	atttcgggtt	tccacaggaa	gagtttgacg	240
gcaatcagtt	ccaaaaggct	caggcaatct	cggttctgca	tgagatgatt	cagcaaatct	300
tcaacctgtt	ctccactaaa	gactgttcgg	ctgcttggaa	cgaatccttg	cttgataaat	360
tctccactga	actctatcag	caactgaacg	tacttgaagc	ttgcgttatc	caggaggtag	420
gcgttgaaga	gactccgctt	atgaatgttg	agtctatcct	ggctgtatct	aagtattttc	480
accgaattac	cctctacctc	agtgagaaga	aatattcacc	gtgtgcgtgg	gaaattgtga	540
gagccgaaat	ctagcgttcc	ctgactcttc	tgacgaacct	ccaggaacgc	ctgcgtaata	600
aaqactaata	a					611

60

<210>

31 2035


<212> DNA <213> Homo sapiens <400> 31 cgagccccgc cgaaccgagg ccacccggag ccgtgcccag tccacgccgg ccgtgcccgg 60 cggccttaag aaccaggcaa cctctgcctt cttccctctt ccactcggag tcgcgctccg 120 cgcgccctca ctgcagcccc tgcgtcgccg ggaccctcgc gcgcgaccag ccgaatcgct 180 cctgcagcag agccaacatg cccatcactc ggatgcgcat gagaccctgg ctagagatgc 240 agattaattc caaccaaatc ccggggctca tctggattaa taaagaggag atgatcttcc 300 agateceatg gaageatget gecaageatg getgggaeat caacaaggat geetgtttgt 360 tccggagctg ggccattcac acaggccgat acaaagcagg ggaaaaggag ccagatccca 420 agacgtggaa ggccaacttt cgctgtgcca tgaactccct gccagatatc gaggaggtga 480 aagaccagag caggaacaag ggcagctcag ctgtgcgagt gtaccggatg cttccacctc 540 tcaccaagaa ccagagaaaa gaaagaaagt cgaagtccag ccgagatgct aagagcaagg 600 ccaagaggaa gtcatgtggg gattccagcc ctgatacctt ctctgatgga ctcagcagct 660 720 ccactctgcc tgatgaccac agcagctaca cagttccagg ctacatgcag gacttggagg tggagcaggc cctgactcca gcactgtcgc catgtgctgt cagcagcact ctccccgact 780 ggcacatccc agtggaagtt gtgccggaca gcaccagtga tctgtacaac ttccaggtgt 840 cacccatgcc ctccacctct gaagctacaa cagatgagga tgaggaaggg aaattacctg 900 aggacatcat gaagctcttg gagcagtcgg agtggcagcc aacaaacgtg gatgggaagg 960 ggtacctact caatgaacct ggagtecage ccacctetgt ctatggagae tttagetgta 1020 aggaggagcc agaaattgac agcccagggg gggatattgg gctgagtcta cagcgtgtct 1080 teacagatet gaagaacatg gatgeeacet ggetggaeag cetgetgaee eeagteeggt 1140 tgccctccat ccaggccatt ccctgtgcac cgtagcaggg cccctgggcc cctcttattc 1200 1260 ctctaggcaa gcaggacctg gcatcatggt ggatatggtg cagagaagct ggacttctgt gggcccctca acagccaagt gtgaccccac tgccaagtgg ggatgggcct ccctccttgg 1320 gtcattgacc tctcagggcc tggcaggcca gtgtctgggt ttttcttgtg gtgtaaagct 1380 ggccctgcct cctgggaaga tgaggttctg agaccagtgt atcaggtcag ggacttggac 1440 aggagtcagt gtctggcttt ttcctctgag cccagctgcc tggagagggt ctcgctgtca 1500 ctggctggct cctaggggaa cagaccagtg accccagaaa agcataacac caatcccagg 1560 gctggctctg cactaagcga aaattgcact aaatgaatct cgttccaaag aactacccct 1620

tttcagctga	gccctgggga	ctgttccaaa	gccagtgaat	gtgaaggaaa	ctcccctcct	1680
tcggggcaat	gctccctcag	cctcagagga	gctctaccct	getecetget	ttggctgagg	1740
ggcttgggaa	aaaaacttgg	cactttttcg	tgtggatctt	gccacatttc	tgatcagagg	1800
tgtacactaa	catttccccc	gagctcttgg	cctttgcatt	tatttataca	gtgccttgct	1860
cggggcccac	cacccctca	agccccagca	gccctcaaca	ggcccaggga	gggaagtgtg	1920
agcgccttgg	tatgacttaa	aattggaaat	gtcatctaac	cattaagtca	tgtgtgaaca	1980
cataaggacg	tgtgtaaata	tgtacatttg	tctttttata	aaaagtaaaa	ttgtt	2035

al Application No PCT/US2005/014626

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/21 A61K A61K9/00 A61K9/127 A61K9/51 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, EMBASE, MEDLINE, BIOSIS, WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. WO 2004/074314 A (UNIVERSITY OF SOUTH P,X 23 - 25FLORIDA; MOHAPATRA, SHYAM, S) 2 September 2004 (2004-09-02) claims 1-4 γ WO 03/092618 A (UNIVERSITY OF SOUTH 26 - 31FLORIDA; MOHAPATRA, SHYAM, S; BEHERA, ARUNA, K) 13 November 2003 (2003-11-13) claims 1-54 -/-χ Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed in the art. "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 28 September 2005 12/10/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016

Ganschow, S



	ation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
Y	KUMAR M ET AL: "ROLE OF MUCOSAL IFN-GAMMA GENE TRANSFER ALLERGIC SENSITIZATION AND RSV INFECTION" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 109, no. 1, January 2002 (2002-01), page S43, XP008033852 ISSN: 0091-6749 abstract	26-31 1-22			
.,	Novel D. HT.	1 00			
Y	LENGYEL P: "Tumor-suppressor genes: News about the interferon connection" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1993 UNITED STATES, vol. 90, no. 13, 1993, pages 5893-5895, XP002347048 ISSN: 0027-8424 the whole document	1-22			
A	WO 01/22970 A (THE CLEVELAND CLINIC FOUNDATION; SILVERMAN, ROBERT, H; RUSCH, LORRAINE) 5 April 2001 (2001-04-05) claims 1,2	1-22			



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X Claims Nos.: - because they relate to subject matter not required to be searched by this Authority, namely: Although claims 1-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.					
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:					
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

Information on patent family members

Internation No PCT/US2005/014626

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 2004074314	Α	02-09-2004	NONE		
WO 03092618	Α	13-11-2003	AU CA EP	2003225281 A1 2484251 A1 1579001 A2	17-11-2003 13-11-2003 28-09-2005
WO 0122970	Α	05-04-2001	AU CA EP JP	1494801 A 2388025 A1 1229920 A1 2003510281 T	30-04-2001 05-04-2001 14-08-2002 18-03-2003